

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

## Overview for Request: cder\_mpl1r\_wp252

**Request ID:** cder\_mpl1r\_wp252\_nsdp\_v01

**Request Description:** In this report, we characterized dispensing and administration patterns of 26 New Molecular Entities (NMEs) approved from January 1 to August 31, 2019, stratified by age and sex in the Sentinel Distributed Database (SDD).

**Sentinel Routine Querying Module:** Cohort Identification and Descriptive Analysis module, version 12.1.2

**Data Source:** We distributed this request to 14 Sentinel Data Partners on July 25, 2023. Because of potential overlap in patient populations between two data partners for one year in the query period, we excluded results from one data partner and aggregated the results of the remaining 13 data partners in this report. The study period included available data from January 1, 2019 to most recent available data. Please see Appendix A for a list of dates of available data for each Data Partner.

**Study Design:** We identified individuals initiating any of the 26 NME drugs. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.<sup>1</sup>

**Exposures of Interest:** Our exposures of interest were NMEs approved between January 1, 2019, and August 31, 2019, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products, and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

**Cohort Eligibility Criteria:** We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the query period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

**Baseline Characteristics:** We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 24 chronic conditions and seven lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse<sup>2</sup> (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes used to define baseline characteristics in this request, and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

**Please refer to Appendices F, G, and H for the specifications of parameters used in this request, design diagram., and baseline characteristics used in this request.**

**Overview for Request: cder\_mpl1r\_wp252**

**Limitations:** Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

**Notes:** Please contact the Sentinel Operations Center ([info@sentinelssystem.org](mailto:info@sentinelssystem.org)) for questions and to provide comments/suggestions for future enhancements to this document.

<sup>1</sup>For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

<sup>2</sup>Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

## Table of Contents

<b><u>Glossary (CIDA)</u></b>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<b><u>Table 1a</u></b>	Aggregated Characteristics of PrabotulinumtoxinA-xvfs in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1b</u></b>	Aggregated Characteristics of Caplacizumab-yhdp in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1c</u></b>	Aggregated Characteristics of Triclabendazole in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1d</u></b>	Aggregated Characteristics of Brexanolone in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1e</u></b>	Aggregated Characteristics of Solriamfetol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1f</u></b>	Aggregated Characteristics of Siponimod in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1g</u></b>	Aggregated Characteristics of Romosozumab-aqqg in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1h</u></b>	Aggregated Characteristics of Erdafitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1i</u></b>	Aggregated Characteristics of Risankizumab-rzaa in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1j</u></b>	Aggregated Characteristics of Tafamidis in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1k</u></b>	Aggregated Characteristics of Alpelisib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1l</u></b>	Aggregated Characteristics of Polatuzumab Vedotin-piiq in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1m</u></b>	Aggregated Characteristics of Bremelanotide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1n</u></b>	Aggregated Characteristics of Selinexor in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1o</u></b>	Aggregated Characteristics of Imipenem Cilastatin and Relebactam in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1p</u></b>	Aggregated Characteristics of Ferric Maltol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1q</u></b>	Aggregated Characteristics of Darolutamide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1r</u></b>	Aggregated Characteristics of Pexidartinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1s</u></b>	Aggregated Characteristics of Pretomanid in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1t</u></b>	Aggregated Characteristics of Pitolisant in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023

## Table of Contents

<b><u>Table 1u</u></b>	Aggregated Characteristics of Entrectinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1v</u></b>	Aggregated Characteristics of Fedratinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1w</u></b>	Aggregated Characteristics of Upadacitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1x</u></b>	Aggregated Characteristics of Lefamulin in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1y</u></b>	Aggregated Characteristics of Ga-68-DOTATOC in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 1z</u></b>	Aggregated Characteristics of Istradefylline in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 2a</u></b>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 2b</u></b>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 2c</u></b>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 2d</u></b>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 2e</u></b>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 2f</u></b>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 3a</u></b>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 3b</u></b>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 3c</u></b>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 3d</u></b>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 3e</u></b>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 3f</u></b>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 4a</u></b>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 4b</u></b>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 4c</u></b>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex

## Table of Contents

<b><u>Table 4d</u></b>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 4e</u></b>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 4f</u></b>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 5a</u></b>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 5b</u></b>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 5c</u></b>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 5d</u></b>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 5e</u></b>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 5f</u></b>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 6a</u></b>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 6b</u></b>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 6c</u></b>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 6d</u></b>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 6e</u></b>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 6f</u></b>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 7a</u></b>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 7b</u></b>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 7c</u></b>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group
<b><u>Table 8a</u></b>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 8b</u></b>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex
<b><u>Table 8c</u></b>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group

## Table of Contents

<b><u>Table 9</u></b>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Table 10</u></b>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1a</u></b>	Patient Entry into Study by Month for PrabotulinumtoxinA-xvfs in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1b</u></b>	Patient Entry into Study by Month for Caplacizumab-yhdp in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1c</u></b>	Patient Entry into Study by Month for Triclabendazole in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1d</u></b>	Patient Entry into Study by Month for Brexanolone in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1e</u></b>	Patient Entry into Study by Month for Solriamfetol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1f</u></b>	Patient Entry into Study by Month for Siponimod in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1g</u></b>	Patient Entry into Study by Month for Romosozumab-aqqg in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1h</u></b>	Patient Entry into Study by Month for Erdafitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1i</u></b>	Patient Entry into Study by Month for Risankizumab-rzaa in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1j</u></b>	Patient Entry into Study by Month for Tafamidis in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1k</u></b>	Patient Entry into Study by Month for Alpelisib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1l</u></b>	Patient Entry into Study by Month for Polatuzumab Vedotin-piiq in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1m</u></b>	Patient Entry into Study by Month for Bremelanotide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1n</u></b>	Patient Entry into Study by Month for Selinexor in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1o</u></b>	Patient Entry into Study by Month for Imipenem Cilastatin and Relebactam in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1p</u></b>	Patient Entry into Study by Month for Ferric Maltol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1q</u></b>	Patient Entry into Study by Month for Darolutamide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1r</u></b>	Patient Entry into Study by Month for Pexidartinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023
<b><u>Figure 1s</u></b>	Patient Entry into Study by Month for Pretomanid in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023

## Table of Contents

**Figure 1t** Patient Entry into Study by Month for Pitolisant in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023

**Figure 1u** Patient Entry into Study by Month for Entrectinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023

**Figure 1v** Patient Entry into Study by Month for Fedratinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023

**Figure 1w** Patient Entry into Study by Month for Upadacitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023

**Figure 1x** Patient Entry into Study by Month for Lefamulin in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023

**Figure 1y** Patient Entry into Study by Month for Ga-68-DOTATOC in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023

**Figure 1z** Patient Entry into Study by Month for Istradefylline in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023

**Appendix A** Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (July 25, 2023)

**Appendix B** List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

**Appendix C** List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, and Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

**Appendix D** List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

**Appendix E** List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request

**Appendix F** Specifications Defining Parameters for this Request

**Appendix G** Design Diagram Used in this Request

**Appendix H** Specifications Defining Parameters for Baseline Characteristics in this Request



**Glossary of Terms for Analyses Using  
Cohort Identification and Descriptive Analysis (CIDA) Module\***

**Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

**Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

**Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded.

Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

**Ambulatory Visit (AV)** - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

**Emergency Department (ED)** - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

**Inpatient Hospital Stay (IP)** - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

**Non-Acute Institutional Stay (IS)** - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

**Other Ambulatory Visit (OA)** - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

**Charlson/Elixhauser Combined Comorbidity Score** - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

**Code Days** - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

**Cohort Definition (drug/exposure)** - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

**Computed Start Marketing Date** - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

**Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.

**Eligible Members** - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

**Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

**Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

**Glossary of Terms for Analyses Using  
Cohort Identification and Descriptive Analysis (CIDA) Module\***

**Event Deduplication** - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

**Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."

**Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

**Lookback Period** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

**Maximum Episode Duration** - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Member-Years** - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

**Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered.

**Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Monitoring Period** - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

**Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the CareSetting/PDX parameter.

**Query Period** - period in which the modular program looks for exposures and outcomes of interest.

**Switch Evaluation Step Value** - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

**Switch Gap Inclusion Indicator** - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

**Switch Pattern Cohort Inclusion Date** - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

**Switch Pattern Cohort Inclusion Strategy** - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

**Treatment Episode Truncation Indicator** - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

**Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

**Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

**Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

**Glossary of Terms for Analyses Using  
Cohort Identification and Descriptive Analysis (CIDA) Module\***

\*all terms may not be used in this report

**Table 1a. Aggregated Characteristics of PrabotulinumtoxinA-xvfs in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	PrabotulinumtoxinA-xvfs	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	*****	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	*****	*****
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	*****	*****
Year		
2019	0	0.0%
2020	*****	*****
2021	*****	*****
2022	0	0.0%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	0	0.0%
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA <sup>4</sup>	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%

**Table 1a. Aggregated Characteristics of PrabotulinumtoxinA-xvfs in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	PrabotulinumtoxinA-xvfs	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	0	0.0%
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD <sup>5</sup> and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	*****	*****
Mean number of emergency room encounters	*****	*****
Mean number of inpatient hospital encounters	*****	*****
Mean number of non-acute institutional encounters	*****	*****
Mean number of other ambulatory encounters	*****	*****

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1b. Aggregated Characteristics of Caplacizumab-yhdp in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

<b>Caplacizumab-yhdp</b>		
<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	147	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	46.8	14.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	42	28.6%
41-64 years	72	49.0%
≥ 65 years	19	12.9%
Sex		
Female	105	71.4%
Male	42	28.6%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	50	34.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	59	40.1%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	76	51.7%
Unknown	*****	*****
Year		
2019	39	26.5%
2020	52	35.4%
2021	33	22.4%
2022	23	15.6%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	26	17.7%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	13	8.8%
Diabetes Mellitus	45	30.6%
Heart Failure	30	20.4%
Hyperlipidemia	56	38.1%
Hypertension	92	62.6%
Depression	33	22.4%
Ischemic Heart Disease	48	32.7%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA <sup>4</sup>	46	31.3%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****

**Table 1b. Aggregated Characteristics of Caplacizumab-yhdp in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Caplacizumab-yhdp	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	13	8.8%
Anemia	132	89.8%
Asthma	20	13.6%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	80	54.4%
COPD <sup>5</sup> and Bronchiectasis	15	10.2%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	58	39.5%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	13	8.8%
Smoking: diagnosed or identified by smoking cessation procedures	58	39.5%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	17	11.6%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	13.3	19.0
Mean number of emergency room encounters	1.3	1.6
Mean number of inpatient hospital encounters	1.6	1.1
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	17.0	24.6

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1c. Aggregated Characteristics of Triclabendazole in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Triclabendazole	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	0	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race <sup>3</sup>		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2019	.	.
2020	.	.
2021	.	.
2022	.	.
2023	.	.
<b>Health Characteristics</b>		
Acute Myocardial Infarction	.	.
Alzheimer's Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA <sup>4</sup>	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.



**Table 1c. Aggregated Characteristics of Triclabendazole in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Triclabendazole	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD <sup>5</sup> and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity: diagnosed or identified by weight management procedures	.	.
Obesity: identified by weight management-related prescriptions	.	.
Overweight	.	.
Smoking: diagnosed or identified by smoking cessation procedures	.	.
Smoking: identified by smoking-related prescriptions	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.

<sup>1</sup>Value represents standard deviation where no % follows the value.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 1d. Aggregated Characteristics of Brexanolone in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Brexanolone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	76	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	33.3	8.1
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	65	85.5%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	55	72.4%
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	11	14.5%
Unknown	65	85.5%
Year		
2019	*****	*****
2020	23	30.3%
2021	26	34.2%
2022	*****	*****
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	55	72.4%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA <sup>4</sup>	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%

**Table 1d. Aggregated Characteristics of Brexanolone in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Brexanolone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	19	25.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD <sup>5</sup> and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	18	23.7%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.7	11.3
Mean number of emergency room encounters	0.9	1.3
Mean number of inpatient hospital encounters	1.0	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.4	3.8

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1e. Aggregated Characteristics of Solriamfetol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

<b>Solriamfetol</b>		
<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	9,289	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	48.6	14.0
Age		
0-17 years	51	0.5%
18-24 years	665	7.2%
25-40 years	2,523	27.2%
41-64 years	4,322	46.5%
≥ 65 years	1,728	18.6%
Sex		
Female	5,561	59.9%
Male	3,728	40.1%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	56	0.6%
Black or African American	324	3.5%
Multi-racial	71	0.8%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	5,172	55.7%
White	3,642	39.2%
Hispanic origin		
Yes	163	1.8%
No	3,227	34.7%
Unknown	5,899	63.5%
Year		
2019	*****	*****
2020	3,068	33.0%
2021	3,199	34.4%
2022	1,865	20.1%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	129	1.4%
Atrial Fibrillation	268	2.9%
Diabetes Mellitus	1,425	15.3%
Heart Failure	331	3.6%
Hyperlipidemia	1,909	20.6%
Hypertension	2,517	27.1%
Depression	3,945	42.5%
Ischemic Heart Disease	770	8.3%
Rheumatoid Arthritis/Osteoarthritis	1,503	16.2%
Stroke/TIA <sup>4</sup>	118	1.3%
Breast Cancer	95	1.0%
Colorectal Cancer	27	0.3%

**Table 1e. Aggregated Characteristics of Solriamfetol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Solriamfetol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	55	0.6%
Lung Cancer	14	0.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	993	10.7%
Anemia	1,106	11.9%
Asthma	714	7.7%
Benign Prostatic Hyperplasia	258	2.8%
Chronic Kidney Disease	499	5.4%
COPD <sup>5</sup> and Bronchiectasis	524	5.6%
Glaucoma	146	1.6%
Osteoporosis	151	1.6%
Obesity: diagnosed or identified by weight management procedures	2,847	30.6%
Obesity: identified by weight management-related prescriptions	178	1.9%
Overweight	744	8.0%
Smoking: diagnosed or identified by smoking cessation procedures	1,317	14.2%
Smoking: identified by smoking-related prescriptions	135	1.5%
Alcohol Abuse or Dependence	201	2.2%
Drug Abuse or Dependence	520	5.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	177	1.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.6	13.0
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.2	9.0

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1f. Aggregated Characteristics of Siponimod in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Siponimod		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	1,685	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	52.0	11.0
Age		
0-17 years	0	0.0%
18-24 years	20	1.2%
25-40 years	304	18.0%
41-64 years	1,127	66.9%
≥ 65 years	234	13.9%
Sex		
Female	1,256	74.5%
Male	429	25.5%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	705	41.8%
White	814	48.3%
Hispanic origin		
Yes	56	3.3%
No	864	51.3%
Unknown	765	45.4%
Year		
2019	346	20.5%
2020	743	44.1%
2021	414	24.6%
2022	182	10.8%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	41	2.4%
Atrial Fibrillation	12	0.7%
Diabetes Mellitus	134	8.0%
Heart Failure	26	1.5%
Hyperlipidemia	258	15.3%
Hypertension	364	21.6%
Depression	519	30.8%
Ischemic Heart Disease	69	4.1%
Rheumatoid Arthritis/Osteoarthritis	174	10.3%
Stroke/TIA <sup>4</sup>	23	1.4%
Breast Cancer	16	0.9%
Colorectal Cancer	*****	*****

**Table 1f. Aggregated Characteristics of Siponimod in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Siponimod		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	127	7.5%
Anemia	204	12.1%
Asthma	54	3.2%
Benign Prostatic Hyperplasia	27	1.6%
Chronic Kidney Disease	63	3.7%
COPD <sup>5</sup> and Bronchiectasis	50	3.0%
Glaucoma	41	2.4%
Osteoporosis	67	4.0%
Obesity: diagnosed or identified by weight management procedures	255	15.1%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	100	5.9%
Smoking: diagnosed or identified by smoking cessation procedures	280	16.6%
Smoking: identified by smoking-related prescriptions	19	1.1%
Alcohol Abuse or Dependence	18	1.1%
Drug Abuse or Dependence	63	3.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.2	11.5
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.9	18.4

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1g. Aggregated Characteristics of Romosozumab-aqqg in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Romosozumab-aqqg	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	38,408	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	73.8	8.0
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	86	0.2%
41-64 years	3,480	9.1%
≥ 65 years	34,831	90.7%
Sex		
Female	37,601	97.9%
Male	807	2.1%
Race <sup>3</sup>		
American Indian or Alaska Native	73	0.2%
Asian	1,241	3.2%
Black or African American	524	1.4%
Multi-racial	20	0.1%
Native Hawaiian or Other Pacific Islander	30	0.1%
Unknown	5,305	13.8%
White	31,215	81.3%
Hispanic origin		
Yes	503	1.3%
No	31,982	83.3%
Unknown	5,923	15.4%
Year		
2019	*****	*****
2020	8,628	22.5%
2021	13,082	34.1%
2022	13,352	34.8%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	88	0.2%
Alzheimer's Disease and related conditions	1,804	4.7%
Atrial Fibrillation	2,853	7.4%
Diabetes Mellitus	4,490	11.7%
Heart Failure	2,852	7.4%
Hyperlipidemia	14,880	38.7%
Hypertension	17,056	44.4%
Depression	8,998	23.4%
Ischemic Heart Disease	5,299	13.8%
Rheumatoid Arthritis/Osteoarthritis	16,406	42.7%
Stroke/TIA <sup>4</sup>	718	1.9%
Breast Cancer	2,219	5.8%
Colorectal Cancer	368	1.0%



**Table 1g. Aggregated Characteristics of Romosozumab-aqqg in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Romosozumab-aqqg	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	80	0.2%
Lung Cancer	406	1.1%
Endometrial Cancer	170	0.4%
Acquired Hypothyroidism	8,297	21.6%
Anemia	10,158	26.4%
Asthma	2,353	6.1%
Benign Prostatic Hyperplasia	156	0.4%
Chronic Kidney Disease	4,485	11.7%
COPD <sup>5</sup> and Bronchiectasis	4,167	10.8%
Glaucoma	1,943	5.1%
Osteoporosis	31,449	81.9%
Obesity: diagnosed or identified by weight management procedures	4,063	10.6%
Obesity: identified by weight management-related prescriptions	117	0.3%
Overweight	3,341	8.7%
Smoking: diagnosed or identified by smoking cessation procedures	7,040	18.3%
Smoking: identified by smoking-related prescriptions	143	0.4%
Alcohol Abuse or Dependence	565	1.5%
Drug Abuse or Dependence	1,354	3.5%
History of Cardiac Arrest	28	0.1%
History of Coronary Angioplasty or Bypass	852	2.2%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	18.5	13.1
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	5.3	8.8

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1h. Aggregated Characteristics of Erdafitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

<b>Erdafitinib</b>		
<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	566	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	70.0	10.4
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	126	22.3%
≥ 65 years	422	74.6%
Sex		
Female	204	36.0%
Male	362	64.0%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	29	5.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	139	24.6%
White	379	67.0%
Hispanic origin		
Yes	15	2.7%
No	398	70.3%
Unknown	153	27.0%
Year		
2019	141	24.9%
2020	189	33.4%
2021	138	24.4%
2022	98	17.3%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	22	3.9%
Atrial Fibrillation	61	10.8%
Diabetes Mellitus	125	22.1%
Heart Failure	60	10.6%
Hyperlipidemia	237	41.9%
Hypertension	363	64.1%
Depression	103	18.2%
Ischemic Heart Disease	164	29.0%
Rheumatoid Arthritis/Osteoarthritis	89	15.7%
Stroke/TIA <sup>4</sup>	19	3.4%
Breast Cancer	20	3.5%
Colorectal Cancer	26	4.6%

**Table 1h. Aggregated Characteristics of Erdafitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Erdafitinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	68	12.0%
Lung Cancer	53	9.4%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	89	15.7%
Anemia	381	67.3%
Asthma	20	3.5%
Benign Prostatic Hyperplasia	65	11.5%
Chronic Kidney Disease	412	72.8%
COPD <sup>5</sup> and Bronchiectasis	93	16.4%
Glaucoma	23	4.1%
Osteoporosis	17	3.0%
Obesity: diagnosed or identified by weight management procedures	91	16.1%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	68	12.0%
Smoking: diagnosed or identified by smoking cessation procedures	277	48.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	13	2.3%
Drug Abuse or Dependence	19	3.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	54	9.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	32.9	15.5
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	0.8	1.1
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	12.0	13.5

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1i. Aggregated Characteristics of Risankizumab-rzaa in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Risankizumab-rzaa	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	29,747	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	50.4	13.4
Age		
0-17 years	42	0.1%
18-24 years	1,452	4.9%
25-40 years	7,170	24.1%
41-64 years	15,604	52.5%
≥ 65 years	5,479	18.4%
Sex		
Female	14,823	49.8%
Male	14,924	50.2%
Race <sup>3</sup>		
American Indian or Alaska Native	82	0.3%
Asian	464	1.6%
Black or African American	841	2.8%
Multi-racial	230	0.8%
Native Hawaiian or Other Pacific Islander	26	0.1%
Unknown	19,137	64.3%
White	8,967	30.1%
Hispanic origin		
Yes	728	2.4%
No	8,097	27.2%
Unknown	20,922	70.3%
Year		
2019	2,963	10.0%
2020	7,772	26.1%
2021	8,592	28.9%
2022	10,409	35.0%
2023	11	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	50	0.2%
Alzheimer's Disease and related conditions	240	0.8%
Atrial Fibrillation	652	2.2%
Diabetes Mellitus	4,498	15.1%
Heart Failure	1,121	3.8%
Hyperlipidemia	5,251	17.7%
Hypertension	6,869	23.1%
Depression	5,206	17.5%
Ischemic Heart Disease	2,232	7.5%
Rheumatoid Arthritis/Osteoarthritis	4,785	16.1%
Stroke/TIA <sup>4</sup>	208	0.7%
Breast Cancer	222	0.7%
Colorectal Cancer	87	0.3%

**Table 1i. Aggregated Characteristics of Risankizumab-rzaa in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Risankizumab-rzaa	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	168	0.6%
Lung Cancer	52	0.2%
Endometrial Cancer	28	0.1%
Acquired Hypothyroidism	1,765	5.9%
Anemia	2,493	8.4%
Asthma	818	2.7%
Benign Prostatic Hyperplasia	430	1.4%
Chronic Kidney Disease	1,473	5.0%
COPD <sup>5</sup> and Bronchiectasis	1,290	4.3%
Glaucoma	369	1.2%
Osteoporosis	364	1.2%
Obesity: diagnosed or identified by weight management procedures	6,384	21.5%
Obesity: identified by weight management-related prescriptions	363	1.2%
Overweight	1,733	5.8%
Smoking: diagnosed or identified by smoking cessation procedures	4,087	13.7%
Smoking: identified by smoking-related prescriptions	311	1.0%
Alcohol Abuse or Dependence	715	2.4%
Drug Abuse or Dependence	831	2.8%
History of Cardiac Arrest	14	0.0%
History of Coronary Angioplasty or Bypass	574	1.9%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	9.7	10.8
Mean number of emergency room encounters	0.2	0.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.9	7.9

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

**Table 1j. Aggregated Characteristics of Tafamidis in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Tafamidis		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	4,927	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	79.2	7.6
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	4,695	95.3%
Sex		
Female	897	18.2%
Male	4,030	81.8%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	32	0.6%
Black or African American	936	19.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	697	14.1%
White	3,248	65.9%
Hispanic origin		
Yes	31	0.6%
No	3,989	81.0%
Unknown	907	18.4%
Year		
2019	1,292	26.2%
2020	*****	*****
2021	1,320	26.8%
2022	1,203	24.4%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	276	5.6%
Alzheimer's Disease and related conditions	327	6.6%
Atrial Fibrillation	2,901	58.9%
Diabetes Mellitus	1,243	25.2%
Heart Failure	4,734	96.1%
Hyperlipidemia	3,023	61.4%
Hypertension	3,757	76.3%
Depression	603	12.2%
Ischemic Heart Disease	2,953	59.9%
Rheumatoid Arthritis/Osteoarthritis	1,199	24.3%
Stroke/TIA <sup>4</sup>	288	5.8%
Breast Cancer	65	1.3%
Colorectal Cancer	49	1.0%

**Table 1j. Aggregated Characteristics of Tafamidis in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Tafamidis		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	468	9.5%
Lung Cancer	47	1.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	649	13.2%
Anemia	1,713	34.8%
Asthma	328	6.7%
Benign Prostatic Hyperplasia	952	19.3%
Chronic Kidney Disease	2,113	42.9%
COPD <sup>5</sup> and Bronchiectasis	645	13.1%
Glaucoma	347	7.0%
Osteoporosis	163	3.3%
Obesity: diagnosed or identified by weight management procedures	922	18.7%
Obesity: identified by weight management-related prescriptions	19	0.4%
Overweight	590	12.0%
Smoking: diagnosed or identified by smoking cessation procedures	1,484	30.1%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	81	1.6%
Drug Abuse or Dependence	65	1.3%
History of Cardiac Arrest	24	0.5%
History of Coronary Angioplasty or Bypass	798	16.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.5	13.7
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.6	0.9
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	8.1	11.4

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1k. Aggregated Characteristics of Alpelisib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

<b>Alpelisib</b>		
<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	4,484	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	66.0	10.5
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	95	2.1%
41-64 years	1,649	36.8%
≥ 65 years	2,706	60.3%
Sex		
Female	4,380	97.7%
Male	104	2.3%
Race <sup>3</sup>		
American Indian or Alaska Native	19	0.4%
Asian	109	2.4%
Black or African American	335	7.5%
Multi-racial	17	0.4%
Native Hawaiian or Other Pacific Islander	13	0.3%
Unknown	1,179	26.3%
White	2,812	62.7%
Hispanic origin		
Yes	146	3.3%
No	3,123	69.6%
Unknown	1,215	27.1%
Year		
2019	1,130	25.2%
2020	1,664	37.1%
2021	1,012	22.6%
2022	*****	*****
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	27	0.6%
Alzheimer's Disease and related conditions	76	1.7%
Atrial Fibrillation	255	5.7%
Diabetes Mellitus	773	17.2%
Heart Failure	406	9.1%
Hyperlipidemia	1,045	23.3%
Hypertension	1,669	37.2%
Depression	997	22.2%
Ischemic Heart Disease	473	10.5%
Rheumatoid Arthritis/Osteoarthritis	560	12.5%
Stroke/TIA <sup>4</sup>	102	2.3%
Breast Cancer	4,326	96.5%
Colorectal Cancer	75	1.7%



**Table 1k. Aggregated Characteristics of Alpelisib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

<b>Alpelisib</b>		
<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Prostate Cancer	17	0.4%
Lung Cancer	144	3.2%
Endometrial Cancer	47	1.0%
Acquired Hypothyroidism	626	14.0%
Anemia	1,836	40.9%
Asthma	202	4.5%
Benign Prostatic Hyperplasia	12	0.3%
Chronic Kidney Disease	745	16.6%
COPD <sup>5</sup> and Bronchiectasis	300	6.7%
Glaucoma	112	2.5%
Osteoporosis	316	7.0%
Obesity: diagnosed or identified by weight management procedures	651	14.5%
Obesity: identified by weight management-related prescriptions	17	0.4%
Overweight	367	8.2%
Smoking: diagnosed or identified by smoking cessation procedures	962	21.5%
Smoking: identified by smoking-related prescriptions	13	0.3%
Alcohol Abuse or Dependence	50	1.1%
Drug Abuse or Dependence	128	2.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	76	1.7%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	25.4	13.1
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.4
Mean number of other ambulatory encounters	8.7	12.9

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1I. Aggregated Characteristics of Polatuzumab Vedotin-piiq in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Polatuzumab Vedotin-piiq		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	2,469	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	73.0	9.4
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	336	13.6%
≥ 65 years	2,085	84.4%
Sex		
Female	1,028	41.6%
Male	1,441	58.4%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	48	1.9%
Black or African American	120	4.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	515	20.9%
White	1,775	71.9%
Hispanic origin		
Yes	59	2.4%
No	1,847	74.8%
Unknown	563	22.8%
Year		
2019	45	1.8%
2020	853	34.5%
2021	738	29.9%
2022	833	33.7%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	41	1.7%
Alzheimer's Disease and related conditions	129	5.2%
Atrial Fibrillation	447	18.1%
Diabetes Mellitus	630	25.5%
Heart Failure	558	22.6%
Hyperlipidemia	1,165	47.2%
Hypertension	1,521	61.6%
Depression	515	20.9%
Ischemic Heart Disease	797	32.3%
Rheumatoid Arthritis/Osteoarthritis	490	19.8%
Stroke/TIA <sup>4</sup>	115	4.7%
Breast Cancer	105	4.3%
Colorectal Cancer	78	3.2%

**Table 1I. Aggregated Characteristics of Polatuzumab Vedotin-piiq in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Polatuzumab Vedotin-piiq	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	135	5.5%
Lung Cancer	70	2.8%
Endometrial Cancer	13	0.5%
Acquired Hypothyroidism	392	15.9%
Anemia	1,677	67.9%
Asthma	129	5.2%
Benign Prostatic Hyperplasia	342	13.9%
Chronic Kidney Disease	824	33.4%
COPD <sup>5</sup> and Bronchiectasis	296	12.0%
Glaucoma	87	3.5%
Osteoporosis	127	5.1%
Obesity: diagnosed or identified by weight management procedures	502	20.3%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	344	13.9%
Smoking: diagnosed or identified by smoking cessation procedures	922	37.3%
Smoking: identified by smoking-related prescriptions	11	0.4%
Alcohol Abuse or Dependence	51	2.1%
Drug Abuse or Dependence	80	3.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	277	11.2%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	32.1	15.6
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	1.2	1.5
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	12.6	15.2

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1m. Aggregated Characteristics of Bremelanotide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

<b>Bremelanotide</b>		
<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	899	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	43.4	9.3
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	347	38.6%
41-64 years	530	59.0%
≥ 65 years	*****	*****
Sex		
Female	888	98.8%
Male	11	1.2%
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	811	90.2%
White	73	8.1%
Hispanic origin		
Yes	11	1.2%
No	12	1.3%
Unknown	876	97.4%
Year		
2019	71	7.9%
2020	179	19.9%
2021	347	38.6%
2022	302	33.6%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	33	3.7%
Heart Failure	*****	*****
Hyperlipidemia	53	5.9%
Hypertension	75	8.3%
Depression	242	26.9%
Ischemic Heart Disease	12	1.3%
Rheumatoid Arthritis/Osteoarthritis	70	7.8%
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	15	1.7%
Colorectal Cancer	*****	*****

**Table 1m. Aggregated Characteristics of Bremelanotide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Bremelanotide	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	62	6.9%
Anemia	65	7.2%
Asthma	14	1.6%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD <sup>5</sup> and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	138	15.4%
Obesity: identified by weight management-related prescriptions	29	3.2%
Overweight	92	10.2%
Smoking: diagnosed or identified by smoking cessation procedures	60	6.7%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	11	1.2%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	9.0	8.6
Mean number of emergency room encounters	0.1	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.0	3.2

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1n. Aggregated Characteristics of Selinexor in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Selinexor		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	2,314	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	70.4	9.4
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	517	22.3%
≥ 65 years	1,775	76.7%
Sex		
Female	1,103	47.7%
Male	1,211	52.3%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	40	1.7%
Black or African American	315	13.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	442	19.1%
White	1,506	65.1%
Hispanic origin		
Yes	61	2.6%
No	1,806	78.0%
Unknown	447	19.3%
Year		
2019	365	15.8%
2020	684	29.6%
2021	719	31.1%
2022	546	23.6%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	41	1.8%
Alzheimer's Disease and related conditions	99	4.3%
Atrial Fibrillation	357	15.4%
Diabetes Mellitus	506	21.9%
Heart Failure	525	22.7%
Hyperlipidemia	782	33.8%
Hypertension	1,328	57.4%
Depression	509	22.0%
Ischemic Heart Disease	499	21.6%
Rheumatoid Arthritis/Osteoarthritis	444	19.2%
Stroke/TIA <sup>4</sup>	85	3.7%
Breast Cancer	86	3.7%
Colorectal Cancer	31	1.3%

**Table 1n. Aggregated Characteristics of Selinexor in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Selinexor		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	94	4.1%
Lung Cancer	30	1.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	346	15.0%
Anemia	1,786	77.2%
Asthma	121	5.2%
Benign Prostatic Hyperplasia	217	9.4%
Chronic Kidney Disease	978	42.3%
COPD <sup>5</sup> and Bronchiectasis	253	10.9%
Glaucoma	86	3.7%
Osteoporosis	141	6.1%
Obesity: diagnosed or identified by weight management procedures	405	17.5%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	262	11.3%
Smoking: diagnosed or identified by smoking cessation procedures	704	30.4%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	31	1.3%
Drug Abuse or Dependence	119	5.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	130	5.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	38.6	19.3
Mean number of emergency room encounters	0.6	1.2
Mean number of inpatient hospital encounters	0.9	1.3
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	13.3	14.7

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1o. Aggregated Characteristics of Imipenem Cilastatin and Relebactam in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Imipenem Cilastatin and Relebactam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	312	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	64.5	14.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	101	32.4%
≥ 65 years	179	57.4%
Sex		
Female	136	43.6%
Male	176	56.4%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	55	17.6%
White	220	70.5%
Hispanic origin		
Yes	*****	*****
No	244	78.2%
Unknown	*****	*****
Year		
2019	*****	*****
2020	*****	*****
2021	173	55.4%
2022	98	31.4%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	12	3.8%
Alzheimer's Disease and related conditions	56	17.9%
Atrial Fibrillation	88	28.2%
Diabetes Mellitus	156	50.0%
Heart Failure	123	39.4%
Hyperlipidemia	147	47.1%
Hypertension	231	74.0%
Depression	138	44.2%
Ischemic Heart Disease	126	40.4%
Rheumatoid Arthritis/Osteoarthritis	84	26.9%
Stroke/TIA <sup>4</sup>	38	12.2%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****



**Table 1o. Aggregated Characteristics of Imipenem Cilastatin and Relebactam in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Imipenem Cilastatin and Relebactam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	17	5.4%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	75	24.0%
Anemia	223	71.5%
Asthma	33	10.6%
Benign Prostatic Hyperplasia	47	15.1%
Chronic Kidney Disease	194	62.2%
COPD <sup>5</sup> and Bronchiectasis	114	36.5%
Glaucoma	13	4.2%
Osteoporosis	36	11.5%
Obesity: diagnosed or identified by weight management procedures	100	32.1%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	34	10.9%
Smoking: diagnosed or identified by smoking cessation procedures	131	42.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	23	7.4%
Drug Abuse or Dependence	31	9.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	39	12.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.4	28.4
Mean number of emergency room encounters	1.6	4.4
Mean number of inpatient hospital encounters	1.8	1.8
Mean number of non-acute institutional encounters	0.5	1.0
Mean number of other ambulatory encounters	42.6	45.6

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1p. Aggregated Characteristics of Ferric Maltol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Ferric Maltol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	330	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	42.0	12.3
Age		
0-17 years	*****	*****
18-24 years	20	6.1%
25-40 years	140	42.4%
41-64 years	152	46.1%
≥ 65 years	*****	*****
Sex		
Female	303	91.8%
Male	27	8.2%
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	293	88.8%
White	18	5.5%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	315	95.5%
Year		
2019	0	0.0%
2020	0	0.0%
2021	31	9.4%
2022	299	90.6%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	23	7.0%
Heart Failure	*****	*****
Hyperlipidemia	46	13.9%
Hypertension	47	14.2%
Depression	38	11.5%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	21	6.4%
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%

**Table 1p. Aggregated Characteristics of Ferric Maltol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Ferric Maltol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	36	10.9%
Anemia	169	51.2%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	17	5.2%
COPD <sup>5</sup> and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	67	20.3%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	21	6.4%
Smoking: diagnosed or identified by smoking cessation procedures	26	7.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.8	10.1
Mean number of emergency room encounters	0.4	0.8
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN*
Mean number of other ambulatory encounters	3.1	2.9

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*NaN: Not a number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1q. Aggregated Characteristics of Darolutamide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Darolutamide		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	3,777	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	77.6	8.4
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	253	6.7%
≥ 65 years	3,524	93.3%
Sex		
Female	*****	*****
Male	*****	*****
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	45	1.2%
Black or African American	478	12.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	633	16.8%
White	2,609	69.1%
Hispanic origin		
Yes	53	1.4%
No	2,988	79.1%
Unknown	736	19.5%
Year		
2019	*****	*****
2020	1,022	27.1%
2021	1,295	34.3%
2022	1,220	32.3%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	38	1.0%
Alzheimer's Disease and related conditions	238	6.3%
Atrial Fibrillation	644	17.1%
Diabetes Mellitus	967	25.6%
Heart Failure	576	15.3%
Hyperlipidemia	1,626	43.1%
Hypertension	2,160	57.2%
Depression	505	13.4%
Ischemic Heart Disease	1,199	31.7%
Rheumatoid Arthritis/Osteoarthritis	630	16.7%
Stroke/TIA <sup>4</sup>	147	3.9%
Breast Cancer	374	9.9%
Colorectal Cancer	76	2.0%

**Table 1q. Aggregated Characteristics of Darolutamide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Darolutamide		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	3,745	99.2%
Lung Cancer	46	1.2%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	304	8.0%
Anemia	1,253	33.2%
Asthma	84	2.2%
Benign Prostatic Hyperplasia	503	13.3%
Chronic Kidney Disease	835	22.1%
COPD <sup>5</sup> and Bronchiectasis	314	8.3%
Glaucoma	202	5.3%
Osteoporosis	266	7.0%
Obesity: diagnosed or identified by weight management procedures	662	17.5%
Obesity: identified by weight management-related prescriptions	21	0.6%
Overweight	399	10.6%
Smoking: diagnosed or identified by smoking cessation procedures	982	26.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	68	1.8%
Drug Abuse or Dependence	74	2.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	393	10.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.3	12.1
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.6	8.7

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1r. Aggregated Characteristics of Pexidartinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Pexidartinib	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	85	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	41.2	12.2
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	35	41.2%
41-64 years	36	42.4%
≥ 65 years	*****	*****
Sex		
Female	57	67.1%
Male	28	32.9%
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	55	64.7%
White	18	21.2%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	57	67.1%
Year		
2019	15	17.6%
2020	32	37.6%
2021	24	28.2%
2022	14	16.5%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertension	12	14.1%
Depression	20	23.5%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA <sup>4</sup>	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%

**Table 1r. Aggregated Characteristics of Pexidartinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Pexidartinib	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	12	14.1%
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD <sup>5</sup> and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	11	12.9%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	15	17.6%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	14.0	9.2
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.6	6.1

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1s. Aggregated Characteristics of Pretomanid in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Pretomanid		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	23	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	53.2	13.0
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2019	*****	*****
2020	*****	*****
2021	*****	*****
2022	*****	*****
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%



**Table 1s. Aggregated Characteristics of Pretomanid in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Pretomanid		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD <sup>5</sup> and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.5	11.7
Mean number of emergency room encounters	0.6	0.9
Mean number of inpatient hospital encounters	0.8	0.8
Mean number of non-acute institutional encounters	0.0	NaN*
Mean number of other ambulatory encounters	18.3	20.3

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*NaN: Not a number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1t. Aggregated Characteristics of Pitolisant in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Pitolisant		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	2,703	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	43.0	13.7
Age		
0-17 years	29	1.1%
18-24 years	320	11.8%
25-40 years	986	36.5%
41-64 years	1,071	39.6%
≥ 65 years	297	11.0%
Sex		
Female	1,857	68.7%
Male	846	31.3%
Race <sup>3</sup>		
American Indian or Alaska Native	15	0.6%
Asian	18	0.7%
Black or African American	128	4.7%
Multi-racial	14	0.5%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	1,426	52.8%
White	1,102	40.8%
Hispanic origin		
Yes	52	1.9%
No	1,073	39.7%
Unknown	1,578	58.4%
Year		
2019	138	5.1%
2020	1,211	44.8%
2021	726	26.9%
2022	628	23.2%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	31	1.1%
Atrial Fibrillation	32	1.2%
Diabetes Mellitus	299	11.1%
Heart Failure	62	2.3%
Hyperlipidemia	375	13.9%
Hypertension	527	19.5%
Depression	1,162	43.0%
Ischemic Heart Disease	151	5.6%
Rheumatoid Arthritis/Osteoarthritis	354	13.1%
Stroke/TIA <sup>4</sup>	36	1.3%
Breast Cancer	16	0.6%
Colorectal Cancer	*****	*****

**Table 1t. Aggregated Characteristics of Pitolisant in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Pitolisant		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	14	0.5%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	243	9.0%
Anemia	306	11.3%
Asthma	189	7.0%
Benign Prostatic Hyperplasia	46	1.7%
Chronic Kidney Disease	94	3.5%
COPD <sup>5</sup> and Bronchiectasis	90	3.3%
Glaucoma	27	1.0%
Osteoporosis	38	1.4%
Obesity: diagnosed or identified by weight management procedures	586	21.7%
Obesity: identified by weight management-related prescriptions	26	1.0%
Overweight	204	7.5%
Smoking: diagnosed or identified by smoking cessation procedures	373	13.8%
Smoking: identified by smoking-related prescriptions	28	1.0%
Alcohol Abuse or Dependence	65	2.4%
Drug Abuse or Dependence	173	6.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	31	1.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.2	12.9
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.1	10.3

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1u. Aggregated Characteristics of Entrectinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

<b>Entrectinib</b>		
<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	331	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	64.4	12.6
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	116	35.0%
≥ 65 years	188	56.8%
Sex		
Female	195	58.9%
Male	136	41.1%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	46	13.9%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	108	32.6%
White	147	44.4%
Hispanic origin		
Yes	*****	*****
No	205	61.9%
Unknown	*****	*****
Year		
2019	28	8.5%
2020	110	33.2%
2021	98	29.6%
2022	95	28.7%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	15	4.5%
Atrial Fibrillation	39	11.8%
Diabetes Mellitus	67	20.2%
Heart Failure	42	12.7%
Hyperlipidemia	124	37.5%
Hypertension	152	45.9%
Depression	72	21.8%
Ischemic Heart Disease	79	23.9%
Rheumatoid Arthritis/Osteoarthritis	41	12.4%
Stroke/TIA <sup>4</sup>	28	8.5%
Breast Cancer	24	7.3%
Colorectal Cancer	15	4.5%

**Table 1u. Aggregated Characteristics of Entrectinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Entrectinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	*****	*****
Lung Cancer	278	84.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	51	15.4%
Anemia	135	40.8%
Asthma	33	10.0%
Benign Prostatic Hyperplasia	23	6.9%
Chronic Kidney Disease	75	22.7%
COPD <sup>5</sup> and Bronchiectasis	65	19.6%
Glaucoma	12	3.6%
Osteoporosis	18	5.4%
Obesity: diagnosed or identified by weight management procedures	62	18.7%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	29	8.8%
Smoking: diagnosed or identified by smoking cessation procedures	124	37.5%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	12	3.6%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	23.3	13.4
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.7	1.0
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	10.8	11.6

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1v. Aggregated Characteristics of Fedratinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Fedratinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	807	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	73.1	8.3
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	692	85.7%
Sex		
Female	388	48.1%
Male	419	51.9%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	54	6.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	110	13.6%
White	619	76.7%
Hispanic origin		
Yes	*****	*****
No	662	82.0%
Unknown	*****	16.9%
Year		
2019	170	21.1%
2020	270	33.5%
2021	212	26.3%
2022	*****	*****
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	35	4.3%
Atrial Fibrillation	94	11.6%
Diabetes Mellitus	161	20.0%
Heart Failure	185	22.9%
Hyperlipidemia	296	36.7%
Hypertension	476	59.0%
Depression	169	20.9%
Ischemic Heart Disease	222	27.5%
Rheumatoid Arthritis/Osteoarthritis	127	15.7%
Stroke/TIA <sup>4</sup>	23	2.9%
Breast Cancer	32	4.0%
Colorectal Cancer	*****	*****

**Table 1v. Aggregated Characteristics of Fedratinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Fedratinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	41	5.1%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	165	20.4%
Anemia	764	94.7%
Asthma	32	4.0%
Benign Prostatic Hyperplasia	64	7.9%
Chronic Kidney Disease	298	36.9%
COPD <sup>5</sup> and Bronchiectasis	113	14.0%
Glaucoma	30	3.7%
Osteoporosis	34	4.2%
Obesity: diagnosed or identified by weight management procedures	105	13.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	93	11.5%
Smoking: diagnosed or identified by smoking cessation procedures	252	31.2%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	17	2.1%
Drug Abuse or Dependence	27	3.3%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	60	7.4%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	27.0	15.8
Mean number of emergency room encounters	0.7	1.6
Mean number of inpatient hospital encounters	0.5	1.0
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	8.7	13.2

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1w. Aggregated Characteristics of Upadacitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Upadacitinib	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	23,228	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	57.0	12.2
Age		
0-17 years	91	0.4%
18-24 years	446	1.9%
25-40 years	2,412	10.4%
41-64 years	13,502	58.1%
≥ 65 years	6,777	29.2%
Sex		
Female	18,421	79.3%
Male	4,807	20.7%
Race <sup>3</sup>		
American Indian or Alaska Native	161	0.7%
Asian	359	1.5%
Black or African American	1,787	7.7%
Multi-racial	120	0.5%
Native Hawaiian or Other Pacific Islander	40	0.2%
Unknown	11,334	48.8%
White	9,427	40.6%
Hispanic origin		
Yes	1,156	5.0%
No	10,367	44.6%
Unknown	11,705	50.4%
Year		
2019	*****	*****
2020	7,925	34.1%
2021	7,300	31.4%
2022	6,653	28.6%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	65	0.3%
Alzheimer's Disease and related conditions	254	1.1%
Atrial Fibrillation	657	2.8%
Diabetes Mellitus	3,819	16.4%
Heart Failure	1,192	5.1%
Hyperlipidemia	5,609	24.1%
Hypertension	7,723	33.2%
Depression	5,457	23.5%
Ischemic Heart Disease	2,309	9.9%
Rheumatoid Arthritis/Osteoarthritis	20,187	86.9%
Stroke/TIA <sup>4</sup>	232	1.0%
Breast Cancer	279	1.2%
Colorectal Cancer	55	0.2%



**Table 1w. Aggregated Characteristics of Upadacitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Patient Characteristics	Upadacitinib	
	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	85	0.4%
Lung Cancer	66	0.3%
Endometrial Cancer	23	0.1%
Acquired Hypothyroidism	2,711	11.7%
Anemia	4,319	18.6%
Asthma	1,344	5.8%
Benign Prostatic Hyperplasia	302	1.3%
Chronic Kidney Disease	1,682	7.2%
COPD <sup>5</sup> and Bronchiectasis	1,724	7.4%
Glaucoma	527	2.3%
Osteoporosis	2,256	9.7%
Obesity: diagnosed or identified by weight management procedures	5,943	25.6%
Obesity: identified by weight management-related prescriptions	247	1.1%
Overweight	2,133	9.2%
Smoking: diagnosed or identified by smoking cessation procedures	3,988	17.2%
Smoking: identified by smoking-related prescriptions	244	1.1%
Alcohol Abuse or Dependence	295	1.3%
Drug Abuse or Dependence	1,172	5.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	473	2.0%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	13.3	10.7
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.9	9.6

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1x. Aggregated Characteristics of Lefamulin in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Lefamulin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	170	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	64.1	13.0
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	65	38.2%
≥ 65 years	89	52.4%
Sex		
Female	103	60.6%
Male	67	39.4%
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	67	39.4%
White	89	52.4%
Hispanic origin		
Yes	*****	*****
No	90	52.9%
Unknown	*****	*****
Year		
2019	*****	*****
2020	49	28.8%
2021	78	45.9%
2022	*****	*****
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	18	10.6%
Diabetes Mellitus	51	30.0%
Heart Failure	33	19.4%
Hyperlipidemia	71	41.8%
Hypertension	87	51.2%
Depression	49	28.8%
Ischemic Heart Disease	52	30.6%
Rheumatoid Arthritis/Osteoarthritis	42	24.7%
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****

**Table 1x. Aggregated Characteristics of Lefamulin in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Lefamulin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	31	18.2%
Anemia	61	35.9%
Asthma	29	17.1%
Benign Prostatic Hyperplasia	11	6.5%
Chronic Kidney Disease	33	19.4%
COPD <sup>5</sup> and Bronchiectasis	54	31.8%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	42	24.7%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	16	9.4%
Smoking: diagnosed or identified by smoking cessation procedures	57	33.5%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	12	7.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	13	7.6%
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	18.4	13.2
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.4	1.3
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.2	18.9

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1y. Aggregated Characteristics of Ga-68-DOTATOC in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Ga-68-DOTATOC		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	183	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	67.6	10.2
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	133	72.7%
Sex		
Female	98	53.6%
Male	85	46.4%
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	139	76.0%
Hispanic origin		
Yes	*****	*****
No	129	70.5%
Unknown	*****	*****
Year		
2019	0	0.0%
2020	34	18.6%
2021	89	48.6%
2022	60	32.8%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	11	6.0%
Diabetes Mellitus	51	27.9%
Heart Failure	26	14.2%
Hyperlipidemia	53	29.0%
Hypertension	87	47.5%
Depression	39	21.3%
Ischemic Heart Disease	27	14.8%
Rheumatoid Arthritis/Osteoarthritis	22	12.0%
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****

**Table 1y. Aggregated Characteristics of Ga-68-DOTATOC in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Ga-68-DOTATOC		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	28	15.3%
Anemia	48	26.2%
Asthma	12	6.6%
Benign Prostatic Hyperplasia	15	8.2%
Chronic Kidney Disease	35	19.1%
COPD <sup>5</sup> and Bronchiectasis	13	7.1%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	40	21.9%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	11	6.0%
Smoking: diagnosed or identified by smoking cessation procedures	43	23.5%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.4	12.0
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.3	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.9	5.6

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1z. Aggregated Characteristics of Istradefylline in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

<b>Istradefylline</b>		
<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	4,221	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	73.2	8.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	12	0.3%
41-64 years	576	13.6%
≥ 65 years	3,633	86.1%
Sex		
Female	1,710	40.5%
Male	2,511	59.5%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	121	2.9%
Black or African American	106	2.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	780	18.5%
White	3,198	75.8%
Hispanic origin		
Yes	114	2.7%
No	3,272	77.5%
Unknown	835	19.8%
Year		
2019	103	2.4%
2020	1,923	45.6%
2021	1,447	34.3%
2022	748	17.7%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	14	0.3%
Alzheimer's Disease and related conditions	643	15.2%
Atrial Fibrillation	329	7.8%
Diabetes Mellitus	663	15.7%
Heart Failure	355	8.4%
Hyperlipidemia	1,396	33.1%
Hypertension	1,732	41.0%
Depression	1,247	29.5%
Ischemic Heart Disease	811	19.2%
Rheumatoid Arthritis/Osteoarthritis	844	20.0%
Stroke/TIA <sup>4</sup>	169	4.0%
Breast Cancer	71	1.7%
Colorectal Cancer	27	0.6%

**Table 1z. Aggregated Characteristics of Istradefylline in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

Istradefylline		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Prostate Cancer	155	3.7%
Lung Cancer	13	0.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	447	10.6%
Anemia	805	19.1%
Asthma	108	2.6%
Benign Prostatic Hyperplasia	417	9.9%
Chronic Kidney Disease	408	9.7%
COPD <sup>5</sup> and Bronchiectasis	205	4.9%
Glaucoma	207	4.9%
Osteoporosis	267	6.3%
Obesity: diagnosed or identified by weight management procedures	425	10.1%
Obesity: identified by weight management-related prescriptions	15	0.4%
Overweight	370	8.8%
Smoking: diagnosed or identified by smoking cessation procedures	508	12.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	35	0.8%
Drug Abuse or Dependence	77	1.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	208	4.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.8	14.2
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	6.1	13.2

<sup>1</sup>Value represents standard deviation where no % follows the value.

<sup>2</sup>N/A : Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Caplacizumab-yhdp</i>	591	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.	.
<i>Brexanolone</i>	157	157	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	56,376	52,988	94.0%	*****	*****	2,564	4.5%	*****	*****
<i>Siponimod</i>	18,219	17,174	94.3%	271	1.5%	762	4.2%	12	0.1%
<i>Romozosumab-aqqg</i>	290,335	289,881	99.8%	102	0.0%	352	0.1%	0	0.0%
<i>Erdafitinib</i>	2,270	2,178	95.9%	92	4.1%	0	0.0%	0	0.0%
<i>Risankizumab-rzaa</i>	130,482	58,112	44.5%	18,005	13.8%	54,258	41.6%	107	0.1%
<i>Tafamidis</i>	56,168	52,401	93.3%	*****	*****	3,400	6.1%	*****	*****
<i>Alpelisib</i>	20,372	20,109	98.7%	248	1.2%	*****	*****	*****	*****
<i>Polatuzumab Vedotin-piiq</i>	8,720	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Bremelanotide</i>	1,534	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Selinexor</i>	6,468	6,349	98.2%	104	1.6%	*****	*****	*****	*****
<i>Imipenem Cilastatin and Relebactam</i>	1,614	1,614	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ferric Maltol</i>	675	649	96.1%	*****	*****	*****	*****	0	0.0%
<i>Darolutamide</i>	30,605	30,454	99.5%	73	0.2%	78	0.3%	0	0.0%
<i>Pexidartinib</i>	618	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Pretomanid</i>	142	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Pitolisant</i>	19,432	18,958	97.6%	311	1.6%	*****	*****	*****	*****
<i>Entrectinib</i>	1,491	1,468	98.5%	*****	1.4%	*****	*****	0	0.0%
<i>Fedratinib</i>	5,451	5,428	99.6%	11	0.2%	12	0.2%	0	0.0%
<i>Upadacitinib</i>	180,403	175,945	97.5%	*****	*****	3,807	2.1%	*****	*****
<i>Lefamulin</i>	325	325	100.0%	0	0.0%	0	0.0%	0	0.0%



**Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Ga-68-DOTATOC</i>	205	205	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Istradefylline</i>	27,278	22,678	83.1%	****	****	4,126	15.1%	****	****

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>PrabotulinumtoxinA-xvfs</i>	****	****	****	****	****	****	****	****
<i>Caplacizumab-yhdp</i>	591	1	1	10	30	68	14.5	13.5
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.
<i>Brexanolone</i>	157	1	1	1	1	30	1.2	2.3
<i>Solriamfetol</i>	56,376	1	30	30	30	180	31.7	13.7
<i>Siponimod</i>	18,219	1	30	30	30	180	31.5	13.1
<i>Romosozumab-aqqg</i>	290,335	1	1	1	1	90	3.1	7.9
<i>Erdafitinib</i>	2,270	1	28	28	28	60	27.3	7.4
<i>Risankizumab-rzaa</i>	130,482	1	28	31	84	198	51.2	28.2
<i>Tafamidis</i>	56,168	1	30	30	30	180	33.0	14.9
<i>Alpelisib</i>	20,372	1	28	28	28	118	27.7	4.8
<i>Polatuzumab Vedotin-piiq</i>	8,720	1	1	1	1	56	1.1	1.3
<i>Bremelanotide</i>	1,534	1	15	15	28	60	19.4	7.5
<i>Selinexor</i>	6,468	1	28	28	28	168	27.1	6.2
<i>Imipenem Cilastatin and Relebactam</i>	1,614	1	1	1	1	28	1.6	2.0
<i>Ferric Maltol</i>	675	1	30	30	30	90	28.9	12.0
<i>Darolutamide</i>	30,605	1	30	30	30	90	29.2	5.4
<i>Pexidartinib</i>	618	2	30	30	30	60	28.9	4.7
<i>Pretomanid</i>	142	6	26	26	26	52	25.7	3.9
<i>Pitolisant</i>	19,432	1	30	30	30	180	29.5	7.8
<i>Entrectinib</i>	1,491	1	30	30	30	90	27.8	7.6
<i>Fedratinib</i>	5,451	1	30	30	30	90	29.2	5.1
<i>Upadacitinib</i>	180,403	1	30	30	30	180	30.4	9.8
<i>Lefamulin</i>	325	1	1	3	5	30	4.0	4.1
<i>Ga-68-DOTATOC</i>	205	1	1	1	1	1	1.0	0.0
<i>Istradefylline</i>	27,278	1	30	30	30	180	38.5	22.0

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.



**Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	591	*****	*****	*****	*****	*****	*****	0	NaN*
Female	332	*****	*****	0	0.0%	*****	*****	0	NaN*
Male	259	*****	*****	*****	*****	0	0.0%	0	NaN*
<b>Triclabendazole</b>	0	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	157	157	100.0%	0	NaN*	0	NaN*	0	NaN*
Female	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
Male	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
<b>Solriamfetol</b>	56,376	52,988	100.0%	*****	*****	2,564	100.0%	*****	*****
Female	33,949	32,109	60.6%	*****	*****	1,404	54.8%	*****	*****
Male	22,427	20,879	39.4%	*****	*****	1,160	45.2%	*****	*****
<b>Siponimod</b>	18,219	17,174	100.0%	271	100.0%	762	100.0%	12	100.0%
Female	13,756	12,955	75.4%	*****	*****	584	76.6%	*****	*****
Male	4,463	4,219	24.6%	*****	*****	178	23.4%	*****	*****
<b>Romosozumab-aqqg</b>	290,335	289,881	100.0%	102	100.0%	352	100.0%	0	NaN*
Female	284,860	284,440	98.1%	88	86.3%	332	94.3%	0	NaN*
Male	5,475	5,441	1.9%	14	13.7%	20	5.7%	0	NaN*
<b>Erdafitinib</b>	2,270	2,178	100.0%	92	100.0%	0	NaN*	0	NaN*

**Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Female	805	770	35.4%	35	38.0%	0	NaN*	0	NaN*
Male	1,465	1,408	64.6%	57	62.0%	0	NaN*	0	NaN*
<b>Risankizumab-rzaa</b>	<b>130,482</b>	<b>58,112</b>	<b>100.0%</b>	<b>18,005</b>	<b>100.0%</b>	<b>54,258</b>	<b>100.0%</b>	<b>107</b>	<b>100.0%</b>
Female	63,530	28,387	48.8%	8,316	46.2%	26,769	49.3%	58	54.2%
Male	66,952	29,725	51.2%	9,689	53.8%	27,489	50.7%	49	45.8%
<b>Tafamidis</b>	<b>56,168</b>	<b>52,401</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>3,400</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
Female	8,962	8,331	15.9%	*****	*****	568	16.7%	0	0.0%
Male	47,206	44,070	84.1%	*****	*****	2,832	83.3%	*****	*****
<b>Alpelisib</b>	<b>20,372</b>	<b>20,109</b>	<b>100.0%</b>	<b>248</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	20,015	*****	*****	*****	*****	*****	*****	*****	*****
Male	357	*****	*****	*****	*****	0	0.0%	*****	*****
<b>Polatuzumab Vedotin-piiq</b>	<b>8,720</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	3,689	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	5,031	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>1,534</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	1,484	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	50	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>6,468</b>	<b>6,349</b>	<b>100.0%</b>	<b>104</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	3,271	3,230	50.9%	*****	*****	*****	*****	*****	*****
Male	3,197	3,119	49.1%	*****	*****	*****	*****	*****	*****
<b>Imipenem Cilastatin and Relebactam</b>	<b>1,614</b>	<b>1,614</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	384	384	23.8%	0	NaN*	0	NaN*	0	NaN*

**Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	1,230	1,230	76.2%	0	NaN*	0	NaN*	0	NaN*
<b>Ferric Maltol</b>	<b>675</b>	<b>649</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
Female	618	*****	*****	*****	*****	*****	*****	0	NaN*
Male	57	*****	*****	*****	*****	*****	*****	0	NaN*
<b>Darolutamide</b>	<b>30,605</b>	<b>30,454</b>	<b>100.0%</b>	<b>73</b>	<b>100.0%</b>	<b>78</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
Female	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
Male	*****	*****	*****	73	100.0%	78	100.0%	0	NaN*
<b>Pexidartinib</b>	<b>618</b>	*****	*****	*****	*****	*****	*****	*****	*****
Female	377	*****	*****	*****	*****	*****	*****	*****	*****
Male	241	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pretomanid</b>	<b>142</b>	*****	*****	*****	*****	*****	*****	*****	*****
Female	92	*****	*****	*****	*****	*****	*****	*****	*****
Male	50	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pitolisant</b>	<b>19,432</b>	<b>18,958</b>	<b>100.0%</b>	<b>311</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	13,099	12,802	67.5%	177	56.9%	*****	*****	*****	*****
Male	6,333	6,156	32.5%	134	43.1%	*****	*****	*****	*****
<b>Entrectinib</b>	<b>1,491</b>	<b>1,468</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
Female	995	*****	*****	*****	*****	*****	*****	0	NaN*
Male	496	*****	*****	*****	*****	*****	*****	0	NaN*
<b>Fedratinib</b>	<b>5,451</b>	<b>5,428</b>	<b>100.0%</b>	<b>11</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
Female	2,613	*****	*****	*****	*****	*****	*****	0	NaN*
Male	2,838	*****	*****	*****	*****	*****	*****	0	NaN*

**Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Upadacitinib</b>	<b>180,403</b>	<b>175,945</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>3,807</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
Female	145,551	142,021	80.7%	*****	*****	3,043	79.9%	*****	*****
Male	34,852	33,924	19.3%	*****	*****	764	20.1%	*****	*****
<b>Lefamulin</b>	<b>325</b>	<b>325</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	169	169	52.0%	0	NaN*	0	NaN*	0	NaN*
Male	156	156	48.0%	0	NaN*	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>205</b>	<b>205</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	106	106	51.7%	0	NaN*	0	NaN*	0	NaN*
Male	99	99	48.3%	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>27,278</b>	<b>22,678</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>4,126</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
Female	10,961	9,141	40.3%	*****	*****	1,660	40.2%	*****	*****
Male	16,317	13,537	59.7%	*****	*****	2,466	59.8%	*****	*****

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>591</b>	<b>1</b>	<b>1</b>	<b>10</b>	<b>30</b>	<b>68</b>	<b>14.5</b>	<b>13.5</b>
Female	332	1	1	20	30	68	17.1	13.0
Male	259	1	1	1	30	60	11.3	13.4
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>157</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>30</b>	<b>1.2</b>	<b>2.3</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Solriamfetol</b>	<b>56,376</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>31.7</b>	<b>13.7</b>
Female	33,949	1	30	30	30	180	31.4	13.2
Male	22,427	1	30	30	30	150	32.0	14.5
<b>Siponimod</b>	<b>18,219</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>31.5</b>	<b>13.1</b>
Female	13,756	1	30	30	30	95	31.5	13.1
Male	4,463	1	30	30	30	180	31.3	13.2
<b>Romosozumab-aqqg</b>	<b>290,335</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>90</b>	<b>3.1</b>	<b>7.9</b>
Female	284,860	1	1	1	1	90	3.1	7.8
Male	5,475	1	1	1	1	90	5.4	11.3
<b>Erdafitinib</b>	<b>2,270</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>60</b>	<b>27.3</b>	<b>7.4</b>
Female	805	1	28	28	28	60	27.0	7.2
Male	1,465	1	28	28	28	58	27.4	7.6



**Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>130,482</b>	<b>1</b>	<b>28</b>	<b>31</b>	<b>84</b>	<b>198</b>	<b>51.2</b>	<b>28.2</b>
Female	63,530	1	28	31	84	198	51.4	28.3
Male	66,952	1	28	31	84	168	50.9	28.1
<b>Tafamidis</b>	<b>56,168</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>33.0</b>	<b>14.9</b>
Female	8,962	1	30	30	30	90	33.1	15.2
Male	47,206	1	30	30	30	180	33.0	14.9
<b>Alpelisib</b>	<b>20,372</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>118</b>	<b>27.7</b>	<b>4.8</b>
Female	20,015	1	28	28	28	118	27.7	4.7
Male	357	1	28	28	28	114	26.7	7.4
<b>Polatuzumab Vedotin-piiq</b>	<b>8,720</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>56</b>	<b>1.1</b>	<b>1.3</b>
Female	3,689	1	1	1	1	42	1.1	1.1
Male	5,031	1	1	1	1	56	1.1	1.4
<b>Bremelanotide</b>	<b>1,534</b>	<b>1</b>	<b>15</b>	<b>15</b>	<b>28</b>	<b>60</b>	<b>19.4</b>	<b>7.5</b>
Female	1,484	1	15	15	28	60	19.5	7.5
Male	50	1	15	15	15	30	17.1	5.9
<b>Selinexor</b>	<b>6,468</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>168</b>	<b>27.1</b>	<b>6.2</b>
Female	3,271	1	28	28	28	168	27.0	6.0
Male	3,197	1	28	28	28	140	27.3	6.4
<b>Imipenem Cilastatin and Relebactam</b>	<b>1,614</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>28</b>	<b>1.6</b>	<b>2.0</b>
Female	384	1	1	1	1	13	2.2	2.7
Male	1,230	1	1	1	1	28	1.4	1.7
<b>Ferric Maltol</b>	<b>675</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>28.9</b>	<b>12.0</b>
Female	618	1	30	30	30	90	28.8	11.8
Male	57	4	30	30	30	90	29.5	14.0

**Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>30,605</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>29.2</b>	<b>5.4</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pexidartinib</b>	<b>618</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>28.9</b>	<b>4.7</b>
Female	377	2	30	30	30	60	28.8	5.2
Male	241	2	30	30	30	30	29.1	3.8
<b>Pretomanid</b>	<b>142</b>	<b>6</b>	<b>26</b>	<b>26</b>	<b>26</b>	<b>52</b>	<b>25.7</b>	<b>3.9</b>
Female	92	6	26	26	26	52	26.0	4.2
Male	50	9	26	26	26	26	25.3	3.2
<b>Pitolisant</b>	<b>19,432</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>29.5</b>	<b>7.8</b>
Female	13,099	1	30	30	30	180	29.4	7.9
Male	6,333	1	30	30	30	112	29.6	7.6
<b>Entrectinib</b>	<b>1,491</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>27.8</b>	<b>7.6</b>
Female	995	1	30	30	30	90	27.7	7.7
Male	496	1	30	30	30	90	28.2	7.4
<b>Fedratinib</b>	<b>5,451</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>29.2</b>	<b>5.1</b>
Female	2,613	1	30	30	30	90	29.2	5.7
Male	2,838	1	30	30	30	90	29.1	4.5
<b>Upadacitinib</b>	<b>180,403</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>30.4</b>	<b>9.8</b>
Female	145,551	1	30	30	30	180	30.4	9.7
Male	34,852	1	30	30	30	106	30.3	10.1
<b>Lefamulin</b>	<b>325</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>30</b>	<b>4.0</b>	<b>4.1</b>
Female	169	1	1	5	5	28	4.6	4.3
Male	156	1	1	1	5	30	3.3	3.7

**Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Ga-68-DOTATOC</b>	<b>205</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
Female	106	1	1	1	1	1	1.0	0.0
Male	99	1	1	1	1	1	1.0	0.0
<b>Istradefylline</b>	<b>27,278</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>38.5</b>	<b>22.0</b>
Female	10,961	1	30	30	30	97	38.5	22.0
Male	16,317	1	30	30	30	180	38.6	22.0

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>591</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	12	*****	*****	0	0.0%	*****	*****	0	NaN*
18-24 years	26	26	*****	0	0.0%	0	0.0%	0	NaN*
25-40 years	261	261	*****	0	0.0%	0	0.0%	0	NaN*
41-64 years	209	*****	*****	*****	*****	0	0.0%	0	NaN*
≥ 65 years	83	83	*****	0	0.0%	0	0.0%	0	NaN*
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>157</b>	<b>157</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
25-40 years	134	134	85.4%	0	NaN*	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
<b>Solriamfetol</b>	<b>56,376</b>	<b>52,988</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>2,564</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	315	295	0.6%	*****	*****	*****	*****	*****	*****
18-24 years	4,243	3,976	7.5%	*****	*****	*****	*****	*****	*****
25-40 years	14,937	14,348	27.1%	*****	*****	408	15.9%	*****	*****
41-64 years	27,853	26,286	49.6%	*****	*****	1,209	47.2%	*****	*****
≥ 65 years	9,028	8,083	15.3%	*****	*****	742	28.9%	*****	*****
<b>Siponimod</b>	<b>18,219</b>	<b>17,174</b>	<b>100.0%</b>	<b>271</b>	<b>100.0%</b>	<b>762</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	177	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	3,101	2,998	17.5%	41	15.1%	*****	*****	*****	*****
41-64 years	12,593	11,882	69.2%	*****	*****	522	68.5%	*****	*****
≥ 65 years	2,348	*****	*****	45	16.6%	179	23.5%	*****	*****
<b>Romosozumab-aqqg</b>	<b>290,335</b>	<b>289,881</b>	<b>100.0%</b>	<b>102</b>	<b>100.0%</b>	<b>352</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
25-40 years	487	*****	*****	0	0.0%	*****	*****	0	NaN*
41-64 years	23,915	23,838	8.2%	*****	*****	*****	*****	0	NaN*
≥ 65 years	265,856	265,480	91.6%	*****	*****	*****	*****	0	NaN*
<b>Erdafitinib</b>	<b>2,270</b>	<b>2,178</b>	<b>100.0%</b>	<b>92</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	50	*****	*****	*****	*****	0	NaN*	0	NaN*

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	556	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	1,648	1,590	73.0%	58	63.0%	0	NaN*	0	NaN*
<b>Risankizumab-rzaa</b>	<b>130,482</b>	<b>58,112</b>	<b>100.0%</b>	<b>18,005</b>	<b>100.0%</b>	<b>54,258</b>	<b>100.0%</b>	<b>107</b>	<b>100.0%</b>
0-17 years	207	88	0.2%	25	0.1%	94	0.2%	0	0.0%
18-24 years	5,988	2,967	5.1%	*****	*****	2,061	3.8%	*****	*****
25-40 years	30,466	14,494	24.9%	4,941	27.4%	11,002	20.3%	29	27.1%
41-64 years	70,780	32,416	55.8%	10,600	58.9%	27,716	51.1%	48	44.9%
≥ 65 years	23,041	8,147	14.0%	*****	*****	13,385	24.7%	*****	*****
<b>Tafamidis</b>	<b>56,168</b>	<b>52,401</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>3,400</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	20	20	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	2,177	2,117	4.0%	*****	*****	*****	*****	0	0.0%
≥ 65 years	53,971	50,264	95.9%	*****	*****	*****	*****	*****	*****
<b>Alpelisib</b>	<b>20,372</b>	<b>20,109</b>	<b>100.0%</b>	<b>248</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
0-17 years	105	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	25	*****	*****	0	0.0%	0	0.0%	*****	*****
25-40 years	368	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	8,159	8,085	40.2%	*****	*****	*****	*****	*****	*****
≥ 65 years	11,715	11,532	57.3%	*****	*****	*****	*****	*****	*****
<b>Polatuzumab Vedotin-piiq</b>	<b>8,720</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	*****	*****	0	0.0%	0	NaN*	0	NaN*
18-24 years	17	*****	*****	0	0.0%	0	NaN*	0	NaN*

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	111	111	*****	0	0.0%	0	NaN*	0	NaN*
41-64 years	925	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	7,667	7,667	*****	0	0.0%	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>1,534</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	17	17	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	577	577	*****	0	0.0%	0	NaN*	0	NaN*
41-64 years	915	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	25	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>6,468</b>	<b>6,349</b>	<b>100.0%</b>	<b>104</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	34	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	1,573	1,549	24.4%	*****	*****	*****	*****	0	0.0%
≥ 65 years	4,849	4,755	74.9%	80	76.9%	*****	*****	*****	*****
<b>Imipenem Cilastatin and Relebactam</b>	<b>1,614</b>	<b>1,614</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
25-40 years	764	764	47.3%	0	NaN*	0	NaN*	0	NaN*
41-64 years	387	387	24.0%	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	444	444	27.5%	0	NaN*	0	NaN*	0	NaN*
<b>Ferric Maltol</b>	<b>675</b>	<b>649</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
18-24 years	40	*****	*****	*****	*****	*****	*****	0	NaN*
25-40 years	268	*****	*****	*****	*****	*****	*****	0	NaN*
41-64 years	333	317	48.8%	*****	*****	*****	*****	0	NaN*
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN*
<b>Darolutamide</b>	<b>30,605</b>	<b>30,454</b>	<b>100.0%</b>	<b>73</b>	<b>100.0%</b>	<b>78</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*
41-64 years	1,678	*****	*****	*****	*****	*****	*****	0	NaN*
≥ 65 years	28,927	*****	*****	*****	*****	*****	*****	0	NaN*
<b>Pexidartinib</b>	<b>618</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	245	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	293	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Pretomanid</b>	<b>142</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
41-64 years	46	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	49	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Pitolisant</b>	<b>19,432</b>	<b>18,958</b>	<b>100.0%</b>	<b>311</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>



**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
0-17 years	220	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	2,339	2,279	12.0%	*****	*****	20	*****	*****	*****
25-40 years	6,587	6,427	33.9%	129	41.5%	31	*****	0	0.0%
41-64 years	8,149	7,948	41.9%	135	43.4%	*****	*****	*****	*****
≥ 65 years	2,137	*****	*****	*****	*****	*****	*****	*****	*****
<b>Entrectinib</b>	<b>1,491</b>	<b>1,468</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN*
25-40 years	105	*****	*****	*****	*****	0	0.0%	0	NaN*
41-64 years	567	*****	*****	*****	*****	0	0.0%	0	NaN*
≥ 65 years	781	*****	*****	*****	*****	*****	*****	0	NaN*
<b>Fedratinib</b>	<b>5,451</b>	<b>5,428</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*
25-40 years	92	92	1.7%	0	0.0%	0	0.0%	0	NaN*
41-64 years	722	*****	*****	*****	*****	0	0.0%	0	NaN*
≥ 65 years	4,637	*****	*****	*****	*****	*****	*****	0	NaN*
<b>Upadacitinib</b>	<b>180,403</b>	<b>175,945</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>3,807</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	335	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	2,305	*****	*****	17	*****	*****	*****	0	0.0%
25-40 years	15,067	14,756	8.4%	81	*****	230	6.0%	0	0.0%
41-64 years	106,633	104,452	59.4%	*****	*****	1,838	48.3%	*****	*****
≥ 65 years	56,063	54,144	30.8%	208	*****	1,711	44.9%	0	0.0%

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Lefamulin</b>	<b>325</b>	<b>325</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
41-64 years	160	160	49.2%	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	143	143	44.0%	0	NaN*	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>205</b>	<b>205</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	151	151	73.7%	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>27,278</b>	<b>22,678</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>4,126</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	114	*****	*****	0	0.0%	*****	*****	0	0.0%
41-64 years	3,650	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	23,514	19,483	85.9%	*****	*****	*****	*****	*****	*****

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>591</b>	<b>1</b>	<b>1</b>	<b>10</b>	<b>30</b>	<b>68</b>	<b>14.5</b>	<b>13.5</b>
0-17 years	12	1	26	29	30	68	27.5	16.4
18-24 years	26	1	1	5	17	30	10.8	10.9
25-40 years	261	1	1	1	28	30	10.7	12.6
41-64 years	209	1	7	30	30	60	19.7	12.8
≥ 65 years	83	1	1	1	28	30	12.8	13.3
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>157</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>30</b>	<b>1.2</b>	<b>2.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	134	1	1	1	1	30	1.3	2.5
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Solriamfetol</b>	<b>56,376</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>31.7</b>	<b>13.7</b>
0-17 years	315	1	30	30	30	180	32.7	16.2
18-24 years	4,243	1	30	30	30	120	31.7	13.6
25-40 years	14,937	1	30	30	30	120	30.5	11.2
41-64 years	27,853	1	30	30	30	180	31.5	13.4
≥ 65 years	9,028	1	30	30	30	97	33.9	17.6
<b>Siponimod</b>	<b>18,219</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>31.5</b>	<b>13.1</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	177	1	28	30	30	90	28.5	7.1
25-40 years	3,101	1	30	30	30	95	30.1	9.6
41-64 years	12,593	1	30	30	30	180	31.4	13.0
≥ 65 years	2,348	1	30	30	30	95	33.6	16.9
<b>Romosozumab-aqqg</b>	<b>290,335</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>90</b>	<b>3.1</b>	<b>7.9</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	487	1	1	1	1	75	5.9	11.0
41-64 years	23,915	1	1	1	1	90	4.9	10.4
≥ 65 years	265,856	1	1	1	1	90	3.0	7.6
<b>Erdafitinib</b>	<b>2,270</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>60</b>	<b>27.3</b>	<b>7.4</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	50	1	28	28	28	48	26.9	6.0
41-64 years	556	1	28	28	28	56	27.0	8.4
≥ 65 years	1,648	1	28	28	28	60	27.4	7.1

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>130,482</b>	<b>1</b>	<b>28</b>	<b>31</b>	<b>84</b>	<b>198</b>	<b>51.2</b>	<b>28.2</b>
0-17 years	207	1	28	31	84	84	52.4	29.4
18-24 years	5,988	1	28	31	84	168	47.1	27.3
25-40 years	30,466	1	28	31	84	168	48.1	27.6
41-64 years	70,780	1	28	31	84	198	49.9	27.8
≥ 65 years	23,041	1	28	84	84	180	60.1	28.5
<b>Tafamidis</b>	<b>56,168</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>33.0</b>	<b>14.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	20	3	30	30	30	30	28.3	6.2
41-64 years	2,177	1	30	30	30	90	30.4	10.3
≥ 65 years	53,971	1	30	30	30	180	33.1	15.1
<b>Alpelisib</b>	<b>20,372</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>118</b>	<b>27.7</b>	<b>4.8</b>
0-17 years	105	1	28	28	28	56	25.7	7.4
18-24 years	25	4	21	28	28	114	27.1	19.2
25-40 years	368	1	28	28	28	56	27.0	5.5
41-64 years	8,159	1	28	28	28	112	27.4	4.8
≥ 65 years	11,715	1	28	28	28	118	27.9	4.6
<b>piiq</b>	<b>8,720</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>56</b>	<b>1.1</b>	<b>1.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	17	1	1	1	1	1	1.0	0.0
25-40 years	111	1	1	1	1	1	1.0	0.0
41-64 years	925	1	1	1	1	56	1.2	2.7
≥ 65 years	7,667	1	1	1	1	21	1.1	1.0

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Bremelanotide</b>	<b>1,534</b>	<b>1</b>	<b>15</b>	<b>15</b>	<b>28</b>	<b>60</b>	<b>19.4</b>	<b>7.5</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	17	15	15	15	23	30	19.4	6.0
25-40 years	577	1	15	15	28	30	19.0	7.3
41-64 years	915	1	15	15	28	60	19.7	7.7
≥ 65 years	25	2	15	15	15	28	15.5	4.6
<b>Selinexor</b>	<b>6,468</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>168</b>	<b>27.1</b>	<b>6.2</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	34	2	28	28	28	56	24.6	10.5
41-64 years	1,573	1	28	28	28	74	27.0	5.6
≥ 65 years	4,849	1	28	28	28	168	27.2	6.3
<b>Imipenem Cilastatin and Relebactam</b>	<b>1,614</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>28</b>	<b>1.6</b>	<b>2.0</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	764	1	1	1	1	28	1.1	1.2
41-64 years	387	1	1	1	1	10	2.1	2.2
≥ 65 years	444	1	1	1	1	14	1.9	2.6
<b>Ferric Maltol</b>	<b>675</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>28.9</b>	<b>12.0</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	268	1	30	30	30	90	27.9	9.9
41-64 years	333	1	30	30	30	90	29.6	13.4
≥ 65 years	28	4	30	30	30	90	28.5	14.2

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>30,605</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>29.2</b>	<b>5.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	1,678	1	30	30	30	90	27.4	7.2
≥ 65 years	28,927	1	30	30	30	90	29.3	5.3
<b>Pexidartinib</b>	<b>618</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>28.9</b>	<b>4.7</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	245	2	30	30	30	52	28.8	4.8
41-64 years	293	2	30	30	30	60	29.1	4.7
≥ 65 years	*****	30	30	30	30	30	30.0	0.0
<b>Pretomanid</b>	<b>142</b>	<b>6</b>	<b>26</b>	<b>26</b>	<b>26</b>	<b>52</b>	<b>25.7</b>	<b>3.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	46	9	26	26	26	34	25.5	3.8
≥ 65 years	49	22	26	26	26	52	26.5	3.8
<b>Pitolisant</b>	<b>19,432</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>29.5</b>	<b>7.8</b>
0-17 years	220	4	30	30	30	90	30.9	12.4
18-24 years	2,339	1	30	30	30	180	29.4	8.5
25-40 years	6,587	1	30	30	30	90	29.1	6.9
41-64 years	8,149	1	30	30	30	97	29.6	7.8
≥ 65 years	2,137	1	30	30	30	97	29.9	9.1

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Entrectinib</b>	<b>1,491</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>27.8</b>	<b>7.6</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	105	7	30	30	30	60	31.3	11.7
41-64 years	567	1	28	30	30	60	26.0	7.6
≥ 65 years	781	1	30	30	30	90	28.5	6.1
<b>Fedratinib</b>	<b>5,451</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>29.2</b>	<b>5.1</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	92	9	30	30	30	30	28.9	4.0
41-64 years	722	1	30	30	30	60	28.2	5.7
≥ 65 years	4,637	1	30	30	30	90	29.3	5.1
<b>Upadacitinib</b>	<b>180,403</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>30.4</b>	<b>9.8</b>
0-17 years	335	1	30	30	30	72	27.8	7.4
18-24 years	2,305	1	30	30	30	90	29.3	8.7
25-40 years	15,067	1	30	30	30	90	29.8	8.9
41-64 years	106,633	1	30	30	30	180	30.1	9.1
≥ 65 years	56,063	1	30	30	30	90	31.0	11.2
<b>Lefamulin</b>	<b>325</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>30</b>	<b>4.0</b>	<b>4.1</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	160	1	1	1	5	30	3.7	4.7
≥ 65 years	143	1	1	5	5	10	3.7	2.8



**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Ga-68-DOTATOC</b>	<b>205</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	151	1	1	1	1	1	1.0	0.0
<b>Istradefylline</b>	<b>27,278</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>38.5</b>	<b>22.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	114	3	30	30	30	90	29.3	7.1
41-64 years	3,650	1	30	30	30	90	37.7	21.3
≥ 65 years	23,514	1	30	30	30	180	38.7	22.1

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Caplacizumab-yhdp</i>	147	88	59.9%	48	32.7%	*****	*****	*****	*****	*****	*****
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Brexanolone</i>	76	76	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	9,289	2,242	24.1%	2,276	24.5%	3,250	35.0%	1,172	12.6%	349	3.8%
<i>Siponimod</i>	1,685	155	9.2%	252	15.0%	655	38.9%	399	23.7%	224	13.3%
<i>Romosozumab-aqqg</i>	38,408	35,492	92.4%	678	1.8%	1,996	5.2%	*****	*****	*****	*****
<i>Erdafitinib</i>	566	165	29.2%	155	27.4%	226	39.9%	*****	*****	*****	*****
<i>Risankizumab-rzaa</i>	29,747	3,840	12.9%	5,905	19.9%	14,368	48.3%	4,381	14.7%	1,253	4.2%
<i>Tafamidis</i>	4,927	459	9.3%	650	13.2%	1,904	38.6%	1,071	21.7%	843	17.1%
<i>Alpelisib</i>	4,484	1,317	29.4%	1,244	27.7%	1,663	37.1%	235	5.2%	25	0.6%
<i>Polatuzumab Vedotin-piiq</i>	2,469	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Bremelanotide</i>	899	716	79.6%	134	14.9%	49	5.5%	0	0.0%	0	0.0%
<i>Selinexor</i>	2,314	930	40.2%	828	35.8%	526	22.7%	30	1.3%	0	0.0%
<i>Imipenem Cilastatin and Relebactam</i>	312	298	95.5%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Ferric Maltol</i>	330	144	43.6%	131	39.7%	55	16.7%	0	0.0%	0	0.0%
<i>Darolutamide</i>	3,777	550	14.6%	776	20.5%	1,587	42.0%	705	18.7%	159	4.2%
<i>Pexidartinib</i>	85	19	22.4%	16	18.8%	32	37.6%	*****	*****	*****	*****
<i>Pretomanid</i>	23	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Pitolisant</i>	2,703	551	20.4%	636	23.5%	1,005	37.2%	378	14.0%	133	4.9%
<i>Entrectinib</i>	331	123	37.2%	89	26.9%	94	28.4%	*****	*****	*****	*****
<i>Fedratinib</i>	807	198	24.5%	188	23.3%	286	35.4%	91	11.3%	44	5.5%
<i>Upadacitinib</i>	23,228	3,498	15.1%	5,046	21.7%	9,419	40.6%	4,111	17.7%	1,154	5.0%

**Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<i>Lefamulin</i>	170	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Ga-68-DOTATOC</i>	183	183	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Istradefylline</i>	4,221	748	17.7%	937	22.2%	1,455	34.5%	819	19.4%	262	6.2%

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	*****	*****	*****	*****	*****	*****
<i>Caplacizumab-yhdp</i>	147	1	27	30	58	953	58.2	113.9
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.
<i>Brexanolone</i>	76	1	1	3	3	30	2.6	3.3
<i>Solriamfetol</i>	9,289	1	34	101	270	1,258	192.1	213.3
<i>Siponimod</i>	1,685	1	95	252	515	1,328	340.1	294.3
<i>Romosozumab-aqqg</i>	38,408	1	4	9	12	942	23.7	65.8
<i>Erdafitinib</i>	566	1	28	84	140	925	109.3	108.1
<i>Risankizumab-rzaa</i>	29,747	1	68	153	308	1,333	224.4	214.1
<i>Tafamidis</i>	4,927	1	115	263	569	1,285	374.9	330.0
<i>Alpelisib</i>	4,484	1	28	84	168	1,161	125.6	134.7
<i>Polatuzumab Vedotin-piiq</i>	2,469	1	1	3	5	112	3.8	4.9
<i>Bremelanotide</i>	899	1	15	28	30	323	33.1	33.5
<i>Selinexor</i>	2,314	1	28	56	84	604	75.8	77.2
<i>Imipenem Cilastatin and Relebactam</i>	312	1	1	1	2	686	8.3	42.5
<i>Ferric Maltol</i>	330	1	30	50	90	210	59.0	40.9
<i>Darolutamide</i>	3,777	1	60	153	346	1,121	236.5	221.5
<i>Pexidartinib</i>	85	2	40	126	330	818	210.4	200.7
<i>Pretomanid</i>	23	52	130	177	190	234	159.0	50.2
<i>Pitolisant</i>	2,703	1	60	120	300	1,168	211.8	226.8
<i>Entrectinib</i>	331	2	30	60	165	937	125.4	154.5
<i>Fedratinib</i>	807	2	36	105	257	1,089	196.9	228.3
<i>Upadacitinib</i>	23,228	1	60	150	340	1,217	235.8	226.6
<i>Lefamulin</i>	170	1	5	5	7	93	7.6	10.3
<i>Ga-68-DOTATOC</i>	183	1	1	1	1	3	1.1	0.4
<i>Istradefylline</i>	4,221	1	60	150	380	1,108	249.0	240.6

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>PrabotulinumtoxinA-xvfs</b>	****	****	****	****	****	****	****	****	****	****	****
Female	****	****	****	****	****	****	****	****	****	****	****
Male	****	****	****	****	****	****	****	****	****	****	****
<b>Caplacizumab-yhdp</b>	147	88	100.0%	48	100.0%	****	****	****	****	****	****
Female	105	68	77.3%	****	****	****	****	****	****	****	****
Male	42	20	22.7%	****	****	****	****	0	0.0%	****	****
<b>Triclabendazole</b>	0	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	76	76	100.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Female	****	****	****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Male	****	****	****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Solriamfetol</b>	9,289	2,242	100.0%	2,276	100.0%	3,250	100.0%	1,172	100.0%	349	100.0%
Female	5,561	1,343	59.9%	1,378	60.5%	1,941	59.7%	675	57.6%	224	64.2%
Male	3,728	899	40.1%	898	39.5%	1,309	40.3%	497	42.4%	125	35.8%
<b>Siponimod</b>	1,685	155	100.0%	252	100.0%	655	100.0%	399	100.0%	224	100.0%
Female	1,256	112	72.3%	188	74.6%	484	73.9%	300	75.2%	172	76.8%
Male	429	43	27.7%	64	25.4%	171	26.1%	99	24.8%	52	23.2%
<b>Romosozumab-aqqg</b>	38,408	35,492	100.0%	678	100.0%	1,996	100.0%	****	****	****	****
Female	37,601	34,790	98.0%	****	****	1,916	96.0%	****	****	****	****
Male	807	702	2.0%	****	****	80	4.0%	****	****	****	****
<b>Erdafitinib</b>	566	165	100.0%	155	100.0%	226	100.0%	****	****	****	****

**Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	204	64	38.8%	*****	*****	78	34.5%	*****	*****	*****	*****
Male	362	101	61.2%	*****	*****	148	65.5%	*****	*****	*****	*****
<b>Risankizumab-rzaa</b>	<b>29,747</b>	<b>3,840</b>	<b>100.0%</b>	<b>5,905</b>	<b>100.0%</b>	<b>14,368</b>	<b>100.0%</b>	<b>4,381</b>	<b>100.0%</b>	<b>1,253</b>	<b>100.0%</b>
Female	14,823	1,994	51.9%	2,984	50.5%	7,126	49.6%	2,089	47.7%	630	50.3%
Male	14,924	1,846	48.1%	2,921	49.5%	7,242	50.4%	2,292	52.3%	623	49.7%
<b>Tafamidis</b>	<b>4,927</b>	<b>459</b>	<b>100.0%</b>	<b>650</b>	<b>100.0%</b>	<b>1,904</b>	<b>100.0%</b>	<b>1,071</b>	<b>100.0%</b>	<b>843</b>	<b>100.0%</b>
Female	897	95	20.7%	137	21.1%	365	19.2%	183	17.1%	117	13.9%
Male	4,030	364	79.3%	513	78.9%	1,539	80.8%	888	82.9%	726	86.1%
<b>Alpelisib</b>	<b>4,484</b>	<b>1,317</b>	<b>100.0%</b>	<b>1,244</b>	<b>100.0%</b>	<b>1,663</b>	<b>100.0%</b>	<b>235</b>	<b>100.0%</b>	<b>25</b>	<b>100.0%</b>
Female	4,380	1,283	97.4%	*****	*****	1,629	98.0%	*****	*****	25	100.0%
Male	104	34	2.6%	*****	*****	34	2.0%	*****	*****	0	0.0%
<b>Polatuzumab Vedotin-piiq</b>	<b>2,469</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	1,028	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	1,441	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>899</b>	<b>716</b>	<b>100.0%</b>	<b>134</b>	<b>100.0%</b>	<b>49</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	888	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	11	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>2,314</b>	<b>930</b>	<b>100.0%</b>	<b>828</b>	<b>100.0%</b>	<b>526</b>	<b>100.0%</b>	<b>30</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
Female	1,103	433	46.6%	381	46.0%	270	51.3%	19	63.3%	0	NaN*
Male	1,211	497	53.4%	447	54.0%	256	48.7%	11	36.7%	0	NaN*
<b>Imipenem Cilastatin and Relebactam</b>	<b>312</b>	<b>298</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>
Female	136	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*

**Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	176	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN*
<b>Ferric Maltol</b>	<b>330</b>	<b>144</b>	<b>100.0%</b>	<b>131</b>	<b>100.0%</b>	<b>55</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	303	130	90.3%	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	27	14	9.7%	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Darolutamide</b>	<b>3,777</b>	<b>550</b>	<b>100.0%</b>	<b>776</b>	<b>100.0%</b>	<b>1,587</b>	<b>100.0%</b>	<b>705</b>	<b>100.0%</b>	<b>159</b>	<b>100.0%</b>
Female	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
Male	*****	550	100.0%	*****	*****	1,587	100.0%	705	100.0%	159	100.0%
<b>Pexidartinib</b>	<b>85</b>	<b>19</b>	<b>100.0%</b>	<b>16</b>	<b>100.0%</b>	<b>32</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	57	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	28	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pretomanid</b>	<b>23</b>	<b>0</b>	<b>NaN*</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	*****	0	NaN*	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	*****	0	NaN*	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Pitolisant</b>	<b>2,703</b>	<b>551</b>	<b>100.0%</b>	<b>636</b>	<b>100.0%</b>	<b>1,005</b>	<b>100.0%</b>	<b>378</b>	<b>100.0%</b>	<b>133</b>	<b>100.0%</b>
Female	1,857	391	71.0%	436	68.6%	684	68.1%	267	70.6%	79	59.4%
Male	846	160	29.0%	200	31.4%	321	31.9%	111	29.4%	54	40.6%
<b>Entrectinib</b>	<b>331</b>	<b>123</b>	<b>100.0%</b>	<b>89</b>	<b>100.0%</b>	<b>94</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	195	72	58.5%	48	53.9%	*****	*****	*****	*****	*****	*****
Male	136	51	41.5%	41	46.1%	*****	*****	*****	*****	*****	*****
<b>Fedratinib</b>	<b>807</b>	<b>198</b>	<b>100.0%</b>	<b>188</b>	<b>100.0%</b>	<b>286</b>	<b>100.0%</b>	<b>91</b>	<b>100.0%</b>	<b>44</b>	<b>100.0%</b>
Female	388	107	54.0%	85	45.2%	128	44.8%	47	51.6%	21	47.7%
Male	419	91	46.0%	103	54.8%	158	55.2%	44	48.4%	23	52.3%



**Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Upadacitinib</b>	<b>23,228</b>	<b>3,498</b>	<b>100.0%</b>	<b>5,046</b>	<b>100.0%</b>	<b>9,419</b>	<b>100.0%</b>	<b>4,111</b>	<b>100.0%</b>	<b>1,154</b>	<b>100.0%</b>
Female	18,421	2,711	77.5%	3,892	77.1%	7,530	79.9%	3,364	81.8%	924	80.1%
Male	4,807	787	22.5%	1,154	22.9%	1,889	20.1%	747	18.2%	230	19.9%
<b>Lefamulin</b>	<b>170</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	103	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	67	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>183</b>	<b>183</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	98	98	53.6%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Male	85	85	46.4%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>4,221</b>	<b>748</b>	<b>100.0%</b>	<b>937</b>	<b>100.0%</b>	<b>1,455</b>	<b>100.0%</b>	<b>819</b>	<b>100.0%</b>	<b>262</b>	<b>100.0%</b>
Female	1,710	326	43.6%	366	39.1%	588	40.4%	324	39.6%	106	40.5%
Male	2,511	422	56.4%	571	60.9%	867	59.6%	495	60.4%	156	59.5%

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>147</b>	<b>1</b>	<b>27</b>	<b>30</b>	<b>58</b>	<b>953</b>	<b>58.2</b>	<b>113.9</b>
Female	105	1	27	30	56	953	53.8	104.3
Male	42	1	26	33	60	861	69.4	135.7
<b>Triclabendazole</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>30</b>	<b>2.6</b>	<b>3.3</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Solriamfetol</b>	<b>9,289</b>	<b>1</b>	<b>34</b>	<b>101</b>	<b>270</b>	<b>1,258</b>	<b>192.1</b>	<b>213.3</b>
Female	5,561	1	33	97	269	1,258	191.7	215.6
Male	3,728	1	35	107	270	1,230	192.8	209.7
<b>Siponimod</b>	<b>1,685</b>	<b>1</b>	<b>95</b>	<b>252</b>	<b>515</b>	<b>1,328</b>	<b>340.1</b>	<b>294.3</b>
Female	1,256	2	95	262	524	1,328	345.1	297.2
Male	429	1	93	240	485	1,156	325.4	285.6
<b>Romosozumab-aqqg</b>	<b>38,408</b>	<b>1</b>	<b>4</b>	<b>9</b>	<b>12</b>	<b>942</b>	<b>23.7</b>	<b>65.8</b>
Female	37,601	1	4	9	12	942	23.4	65.2
Male	807	1	3	9	12	829	36.9	88.7
<b>Erdafitinib</b>	<b>566</b>	<b>1</b>	<b>28</b>	<b>84</b>	<b>140</b>	<b>925</b>	<b>109.3</b>	<b>108.1</b>
Female	204	1	28	84	140	757	106.6	107.1
Male	362	1	28	84	140	925	110.8	108.8

**Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>29,747</b>	<b>1</b>	<b>68</b>	<b>153</b>	<b>308</b>	<b>1,333</b>	<b>224.4</b>	<b>214.1</b>
Female	14,823	1	63	150	301	1,333	220.4	212.7
Male	14,924	1	73	158	313	1,246	228.3	215.4
<b>Tafamidis</b>	<b>4,927</b>	<b>1</b>	<b>115</b>	<b>263</b>	<b>569</b>	<b>1,285</b>	<b>374.9</b>	<b>330.0</b>
Female	897	1	90	235	482	1,226	329.5	300.8
Male	4,030	1	120	270	591	1,285	385.1	335.4
<b>Alpelisib</b>	<b>4,484</b>	<b>1</b>	<b>28</b>	<b>84</b>	<b>168</b>	<b>1,161</b>	<b>125.6</b>	<b>134.7</b>
Female	4,380	1	28	84	168	1,161	126.4	135.5
Male	104	2	28	56	118	504	91.6	89.9
<b>Polatuzumab Vedotin-piiq</b>	<b>2,469</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>112</b>	<b>3.8</b>	<b>4.9</b>
Female	1,028	1	2	3	5	105	3.8	4.5
Male	1,441	1	1	3	5	112	3.8	5.1
<b>Bremelanotide</b>	<b>899</b>	<b>1</b>	<b>15</b>	<b>28</b>	<b>30</b>	<b>323</b>	<b>33.1</b>	<b>33.5</b>
Female	888	1	15	28	30	323	32.5	32.7
Male	11	15	30	60	90	195	77.5	60.2
<b>Selinexor</b>	<b>2,314</b>	<b>1</b>	<b>28</b>	<b>56</b>	<b>84</b>	<b>604</b>	<b>75.8</b>	<b>77.2</b>
Female	1,103	1	28	56	103	604	80.0	82.3
Male	1,211	1	28	56	84	540	72.1	72.2
<b>Imipenem Cilastatin and Relebactam</b>	<b>312</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>686</b>	<b>8.3</b>	<b>42.5</b>
Female	136	1	1	1	2	137	6.3	17.8
Male	176	1	1	1	2	686	9.8	54.4
<b>Ferric Maltol</b>	<b>330</b>	<b>1</b>	<b>30</b>	<b>50</b>	<b>90</b>	<b>210</b>	<b>59.0</b>	<b>40.9</b>
Female	303	1	30	53	90	210	58.7	40.6
Male	27	15	30	30	104	161	62.2	45.6

**Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>3,777</b>	<b>1</b>	<b>60</b>	<b>153</b>	<b>346</b>	<b>1,121</b>	<b>236.5</b>	<b>221.5</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pexidartinib</b>	<b>85</b>	<b>2</b>	<b>40</b>	<b>126</b>	<b>330</b>	<b>818</b>	<b>210.4</b>	<b>200.7</b>
Female	57	2	52	120	300	818	190.8	184.2
Male	28	7	30	187	433	734	250.5	229.1
<b>Pretomanid</b>	<b>23</b>	<b>52</b>	<b>130</b>	<b>177</b>	<b>190</b>	<b>234</b>	<b>159.0</b>	<b>50.2</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pitolisant</b>	<b>2,703</b>	<b>1</b>	<b>60</b>	<b>120</b>	<b>300</b>	<b>1,168</b>	<b>211.8</b>	<b>226.8</b>
Female	1,857	1	57	120	295	1,168	207.3	222.0
Male	846	1	60	127	312	1,116	221.6	236.9
<b>Entrectinib</b>	<b>331</b>	<b>2</b>	<b>30</b>	<b>60</b>	<b>165</b>	<b>937</b>	<b>125.4</b>	<b>154.5</b>
Female	195	2	30	60	180	919	141.3	173.5
Male	136	2	30	60	120	937	102.7	119.2
<b>Fedratinib</b>	<b>807</b>	<b>2</b>	<b>36</b>	<b>105</b>	<b>257</b>	<b>1,089</b>	<b>196.9</b>	<b>228.3</b>
Female	388	4	30	98	248	1,089	196.5	234.5
Male	419	2	60	120	261	1,080	197.3	222.7
<b>Upadacitinib</b>	<b>23,228</b>	<b>1</b>	<b>60</b>	<b>150</b>	<b>340</b>	<b>1,217</b>	<b>235.8</b>	<b>226.6</b>
Female	18,421	1	60	152	353	1,168	240.1	227.2
Male	4,807	1	60	131	311	1,217	219.7	223.7
<b>Lefamulin</b>	<b>170</b>	<b>1</b>	<b>5</b>	<b>5</b>	<b>7</b>	<b>93</b>	<b>7.6</b>	<b>10.3</b>
Female	103	1	4	5	6	93	7.5	11.4
Male	67	1	5	5	10	64	7.7	8.4

**Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Ga-68-DOTATOC</b>	<b>183</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>1.1</b>	<b>0.4</b>
Female	98	1	1	1	1	3	1.1	0.3
Male	85	1	1	1	1	3	1.2	0.4
<b>Istradefylline</b>	<b>4,221</b>	<b>1</b>	<b>60</b>	<b>150</b>	<b>380</b>	<b>1,108</b>	<b>249.0</b>	<b>240.6</b>
Female	1,710	1	60	150	367	1,019	246.6	240.7
Male	2,511	1	60	150	386	1,108	250.6	240.6

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>147</b>	<b>88</b>	<b>100.0%</b>	<b>48</b>	<b>100.0%</b>	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	42	21	23.9%	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	72	46	52.3%	*****	*****	*****	*****	0	0.0%	*****	*****
≥ 65 years	19	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>76</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
25-40 years	65	65	85.5%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Solriamfetol</b>	<b>9,289</b>	<b>2,242</b>	<b>100.0%</b>	<b>2,276</b>	<b>100.0%</b>	<b>3,250</b>	<b>100.0%</b>	<b>1,172</b>	<b>100.0%</b>	<b>349</b>	<b>100.0%</b>
0-17 years	51	11	0.5%	*****	*****	20	0.6%	*****	*****	*****	*****
18-24 years	665	167	7.4%	*****	*****	228	7.0%	*****	*****	*****	*****
25-40 years	2,523	590	26.3%	668	29.3%	900	27.7%	286	24.4%	79	22.6%
41-64 years	4,322	953	42.5%	1,034	45.4%	1,563	48.1%	595	50.8%	177	50.7%
≥ 65 years	1,728	521	23.2%	414	18.2%	539	16.6%	194	16.6%	60	17.2%
<b>Siponimod</b>	<b>1,685</b>	<b>155</b>	<b>100.0%</b>	<b>252</b>	<b>100.0%</b>	<b>655</b>	<b>100.0%</b>	<b>399</b>	<b>100.0%</b>	<b>224</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	20	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	304	28	18.1%	48	19.0%	127	19.4%	72	18.0%	29	12.9%
41-64 years	1,127	103	66.5%	164	65.1%	423	64.6%	273	68.4%	164	73.2%
≥ 65 years	234	*****	*****	*****	*****	*****	*****	*****	*****	31	13.8%
<b>Romosozumab-aqqg</b>	<b>38,408</b>	<b>35,492</b>	<b>100.0%</b>	<b>678</b>	<b>100.0%</b>	<b>1,996</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	86	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	3,480	3,045	8.6%	*****	*****	300	15.0%	*****	*****	0	0.0%
≥ 65 years	34,831	32,367	91.2%	572	84.4%	1,683	84.3%	*****	*****	*****	*****
<b>Erdafitinib</b>	<b>566</b>	<b>165</b>	<b>100.0%</b>	<b>155</b>	<b>100.0%</b>	<b>226</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	126	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	422	134	81.2%	110	71.0%	163	72.1%	*****	*****	*****	*****
<b>Risankizumab-rzaa</b>	<b>29,747</b>	<b>3,840</b>	<b>100.0%</b>	<b>5,905</b>	<b>100.0%</b>	<b>14,368</b>	<b>100.0%</b>	<b>4,381</b>	<b>100.0%</b>	<b>1,253</b>	<b>100.0%</b>
0-17 years	42	*****	*****	*****	*****	22	0.2%	*****	*****	0	0.0%
18-24 years	1,452	*****	*****	*****	*****	710	4.9%	*****	*****	36	2.9%
25-40 years	7,170	943	24.6%	1,601	27.1%	3,518	24.5%	872	19.9%	236	18.8%
41-64 years	15,604	1,852	48.2%	3,147	53.3%	7,624	53.1%	2,334	53.3%	647	51.6%
≥ 65 years	5,479	812	21.1%	849	14.4%	2,494	17.4%	990	22.6%	334	26.7%
<b>Tafamidis</b>	<b>4,927</b>	<b>459</b>	<b>100.0%</b>	<b>650</b>	<b>100.0%</b>	<b>1,904</b>	<b>100.0%</b>	<b>1,071</b>	<b>100.0%</b>	<b>843</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	*****	*****	0	0.0%	*****	*****	0	0.0%
41-64 years	*****	28	6.1%	*****	*****	91	4.8%	*****	*****	21	2.5%
≥ 65 years	4,695	431	93.9%	606	93.2%	1,813	95.2%	1,023	95.5%	822	97.5%
<b>Alpelisib</b>	<b>4,484</b>	<b>1,317</b>	<b>100.0%</b>	<b>1,244</b>	<b>100.0%</b>	<b>1,663</b>	<b>100.0%</b>	<b>235</b>	<b>100.0%</b>	<b>25</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	95	*****	*****	29	2.3%	29	1.7%	*****	*****	0	0.0%
41-64 years	1,649	390	29.6%	464	37.3%	696	41.9%	*****	*****	*****	*****
≥ 65 years	2,706	890	67.6%	739	59.4%	921	55.4%	*****	*****	*****	*****
<b>Polatuzumab Vedotin-piiq</b>	<b>2,469</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*



**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
41-64 years	336	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	2,085	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>899</b>	<b>716</b>	<b>100.0%</b>	<b>134</b>	<b>100.0%</b>	<b>49</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	347	285	39.8%	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	530	412	57.5%	83	61.9%	35	71.4%	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>2,314</b>	<b>930</b>	<b>100.0%</b>	<b>828</b>	<b>100.0%</b>	<b>526</b>	<b>100.0%</b>	<b>30</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
41-64 years	517	179	19.2%	*****	*****	*****	*****	*****	*****	0	NaN*
≥ 65 years	1,775	739	79.5%	624	75.4%	*****	*****	*****	*****	0	NaN*
<b>Imipenem Cilastatin and Relebactam</b>	<b>312</b>	<b>298</b>	<b>100.0%</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	*****	*****	0	NaN*
41-64 years	101	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
≥ 65 years	179	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
<b>Ferric Maltol</b>	<b>330</b>	<b>144</b>	<b>100.0%</b>	<b>131</b>	<b>100.0%</b>	<b>55</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	20	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
25-40 years	140	66	45.8%	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	152	58	40.3%	61	46.6%	33	60.0%	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Darolutamide</b>	<b>3,777</b>	<b>550</b>	<b>100.0%</b>	<b>776</b>	<b>100.0%</b>	<b>1,587</b>	<b>100.0%</b>	<b>705</b>	<b>100.0%</b>	<b>159</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	253	59	10.7%	60	7.7%	93	5.9%	*****	*****	*****	*****
≥ 65 years	3,524	491	89.3%	716	92.3%	1,494	94.1%	*****	*****	*****	*****
<b>Pexidartinib</b>	<b>85</b>	<b>19</b>	<b>100.0%</b>	<b>16</b>	<b>100.0%</b>	<b>32</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	35	*****	*****	*****	*****	15	46.9%	*****	*****	*****	*****
41-64 years	36	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<b>Pretomanid</b>	<b>23</b>	<b>0</b>	<b>NaN*</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	NaN*	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	0	NaN*	0	0.0%	*****	*****	0	NaN*	0	NaN*
25-40 years	*****	0	NaN*	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	*****	0	NaN*	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	*****	0	NaN*	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Pitolisant</b>	<b>2,703</b>	<b>551</b>	<b>100.0%</b>	<b>636</b>	<b>100.0%</b>	<b>1,005</b>	<b>100.0%</b>	<b>378</b>	<b>100.0%</b>	<b>133</b>	<b>100.0%</b>

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	29	*****	*****	*****	*****	12	1.2%	*****	*****	*****	*****
18-24 years	320	*****	*****	*****	*****	129	12.8%	48	12.7%	*****	*****
25-40 years	986	199	36.1%	238	37.4%	399	39.7%	113	29.9%	37	27.8%
41-64 years	1,071	219	39.7%	241	37.9%	380	37.8%	170	45.0%	61	45.9%
≥ 65 years	297	70	12.7%	78	12.3%	85	8.5%	*****	*****	*****	*****
<b>Entrectinib</b>	<b>331</b>	<b>123</b>	<b>100.0%</b>	<b>89</b>	<b>100.0%</b>	<b>94</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	116	*****	*****	*****	*****	34	36.2%	*****	*****	*****	*****
≥ 65 years	188	77	62.6%	52	58.4%	45	47.9%	*****	*****	*****	*****
<b>Fedratinib</b>	<b>807</b>	<b>198</b>	<b>100.0%</b>	<b>188</b>	<b>100.0%</b>	<b>286</b>	<b>100.0%</b>	<b>91</b>	<b>100.0%</b>	<b>44</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	24	12.1%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	692	174	87.9%	155	82.4%	250	87.4%	*****	*****	*****	*****
<b>Upadacitinib</b>	<b>23,228</b>	<b>3,498</b>	<b>100.0%</b>	<b>5,046</b>	<b>100.0%</b>	<b>9,419</b>	<b>100.0%</b>	<b>4,111</b>	<b>100.0%</b>	<b>1,154</b>	<b>100.0%</b>
0-17 years	91	*****	*****	31	0.6%	35	0.4%	0	0.0%	*****	*****
18-24 years	446	*****	*****	148	2.9%	171	1.8%	35	0.9%	*****	*****
25-40 years	2,412	*****	*****	644	12.8%	994	10.6%	296	7.2%	*****	*****
41-64 years	13,502	1,906	54.5%	2,885	57.2%	5,623	59.7%	2,447	59.5%	641	55.5%
≥ 65 years	6,777	1,067	30.5%	1,338	26.5%	2,596	27.6%	1,333	32.4%	443	38.4%

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Lefamulin</b>	<b>170</b>	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
41-64 years	65	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	89	89	53.6%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>183</b>	<b>183</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	133	133	72.7%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>4,221</b>	<b>748</b>	<b>100.0%</b>	<b>937</b>	<b>100.0%</b>	<b>1,455</b>	<b>100.0%</b>	<b>819</b>	<b>100.0%</b>	<b>262</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	12	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	576	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	3,633	634	84.8%	817	87.2%	1,241	85.3%	715	87.3%	226	86.3%

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>147</b>	<b>1</b>	<b>27</b>	<b>30</b>	<b>58</b>	<b>953</b>	<b>58.2</b>	<b>113.9</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	42	8	30	32	60	861	66.4	129.9
41-64 years	72	1	27	30	56	953	57.0	118.1
≥ 65 years	19	1	24	30	55	474	55.6	103.1
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>30</b>	<b>2.6</b>	<b>3.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	65	1	1	3	3	30	2.6	3.6
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Solriamfetol</b>	<b>9,289</b>	<b>1</b>	<b>34</b>	<b>101</b>	<b>270</b>	<b>1,258</b>	<b>192.1</b>	<b>213.3</b>
0-17 years	51	1	44	150	270	750	201.7	194.4
18-24 years	665	1	30	120	285	1,146	202.5	225.3
25-40 years	2,523	1	34	91	240	1,258	180.7	202.9
41-64 years	4,322	1	45	120	284	1,230	203.1	219.3
≥ 65 years	1,728	1	30	90	240	1,134	177.0	206.7
<b>Siponimod</b>	<b>1,685</b>	<b>1</b>	<b>95</b>	<b>252</b>	<b>515</b>	<b>1,328</b>	<b>340.1</b>	<b>294.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	20	9	63	186	414	730	252.4	202.6
25-40 years	304	6	91	235	424	1,156	306.6	267.7
41-64 years	1,127	1	95	270	545	1,328	351.2	299.5
≥ 65 years	234	5	92	240	508	1,178	337.6	305.3
<b>Romosozumab-aqqg</b>	<b>38,408</b>	<b>1</b>	<b>4</b>	<b>9</b>	<b>12</b>	<b>942</b>	<b>23.7</b>	<b>65.8</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	86	1	3	7	12	360	33.5	79.0
41-64 years	3,480	1	3	8	12	600	33.4	81.9
≥ 65 years	34,831	1	4	9	12	942	22.7	63.8
<b>Erdafitinib</b>	<b>566</b>	<b>1</b>	<b>28</b>	<b>84</b>	<b>140</b>	<b>925</b>	<b>109.3</b>	<b>108.1</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	126	5	41	88	152	629	119.2	105.0
≥ 65 years	422	1	28	84	140	925	107.0	110.3

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>29,747</b>	<b>1</b>	<b>68</b>	<b>153</b>	<b>308</b>	<b>1,333</b>	<b>224.4</b>	<b>214.1</b>
0-17 years	42	1	96	219	338	663	258.2	199.5
18-24 years	1,452	1	59	136	270	1,182	194.2	186.4
25-40 years	7,170	1	62	142	276	1,246	204.4	199.3
41-64 years	15,604	1	73	158	311	1,333	226.2	212.2
≥ 65 years	5,479	1	73	172	364	1,191	252.9	239.9
<b>Tafamidis</b>	<b>4,927</b>	<b>1</b>	<b>115</b>	<b>263</b>	<b>569</b>	<b>1,285</b>	<b>374.9</b>	<b>330.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	4,695	1	120	268	573	1,285	379.3	331.8
<b>Alpelisib</b>	<b>4,484</b>	<b>1</b>	<b>28</b>	<b>84</b>	<b>168</b>	<b>1,161</b>	<b>125.6</b>	<b>134.7</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	95	1	28	70	140	616	104.6	111.5
41-64 years	1,649	1	40	84	168	1,161	135.4	140.0
≥ 65 years	2,706	1	28	65	168	1,080	120.7	132.4
<b>piiq</b>	<b>2,469</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>112</b>	<b>3.8</b>	<b>4.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	336	1	1	2	4	112	3.3	6.8
≥ 65 years	2,085	1	2	3	6	105	3.9	4.6

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Bremelanotide</b>	<b>899</b>	<b>1</b>	<b>15</b>	<b>28</b>	<b>30</b>	<b>323</b>	<b>33.1</b>	<b>33.5</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	347	1	15	28	30	323	31.6	32.9
41-64 years	530	1	15	28	30	283	34.1	33.3
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Selinexor</b>	<b>2,314</b>	<b>1</b>	<b>28</b>	<b>56</b>	<b>84</b>	<b>604</b>	<b>75.8</b>	<b>77.2</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	517	2	28	56	106	549	82.2	80.9
≥ 65 years	1,775	1	28	56	84	604	74.3	76.3
<b>Imipenem Cilastatin and Relebactam</b>	<b>312</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>686</b>	<b>8.3</b>	<b>42.5</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	101	1	1	1	3	137	8.0	20.1
≥ 65 years	179	1	1	1	1	172	4.7	17.3
<b>Ferric Maltol</b>	<b>330</b>	<b>1</b>	<b>30</b>	<b>50</b>	<b>90</b>	<b>210</b>	<b>59.0</b>	<b>40.9</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	140	1	30	44	66	210	53.5	36.7
41-64 years	152	1	30	60	90	194	64.9	43.7
≥ 65 years	15	12	30	30	90	161	53.1	46.1



**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>3,777</b>	<b>1</b>	<b>60</b>	<b>153</b>	<b>346</b>	<b>1,121</b>	<b>236.5</b>	<b>221.5</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	253	1	48	97	212	990	181.6	201.0
≥ 65 years	3,524	1	60	159	359	1,121	240.5	222.4
<b>Pexidartinib</b>	<b>85</b>	<b>2</b>	<b>40</b>	<b>126</b>	<b>330</b>	<b>818</b>	<b>210.4</b>	<b>200.7</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	35	7	36	132	330	766	201.6	190.9
41-64 years	36	2	50	172	389	734	236.6	208.0
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pretomanid</b>	<b>23</b>	<b>52</b>	<b>130</b>	<b>177</b>	<b>190</b>	<b>234</b>	<b>159.0</b>	<b>50.2</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pitolisant</b>	<b>2,703</b>	<b>1</b>	<b>60</b>	<b>120</b>	<b>300</b>	<b>1,168</b>	<b>211.8</b>	<b>226.8</b>
0-17 years	29	4	60	150	233	988	234.6	259.5
18-24 years	320	1	60	133	304	1,116	215.3	222.7
25-40 years	986	1	60	120	270	1,140	194.7	209.0
41-64 years	1,071	1	60	121	317	1,168	224.9	238.4
≥ 65 years	297	2	38	92	330	944	215.2	239.4

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Entrectinib</b>	<b>331</b>	<b>2</b>	<b>30</b>	<b>60</b>	<b>165</b>	<b>937</b>	<b>125.4</b>	<b>154.5</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	116	2	30	60	176	823	127.2	158.1
≥ 65 years	188	3	30	60	150	937	118.5	155.1
<b>Fedratinib</b>	<b>807</b>	<b>2</b>	<b>36</b>	<b>105</b>	<b>257</b>	<b>1,089</b>	<b>196.9</b>	<b>228.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	692	2	30	112	256	1,089	196.4	228.1
<b>Upadacitinib</b>	<b>23,228</b>	<b>1</b>	<b>60</b>	<b>150</b>	<b>340</b>	<b>1,217</b>	<b>235.8</b>	<b>226.6</b>
0-17 years	91	1	30	72	125	930	102.2	113.9
18-24 years	446	1	44	90	180	970	151.2	174.2
25-40 years	2,412	1	60	120	244	1,090	185.9	192.6
41-64 years	13,502	1	61	150	347	1,217	238.1	224.9
≥ 65 years	6,777	1	60	180	384	1,107	256.5	240.6
<b>Lefamulin</b>	<b>170</b>	<b>1</b>	<b>5</b>	<b>5</b>	<b>7</b>	<b>93</b>	<b>7.6</b>	<b>10.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	65	1	4	5	10	93	9.1	14.7
≥ 65 years	89	1	5	5	7	26	6.0	3.8

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Ga-68-DOTATOC</b>	<b>183</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>1.1</b>	<b>0.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	133	1	1	1	1	3	1.1	0.4
<b>Istradefylline</b>	<b>4,221</b>	<b>1</b>	<b>60</b>	<b>150</b>	<b>380</b>	<b>1,108</b>	<b>249.0</b>	<b>240.6</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	12	30	45	150	442	874	278.8	305.6
41-64 years	576	1	60	150	360	1,108	238.6	235.9
≥ 65 years	3,633	1	60	150	385	1,079	250.5	241.2

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Caplacizumab-yhdp</i>	225	165	73.3%	49	21.8%	*****	*****	*****	*****	0	0.0%
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Brexanolone</i>	76	76	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	31,266	21,132	67.6%	7,072	22.6%	2,653	8.5%	336	1.1%	73	0.2%
<i>Siponimod</i>	5,176	2,265	43.8%	1,418	27.4%	1,177	22.7%	244	4.7%	72	1.4%
<i>Romozumab-aqqg</i>	275,322	271,154	98.5%	2,577	0.9%	1,506	0.5%	85	0.0%	0	0.0%
<i>Erdafitinib</i>	1,211	759	62.7%	310	25.6%	*****	*****	*****	*****	0	0.0%
<i>Risankizumab-rzaa</i>	83,829	34,724	41.4%	32,706	39.0%	14,421	17.2%	1,734	2.1%	244	0.3%
<i>Tafamidis</i>	12,615	4,552	36.1%	3,316	26.3%	3,491	27.7%	903	7.2%	353	2.8%
<i>Alpelisib</i>	9,281	5,599	60.3%	2,294	24.7%	1,284	13.8%	*****	*****	*****	*****
<i>Polatuzumab Vedotin-piiq</i>	8,694	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Bremelanotide</i>	1,216	1,098	90.3%	97	8.0%	21	1.7%	0	0.0%	0	0.0%
<i>Selinexor</i>	4,117	2,840	69.0%	1,011	24.6%	*****	*****	*****	*****	0	0.0%
<i>Imipenem Cilastatin and Relebactam</i>	470	457	97.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Ferric Maltol</i>	436	288	66.1%	115	26.4%	33	7.6%	0	0.0%	0	0.0%
<i>Darolutamide</i>	11,032	5,799	52.6%	2,893	26.2%	2,048	18.6%	257	2.3%	35	0.3%
<i>Pexidartinib</i>	297	180	60.6%	74	24.9%	43	14.5%	0	0.0%	0	0.0%
<i>Pretomanid</i>	59	27	45.8%	19	32.2%	13	22.0%	0	0.0%	0	0.0%
<i>Pitolisant</i>	6,113	2,945	48.2%	1,645	26.9%	1,260	20.6%	222	3.6%	41	0.7%
<i>Entrectinib</i>	690	460	66.7%	139	20.1%	78	11.3%	13	1.9%	0	0.0%
<i>Fedratinib</i>	2,219	1,275	57.5%	564	25.4%	336	15.1%	*****	*****	*****	*****
<i>Upadacitinib</i>	69,073	36,493	52.8%	18,963	27.5%	11,772	17.0%	1,584	2.3%	261	0.4%

**Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Lefamulin</i>	271	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
<i>Ga-68-DOTATOC</i>	205	205	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Istradefylline</i>	8,403	3,239	38.5%	2,384	28.4%	2,154	25.6%	525	6.2%	101	1.2%

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>PrbotulinumtoxinA-xvfs</i>	*****	*****	*****	*****	*****	*****	*****	*****
<i>Caplacizumab-yhdp</i>	225	1	16	30	34	600	38.0	55.4
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.
<i>Brexanolone</i>	76	1	1	3	3	30	2.6	3.3
<i>Solriamfetol</i>	31,266	1	30	30	60	1,146	57.1	78.2
<i>Siponimod</i>	5,176	1	30	60	120	1,160	110.7	152.4
<i>Romosozumab-aqqg</i>	275,322	1	1	1	1	720	3.3	18.1
<i>Erdafitinib</i>	1,211	1	28	28	56	448	51.1	48.8
<i>Risankizumab-rzaa</i>	83,829	1	30	31	84	1,333	79.6	99.2
<i>Tafamidis</i>	12,615	1	30	60	180	1,269	146.4	193.3
<i>Alpelisib</i>	9,281	1	28	28	56	1,161	60.7	74.2
<i>Polatuzumab Vedotin-piiq</i>	8,694	1	1	1	1	112	1.1	2.0
<i>Bremelanotide</i>	1,216	1	15	15	30	323	24.5	22.2
<i>Selinexor</i>	4,117	1	28	28	56	420	42.6	35.4
<i>Imipenem Cilastatin and Relebactam</i>	470	1	1	1	1	310	5.5	20.8
<i>Ferric Maltol</i>	436	1	30	30	60	210	44.7	32.1
<i>Darolutamide</i>	11,032	1	30	30	90	1,121	81.0	101.9
<i>Pexidartinib</i>	297	2	30	30	60	360	60.2	60.3
<i>Pretomanid</i>	59	22	26	50	78	208	62.0	50.4
<i>Pitolisant</i>	6,113	1	30	44	90	1,091	93.6	125.6
<i>Entrectinib</i>	690	1	30	30	60	727	60.2	83.1
<i>Fedratinib</i>	2,219	1	30	30	64	1,027	71.6	94.5
<i>Upadacitinib</i>	69,073	1	30	30	90	1,217	79.3	103.2
<i>Lefamulin</i>	271	1	1	5	5	70	4.8	6.3
<i>Ga-68-DOTATOC</i>	205	1	1	1	1	1	1.0	0.0
<i>Istradefylline</i>	8,403	1	30	60	150	1,079	125.1	153.9

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
<b>PrabotulinumtoxinA-xvfs</b>	****	****	****	****	****	****	****	****	****	****	****
Female	****	****	****	****	****	****	****	****	****	****	****
Male	****	****	****	****	****	****	****	****	****	****	****
<b>Caplacizumab-yhdp</b>	225	165	100.0%	49	100.0%	****	****	****	****	0	NaN*
Female	159	124	75.2%	****	****	****	****	****	****	0	NaN*
Male	66	41	24.8%	****	****	****	****	****	****	0	NaN*
<b>Triclabendazole</b>	0	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	76	76	100.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Female	****	****	****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Male	****	****	****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Solriamfetol</b>	31,266	21,132	100.0%	7,072	100.0%	2,653	100.0%	336	100.0%	73	100.0%
Female	19,010	12,926	61.2%	4,264	60.3%	1,587	59.8%	190	56.5%	43	58.9%
Male	12,256	8,206	38.8%	2,808	39.7%	1,066	40.2%	146	43.5%	30	41.1%
<b>Siponimod</b>	5,176	2,265	100.0%	1,418	100.0%	1,177	100.0%	244	100.0%	72	100.0%
Female	3,819	1,659	73.2%	1,030	72.6%	886	75.3%	****	****	****	****
Male	1,357	606	26.8%	388	27.4%	291	24.7%	****	****	****	****
<b>Romosozumab-aqqg</b>	275,322	271,154	100.0%	2,577	100.0%	1,506	100.0%	85	100.0%	0	NaN*
Female	270,378	266,362	98.2%	2,486	96.5%	****	****	****	****	0	NaN*
Male	4,944	4,792	1.8%	91	3.5%	****	****	****	****	0	NaN*

**Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Erdafitinib</b>	<b>1,211</b>	<b>759</b>	<b>100.0%</b>	<b>310</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	*****	<b>0</b>	<b>NaN*</b>
Female	464	303	39.9%	118	38.1%	*****	*****	0	0.0%	0	NaN*
Male	747	456	60.1%	192	61.9%	*****	*****	*****	*****	0	NaN*
<b>Risankizumab-rzaa</b>	<b>83,829</b>	<b>34,724</b>	<b>100.0%</b>	<b>32,706</b>	<b>100.0%</b>	<b>14,421</b>	<b>100.0%</b>	<b>1,734</b>	<b>100.0%</b>	<b>244</b>	<b>100.0%</b>
Female	40,133	16,586	47.8%	15,268	46.7%	7,307	50.7%	848	48.9%	124	50.8%
Male	43,696	18,138	52.2%	17,438	53.3%	7,114	49.3%	886	51.1%	120	49.2%
<b>Tafamidis</b>	<b>12,615</b>	<b>4,552</b>	<b>100.0%</b>	<b>3,316</b>	<b>100.0%</b>	<b>3,491</b>	<b>100.0%</b>	<b>903</b>	<b>100.0%</b>	<b>353</b>	<b>100.0%</b>
Female	2,364	958	21.0%	639	19.3%	580	16.6%	151	16.7%	36	10.2%
Male	10,251	3,594	79.0%	2,677	80.7%	2,911	83.4%	752	83.3%	317	89.8%
<b>Alpelisib</b>	<b>9,281</b>	<b>5,599</b>	<b>100.0%</b>	<b>2,294</b>	<b>100.0%</b>	<b>1,284</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	9,085	5,473	97.7%	2,247	98.0%	1,261	98.2%	*****	*****	*****	*****
Male	196	126	2.3%	47	2.0%	23	1.8%	0	0.0%	0	0.0%
<b>Polatuzumab Vedotin-piiq</b>	<b>8,694</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	3,684	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
Male	5,010	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>1,216</b>	<b>1,098</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>	<b>21</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	1,189	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	27	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>4,117</b>	<b>2,840</b>	<b>100.0%</b>	<b>1,011</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
Female	2,005	1,361	47.9%	497	49.2%	*****	*****	*****	*****	0	NaN*
Male	2,112	1,479	52.1%	514	50.8%	*****	*****	*****	*****	0	NaN*
<b>Imipenem Cilastatin and Relebactam</b>	<b>470</b>	<b>457</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>



**Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	219	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
Male	251	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Ferric Maltol</b>	<b>436</b>	<b>288</b>	<b>100.0%</b>	<b>115</b>	<b>100.0%</b>	<b>33</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	401	265	92.0%	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	35	23	8.0%	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Darolutamide</b>	<b>11,032</b>	<b>5,799</b>	<b>100.0%</b>	<b>2,893</b>	<b>100.0%</b>	<b>2,048</b>	<b>100.0%</b>	<b>257</b>	<b>100.0%</b>	<b>35</b>	<b>100.0%</b>
Female	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
Male	*****	5,799	100.0%	*****	*****	2,048	100.0%	257	100.0%	35	100.0%
<b>Pexidartinib</b>	<b>297</b>	<b>180</b>	<b>100.0%</b>	<b>74</b>	<b>100.0%</b>	<b>43</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	197	124	68.9%	48	64.9%	25	58.1%	0	NaN*	0	NaN*
Male	100	56	31.1%	26	35.1%	18	41.9%	0	NaN*	0	NaN*
<b>Pretomanid</b>	<b>59</b>	<b>27</b>	<b>100.0%</b>	<b>19</b>	<b>100.0%</b>	<b>13</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	40	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	19	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Pitolisant</b>	<b>6,113</b>	<b>2,945</b>	<b>100.0%</b>	<b>1,645</b>	<b>100.0%</b>	<b>1,260</b>	<b>100.0%</b>	<b>222</b>	<b>100.0%</b>	<b>41</b>	<b>100.0%</b>
Female	4,180	2,063	70.1%	1,079	65.6%	865	68.7%	147	66.2%	26	63.4%
Male	1,933	882	29.9%	566	34.4%	395	31.3%	75	33.8%	15	36.6%
<b>Entrectinib</b>	<b>690</b>	<b>460</b>	<b>100.0%</b>	<b>139</b>	<b>100.0%</b>	<b>78</b>	<b>100.0%</b>	<b>13</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
Female	429	281	61.1%	85	61.2%	*****	*****	*****	*****	0	NaN*
Male	261	179	38.9%	54	38.8%	*****	*****	*****	*****	0	NaN*
<b>Fedratinib</b>	<b>2,219</b>	<b>1,275</b>	<b>100.0%</b>	<b>564</b>	<b>100.0%</b>	<b>336</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	1,064	621	48.7%	270	47.9%	152	45.2%	*****	*****	*****	*****

**Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	1,155	654	51.3%	294	52.1%	184	54.8%	*****	*****	*****	*****
<b>Upadacitinib</b>	<b>69,073</b>	<b>36,493</b>	<b>100.0%</b>	<b>18,963</b>	<b>100.0%</b>	<b>11,772</b>	<b>100.0%</b>	<b>1,584</b>	<b>100.0%</b>	<b>261</b>	<b>100.0%</b>
Female	55,904	29,631	81.2%	15,301	80.7%	9,498	80.7%	1,269	80.1%	205	78.5%
Male	13,169	6,862	18.8%	3,662	19.3%	2,274	19.3%	315	19.9%	56	21.5%
<b>Lefamulin</b>	<b>271</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	154	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
Male	117	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>205</b>	<b>205</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	106	106	51.7%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Male	99	99	48.3%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>8,403</b>	<b>3,239</b>	<b>100.0%</b>	<b>2,384</b>	<b>100.0%</b>	<b>2,154</b>	<b>100.0%</b>	<b>525</b>	<b>100.0%</b>	<b>101</b>	<b>100.0%</b>
Female	3,389	1,333	41.2%	936	39.3%	865	40.2%	219	41.7%	36	35.6%
Male	5,014	1,906	58.8%	1,448	60.7%	1,289	59.8%	306	58.3%	65	64.4%

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>PrabotulinumtoxinA-xvfs</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>225</b>	<b>1</b>	<b>16</b>	<b>30</b>	<b>34</b>	<b>600</b>	<b>38.0</b>	<b>55.4</b>
Female	159	1	13	30	30	600	35.5	55.8
Male	66	1	20	30	58	390	44.2	54.4
<b>Triclabendazole</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>30</b>	<b>2.6</b>	<b>3.3</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Solriamfetol</b>	<b>31,266</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,146</b>	<b>57.1</b>	<b>78.2</b>
Female	19,010	1	30	30	60	1,146	56.1	76.7
Male	12,256	1	30	30	60	1,146	58.6	80.4
<b>Siponimod</b>	<b>5,176</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>1,160</b>	<b>110.7</b>	<b>152.4</b>
Female	3,819	1	30	60	120	1,160	113.5	158.2
Male	1,357	1	30	60	112	1,066	102.9	134.5
<b>Romosozumab-aqqg</b>	<b>275,322</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>720</b>	<b>3.3</b>	<b>18.1</b>
Female	270,378	1	1	1	1	720	3.3	17.9
Male	4,944	1	1	1	1	689	6.0	27.0
<b>Erdafitinib</b>	<b>1,211</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>448</b>	<b>51.1</b>	<b>48.8</b>
Female	464	1	28	28	56	294	46.9	42.3
Male	747	1	28	28	56	448	53.7	52.2

**Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>83,829</b>	<b>1</b>	<b>30</b>	<b>31</b>	<b>84</b>	<b>1,333</b>	<b>79.6</b>	<b>99.2</b>
Female	40,133	1	30	31	84	1,333	81.4	100.7
Male	43,696	1	30	31	84	1,184	78.0	97.7
<b>Tafamidis</b>	<b>12,615</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>180</b>	<b>1,269</b>	<b>146.4</b>	<b>193.3</b>
Female	2,364	1	30	60	150	1,194	125.0	164.0
Male	10,251	1	30	74	180	1,269	151.4	199.1
<b>Alpelisib</b>	<b>9,281</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,161</b>	<b>60.7</b>	<b>74.2</b>
Female	9,085	1	28	28	56	1,161	61.0	74.8
Male	196	1	28	28	56	270	48.6	42.3
<b>Polatuzumab Vedotin-piiq</b>	<b>8,694</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>112</b>	<b>1.1</b>	<b>2.0</b>
Female	3,684	1	1	1	1	63	1.1	1.4
Male	5,010	1	1	1	1	112	1.1	2.3
<b>Bremelanotide</b>	<b>1,216</b>	<b>1</b>	<b>15</b>	<b>15</b>	<b>30</b>	<b>323</b>	<b>24.5</b>	<b>22.2</b>
Female	1,189	1	15	15	30	323	24.3	21.8
Male	27	1	15	27	30	195	31.6	35.4
<b>Selinexor</b>	<b>4,117</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>420</b>	<b>42.6</b>	<b>35.4</b>
Female	2,005	1	28	28	56	420	44.0	38.3
Male	2,112	1	28	28	56	374	41.3	32.4
<b>Imipenem Cilastatin and Relebactam</b>	<b>470</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>310</b>	<b>5.5</b>	<b>20.8</b>
Female	219	1	1	1	1	78	3.9	8.9
Male	251	1	1	1	1	310	6.8	27.2
<b>Ferric Maltol</b>	<b>436</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>210</b>	<b>44.7</b>	<b>32.1</b>
Female	401	1	30	30	60	210	44.4	32.0
Male	35	15	30	30	60	161	48.0	34.3

**Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>11,032</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,121</b>	<b>81.0</b>	<b>101.9</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pexidartinib</b>	<b>297</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>360</b>	<b>60.2</b>	<b>60.3</b>
Female	197	2	30	30	60	360	55.2	53.3
Male	100	3	30	30	79	330	70.1	71.4
<b>Pretomanid</b>	<b>59</b>	<b>22</b>	<b>26</b>	<b>50</b>	<b>78</b>	<b>208</b>	<b>62.0</b>	<b>50.4</b>
Female	40	22	26	28	78	208	59.8	51.2
Male	19	26	26	52	89	208	66.6	49.7
<b>Pitolisant</b>	<b>6,113</b>	<b>1</b>	<b>30</b>	<b>44</b>	<b>90</b>	<b>1,091</b>	<b>93.6</b>	<b>125.6</b>
Female	4,180	1	30	35	90	1,061	92.1	122.5
Male	1,933	1	30	60	92	1,091	97.0	132.0
<b>Entrectinib</b>	<b>690</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>727</b>	<b>60.2</b>	<b>83.1</b>
Female	429	1	30	30	60	727	64.2	91.8
Male	261	2	30	30	60	607	53.5	65.8
<b>Fedratinib</b>	<b>2,219</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>64</b>	<b>1,027</b>	<b>71.6</b>	<b>94.5</b>
Female	1,064	1	30	30	60	1,027	71.7	102.8
Male	1,155	1	30	30	81	775	71.6	86.2
<b>Upadacitinib</b>	<b>69,073</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,217</b>	<b>79.3</b>	<b>103.2</b>
Female	55,904	1	30	30	90	1,116	79.1	102.5
Male	13,169	1	30	30	90	1,217	80.2	106.1
<b>Lefamulin</b>	<b>271</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>5</b>	<b>70</b>	<b>4.8</b>	<b>6.3</b>
Female	154	1	1	5	5	70	5.0	6.5
Male	117	1	1	2	5	55	4.4	6.0

**Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Ga-68-DOTATOC</b>	<b>205</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
Female	106	1	1	1	1	1	1.0	0.0
Male	99	1	1	1	1	1	1.0	0.0
<b>Istradefylline</b>	<b>8,403</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>150</b>	<b>1,079</b>	<b>125.1</b>	<b>153.9</b>
Female	3,389	1	30	60	150	1,019	124.4	152.6
Male	5,014	1	30	60	150	1,079	125.5	154.8

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>225</b>	<b>165</b>	<b>100.0%</b>	<b>49</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
25-40 years	74	55	33.3%	*****	*****	*****	*****	*****	*****	0	NaN*
41-64 years	97	70	42.4%	*****	*****	*****	*****	*****	*****	0	NaN*
≥ 65 years	27	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>76</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
25-40 years	65	65	85.5%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Solriamfetol</b>	<b>31,266</b>	<b>21,132</b>	<b>100.0%</b>	<b>7,072</b>	<b>100.0%</b>	<b>2,653</b>	<b>100.0%</b>	<b>336</b>	<b>100.0%</b>	<b>73</b>	<b>100.0%</b>
0-17 years	163	106	0.5%	41	0.6%	*****	*****	*****	*****	*****	*****
18-24 years	2,449	1,746	8.3%	487	6.9%	*****	*****	*****	*****	*****	*****
25-40 years	8,388	5,808	27.5%	1,846	26.1%	637	24.0%	83	24.7%	14	19.2%
41-64 years	15,016	10,035	47.5%	3,410	48.2%	1,360	51.3%	171	50.9%	40	54.8%
≥ 65 years	5,250	3,437	16.3%	1,288	18.2%	466	17.6%	*****	*****	*****	*****
<b>Siponimod</b>	<b>5,176</b>	<b>2,265</b>	<b>100.0%</b>	<b>1,418</b>	<b>100.0%</b>	<b>1,177</b>	<b>100.0%</b>	<b>244</b>	<b>100.0%</b>	<b>72</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	48	20	0.9%	*****	*****	15	1.3%	*****	*****	0	0.0%
25-40 years	931	449	19.8%	236	16.6%	196	16.7%	*****	*****	*****	*****
41-64 years	3,514	1,531	67.6%	964	68.0%	792	67.3%	175	71.7%	52	72.2%
≥ 65 years	683	265	11.7%	*****	*****	174	14.8%	*****	*****	*****	*****
<b>Romosozumab-aqqg</b>	<b>275,322</b>	<b>271,154</b>	<b>100.0%</b>	<b>2,577</b>	<b>100.0%</b>	<b>1,506</b>	<b>100.0%</b>	<b>85</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
25-40 years	431	413	0.2%	*****	*****	*****	*****	0	0.0%	0	NaN*
41-64 years	21,790	21,159	7.8%	397	15.4%	*****	*****	*****	*****	0	NaN*
≥ 65 years	253,062	249,553	92.0%	2,159	83.8%	*****	*****	*****	*****	0	NaN*
<b>Erdafitinib</b>	<b>1,211</b>	<b>759</b>	<b>100.0%</b>	<b>310</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*



**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	243	127	16.7%	*****	*****	*****	*****	*****	*****	0	NaN*
≥ 65 years	937	614	80.9%	231	74.5%	*****	*****	*****	*****	0	NaN*
<b>Risankizumab-rzaa</b>	<b>83,829</b>	<b>34,724</b>	<b>100.0%</b>	<b>32,706</b>	<b>100.0%</b>	<b>14,421</b>	<b>100.0%</b>	<b>1,734</b>	<b>100.0%</b>	<b>244</b>	<b>100.0%</b>
0-17 years	126	42	0.1%	60	0.2%	*****	*****	*****	*****	0	0.0%
18-24 years	4,227	1,861	5.4%	1,732	5.3%	*****	*****	*****	*****	*****	*****
25-40 years	20,667	9,028	26.0%	8,282	25.3%	2,985	20.7%	*****	*****	*****	*****
41-64 years	45,922	19,567	56.4%	17,956	54.9%	7,380	51.2%	882	50.9%	137	56.1%
≥ 65 years	12,887	4,226	12.2%	4,676	14.3%	3,450	23.9%	468	27.0%	67	27.5%
<b>Tafamidis</b>	<b>12,615</b>	<b>4,552</b>	<b>100.0%</b>	<b>3,316</b>	<b>100.0%</b>	<b>3,491</b>	<b>100.0%</b>	<b>903</b>	<b>100.0%</b>	<b>353</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	0.0%	*****	*****	0	0.0%	*****	*****	0	0.0%
41-64 years	*****	*****	5.6%	*****	*****	138	4.0%	*****	*****	*****	*****
≥ 65 years	12,029	4,299	94.4%	3,157	95.2%	3,353	96.0%	*****	*****	*****	*****
<b>Alpelisib</b>	<b>9,281</b>	<b>5,599</b>	<b>100.0%</b>	<b>2,294</b>	<b>100.0%</b>	<b>1,284</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	53	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	15	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	180	113	2.0%	43	1.9%	*****	*****	*****	*****	0	0.0%
41-64 years	3,471	2,066	36.9%	837	36.5%	512	39.9%	*****	*****	*****	*****
≥ 65 years	5,562	3,379	60.4%	1,396	60.9%	741	57.7%	*****	*****	*****	*****
<b>Polatuzumab Vedotin-piiq</b>	<b>8,694</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	17	17	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	111	111	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
41-64 years	918	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	7,648	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>1,216</b>	<b>1,098</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>	<b>21</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	16	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	455	417	38.0%	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	723	645	58.7%	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	22	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>4,117</b>	<b>2,840</b>	<b>100.0%</b>	<b>1,011</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN*
25-40 years	25	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
41-64 years	*****	648	22.8%	*****	*****	*****	*****	*****	*****	0	NaN*
≥ 65 years	3,126	2,162	76.1%	772	76.4%	192	*****	0	0.0%	0	NaN*
<b>Imipenem Cilastatin and Relebactam</b>	<b>470</b>	<b>457</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN*	0	NaN*
41-64 years	186	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
≥ 65 years	212	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Ferric Maltol</b>	<b>436</b>	<b>288</b>	<b>100.0%</b>	<b>115</b>	<b>100.0%</b>	<b>33</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	22	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
25-40 years	174	119	41.3%	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	216	138	47.9%	62	53.9%	16	48.5%	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Darolutamide</b>	<b>11,032</b>	<b>5,799</b>	<b>100.0%</b>	<b>2,893</b>	<b>100.0%</b>	<b>2,048</b>	<b>100.0%</b>	<b>257</b>	<b>100.0%</b>	<b>35</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	631	361	6.2%	154	5.3%	100	4.9%	*****	*****	*****	*****
≥ 65 years	10,401	5,438	93.8%	2,739	94.7%	1,948	95.1%	*****	*****	*****	*****
<b>Pexidartinib</b>	<b>297</b>	<b>180</b>	<b>100.0%</b>	<b>74</b>	<b>100.0%</b>	<b>43</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
25-40 years	111	64	35.6%	27	36.5%	20	46.5%	0	NaN*	0	NaN*
41-64 years	147	*****	*****	34	45.9%	*****	*****	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
<b>Pretomanid</b>	<b>59</b>	<b>27</b>	<b>100.0%</b>	<b>19</b>	<b>100.0%</b>	<b>13</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	NaN*	0	NaN*
25-40 years	20	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	23	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Pitolisant</b>	<b>6,113</b>	<b>2,945</b>	<b>100.0%</b>	<b>1,645</b>	<b>100.0%</b>	<b>1,260</b>	<b>100.0%</b>	<b>222</b>	<b>100.0%</b>	<b>41</b>	<b>100.0%</b>

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	57	24	0.8%	*****	*****	15	1.2%	*****	*****	*****	*****
18-24 years	781	382	13.0%	219	13.3%	152	12.1%	*****	*****	*****	*****
25-40 years	2,213	1,100	37.4%	596	36.2%	440	34.9%	*****	*****	*****	*****
41-64 years	2,418	1,174	39.9%	615	37.4%	502	39.8%	106	47.7%	21	51.2%
≥ 65 years	644	265	9.0%	*****	*****	151	12.0%	*****	*****	*****	*****
<b>Entrectinib</b>	<b>690</b>	<b>460</b>	<b>100.0%</b>	<b>139</b>	<b>100.0%</b>	<b>78</b>	<b>100.0%</b>	<b>13</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	17	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN*
41-64 years	244	151	32.8%	58	41.7%	*****	*****	*****	*****	0	NaN*
≥ 65 years	381	268	58.3%	70	50.4%	*****	*****	*****	*****	0	NaN*
<b>Fedratinib</b>	<b>2,219</b>	<b>1,275</b>	<b>100.0%</b>	<b>564</b>	<b>100.0%</b>	<b>336</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	33	20	1.6%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	316	190	14.9%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	1,870	1,065	83.5%	472	83.7%	296	88.1%	*****	*****	*****	*****
<b>Upadacitinib</b>	<b>69,073</b>	<b>36,493</b>	<b>100.0%</b>	<b>18,963</b>	<b>100.0%</b>	<b>11,772</b>	<b>100.0%</b>	<b>1,584</b>	<b>100.0%</b>	<b>261</b>	<b>100.0%</b>
0-17 years	155	84	0.2%	45	0.2%	26	0.2%	0	0.0%	0	0.0%
18-24 years	1,110	679	1.9%	272	1.4%	147	1.2%	*****	*****	*****	*****
25-40 years	6,822	3,954	10.8%	1,826	9.6%	940	8.0%	*****	*****	*****	*****
41-64 years	41,072	21,995	60.3%	11,174	58.9%	6,822	58.0%	929	58.6%	152	58.2%
≥ 65 years	19,914	9,781	26.8%	5,646	29.8%	3,837	32.6%	555	35.0%	95	36.4%

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Lefamulin</b>	<b>271</b>	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
0-17 years	0	0	0.0%	0	0.0%	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*	0	NaN*
41-64 years	135	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	117	117	43.5%	0	0.0%	0	NaN*	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>205</b>	<b>205</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	151	151	73.7%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>8,403</b>	<b>3,239</b>	<b>100.0%</b>	<b>2,384</b>	<b>100.0%</b>	<b>2,154</b>	<b>100.0%</b>	<b>525</b>	<b>100.0%</b>	<b>101</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	29	12	0.4%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	1,184	486	15.0%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	7,190	2,741	84.6%	2,037	85.4%	1,868	86.7%	456	86.9%	88	87.1%

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>225</b>	<b>1</b>	<b>16</b>	<b>30</b>	<b>34</b>	<b>600</b>	<b>38.0</b>	<b>55.4</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	74	1	14	30	34	390	37.7	50.7
41-64 years	97	1	21	30	37	600	42.3	67.7
≥ 65 years	27	1	24	30	49	162	39.1	37.3
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>30</b>	<b>2.6</b>	<b>3.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	65	1	1	3	3	30	2.6	3.6
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Solriamfetol</b>	<b>31,266</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,146</b>	<b>57.1</b>	<b>78.2</b>
0-17 years	163	1	30	30	60	750	63.1	94.7
18-24 years	2,449	1	30	30	60	1,146	55.0	82.3
25-40 years	8,388	1	30	30	60	1,079	54.4	73.4
41-64 years	15,016	1	30	30	60	1,146	58.5	80.8
≥ 65 years	5,250	1	30	30	60	1,134	58.3	75.3
<b>Siponimod</b>	<b>5,176</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>1,160</b>	<b>110.7</b>	<b>152.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	48	5	30	60	150	730	105.1	125.6
25-40 years	931	1	30	38	102	1,066	100.1	138.8
41-64 years	3,514	1	30	60	120	1,160	112.6	156.1
≥ 65 years	683	4	30	60	125	1,109	115.7	152.6
<b>Romosozumab-aqqg</b>	<b>275,322</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>720</b>	<b>3.3</b>	<b>18.1</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	431	1	1	1	1	270	6.7	25.6
41-64 years	21,790	1	1	1	1	470	5.3	23.4
≥ 65 years	253,062	1	1	1	1	720	3.1	17.6
<b>Erdafitinib</b>	<b>1,211</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>448</b>	<b>51.1</b>	<b>48.8</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	243	2	28	30	84	392	61.8	58.5
≥ 65 years	937	1	28	28	56	448	48.2	45.5

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>83,829</b>	<b>1</b>	<b>30</b>	<b>31</b>	<b>84</b>	<b>1,333</b>	<b>79.6</b>	<b>99.2</b>
0-17 years	126	1	28	59	84	532	86.1	96.5
18-24 years	4,227	1	28	31	84	1,182	66.7	75.8
25-40 years	20,667	1	30	31	84	1,184	70.9	88.1
41-64 years	45,922	1	30	31	84	1,333	76.9	97.4
≥ 65 years	12,887	1	28	84	117	1,152	107.5	121.5
<b>Tafamidis</b>	<b>12,615</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>180</b>	<b>1,269</b>	<b>146.4</b>	<b>193.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	12,029	1	30	67	180	1,269	148.0	194.7
<b>Alpelisib</b>	<b>9,281</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,161</b>	<b>60.7</b>	<b>74.2</b>
0-17 years	53	1	28	28	56	193	50.9	40.9
18-24 years	15	4	28	28	46	214	45.1	50.9
25-40 years	180	1	28	28	56	504	55.2	65.4
41-64 years	3,471	1	28	28	56	1,161	64.3	84.6
≥ 65 years	5,562	1	28	28	56	977	58.7	67.5
<b>piiq</b>	<b>8,694</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>112</b>	<b>1.1</b>	<b>2.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	17	1	1	1	1	1	1.0	0.0
25-40 years	111	1	1	1	1	1	1.0	0.0
41-64 years	918	1	1	1	1	112	1.2	4.0
≥ 65 years	7,648	1	1	1	1	80	1.1	1.6



**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Bremelanotide</b>	<b>1,216</b>	<b>1</b>	<b>15</b>	<b>15</b>	<b>30</b>	<b>323</b>	<b>24.5</b>	<b>22.2</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	16	15	15	15	28	38	20.6	7.6
25-40 years	455	1	15	15	30	323	24.1	23.5
41-64 years	723	1	15	15	30	222	25.0	21.8
≥ 65 years	22	2	15	15	15	45	17.6	8.4
<b>Selinexor</b>	<b>4,117</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>420</b>	<b>42.6</b>	<b>35.4</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	956	1	28	28	56	420	44.4	41.1
≥ 65 years	3,126	1	28	28	56	336	42.2	33.5
<b>Imipenem Cilastatin and Relebactam</b>	<b>470</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>310</b>	<b>5.5</b>	<b>20.8</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	186	1	1	1	4	87	4.3	9.7
≥ 65 years	212	1	1	1	1	172	3.9	14.1
<b>Ferric Maltol</b>	<b>436</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>210</b>	<b>44.7</b>	<b>32.1</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	174	1	30	30	55	210	43.0	32.5
41-64 years	216	1	30	30	60	169	45.7	30.9
≥ 65 years	20	12	30	30	30	161	39.9	32.9

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>11,032</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,121</b>	<b>81.0</b>	<b>101.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	631	1	30	30	72	869	72.8	102.2
≥ 65 years	10,401	1	30	30	90	1,121	81.5	101.9
<b>Pexidartinib</b>	<b>297</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>360</b>	<b>60.2</b>	<b>60.3</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	111	3	30	30	60	360	63.6	62.5
41-64 years	147	2	30	30	60	330	57.9	62.7
≥ 65 years	*****	30	30	30	30	30	30.0	0.0
<b>Pretomanid</b>	<b>59</b>	<b>22</b>	<b>26</b>	<b>50</b>	<b>78</b>	<b>208</b>	<b>62.0</b>	<b>50.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	20	26	26	30	52	136	48.8	34.6
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	23	22	26	26	78	182	56.5	48.1
<b>Pitolisant</b>	<b>6,113</b>	<b>1</b>	<b>30</b>	<b>44</b>	<b>90</b>	<b>1,091</b>	<b>93.6</b>	<b>125.6</b>
0-17 years	57	4	30	60	120	837	119.4	163.2
18-24 years	781	1	30	37	90	1,091	88.2	124.4
25-40 years	2,213	1	30	33	90	976	86.8	113.6
41-64 years	2,418	1	30	39	110	1,061	99.6	136.9
≥ 65 years	644	2	30	60	120	906	99.3	116.9

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Entrectinib</b>	<b>690</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>727</b>	<b>60.2</b>	<b>83.1</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	47	14	30	30	60	547	69.8	94.6
41-64 years	244	1	30	30	60	727	60.5	87.0
≥ 65 years	381	3	30	30	60	668	58.5	80.1
<b>Fedratinib</b>	<b>2,219</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>64</b>	<b>1,027</b>	<b>71.6</b>	<b>94.5</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	33	15	30	30	60	690	80.5	138.9
41-64 years	316	1	30	30	60	775	64.3	81.4
≥ 65 years	1,870	1	30	30	71	1,027	72.7	95.6
<b>Upadacitinib</b>	<b>69,073</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,217</b>	<b>79.3</b>	<b>103.2</b>
0-17 years	155	1	30	30	75	327	60.0	55.2
18-24 years	1,110	1	30	30	60	967	60.8	75.2
25-40 years	6,822	1	30	30	60	1,054	65.7	82.5
41-64 years	41,072	1	30	30	90	1,217	78.3	102.4
≥ 65 years	19,914	1	30	40	90	1,107	87.3	111.8
<b>Lefamulin</b>	<b>271</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>5</b>	<b>70</b>	<b>4.8</b>	<b>6.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	135	1	1	2	5	70	4.4	8.0
≥ 65 years	117	1	2	5	5	14	4.6	2.6

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023 by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Ga-68-DOTATOC</b>	<b>205</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	151	1	1	1	1	1	1.0	0.0
<b>Istradefylline</b>	<b>8,403</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>150</b>	<b>1,079</b>	<b>125.1</b>	<b>153.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	29	30	30	60	131	874	115.3	172.4
41-64 years	1,184	1	30	60	120	1,031	116.1	149.1
≥ 65 years	7,190	1	30	60	150	1,079	126.6	154.6

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Caplacizumab-yhdp</i>	147	111	75.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Brexanolone</i>	76	76	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	9,289	6,005	64.6%	2,057	22.1%	987	10.6%	188	2.0%	52	0.6%
<i>Siponimod</i>	1,685	680	40.4%	443	26.3%	417	24.7%	100	5.9%	45	2.7%
<i>Romozosumab-aqqg</i>	38,408	37,006	96.3%	733	1.9%	606	1.6%	63	0.2%	0	0.0%
<i>Erdafitinib</i>	566	318	56.2%	149	26.3%	*****	*****	*****	*****	0	0.0%
<i>Risankizumab-rzaa</i>	29,747	15,061	50.6%	7,960	26.8%	5,860	19.7%	719	2.4%	147	0.5%
<i>Tafamidis</i>	4,927	1,348	27.4%	1,048	21.3%	1,748	35.5%	531	10.8%	252	5.1%
<i>Alpelisib</i>	4,484	2,735	61.0%	1,045	23.3%	639	14.3%	*****	*****	*****	*****
<i>Polatuzumab Vedotin-piiq</i>	2,469	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Bremelanotide</i>	899	820	91.2%	66	7.3%	13	1.4%	0	0.0%	0	0.0%
<i>Selinexor</i>	2,314	1,597	69.0%	566	24.5%	*****	*****	*****	*****	0	0.0%
<i>Imipenem Cilastatin and Relebactam</i>	312	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Ferric Maltol</i>	330	202	61.2%	97	29.4%	31	9.4%	0	0.0%	0	0.0%
<i>Darolutamide</i>	3,777	1,761	46.6%	953	25.2%	896	23.7%	144	3.8%	23	0.6%
<i>Pexidartinib</i>	85	51	60.0%	14	16.5%	20	23.5%	0	0.0%	0	0.0%
<i>Pretomanid</i>	23	11	47.80%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Pitolisant</i>	2,703	1,200	44.4%	698	25.8%	632	23.4%	137	5.1%	36	1.3%
<i>Entrectinib</i>	331	224	67.7%	62	18.7%	*****	*****	*****	*****	0	0.0%
<i>Fedratinib</i>	807	466	57.7%	189	23.4%	129	16.0%	*****	*****	*****	*****
<i>Upadacitinib</i>	23,228	10,862	46.8%	6,223	26.8%	5,002	21.5%	947	4.1%	194	0.8%
<i>Lefamulin</i>	170	170	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

**Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Number of Patients by First Treatment Episode Duration											
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
<i>Ga-68-DOTATOC</i>	183	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Istradefylline</i>	4,221	35.8%	1,168	27.7%	1,121	26.6%	339	8.0%	80	1.9%		

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	*****	*****	*****	*****	*****	*****
<i>Caplacizumab-yhdp</i>	147	1	22	30	30	144	31.6	19.8
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.
<i>Brexanolone</i>	76	1	1	3	3	30	2.6	3.3
<i>Solriamfetol</i>	9,289	1	30	30	60	1,146	67.6	104.7
<i>Siponimod</i>	1,685	1	30	60	150	1,156	130.8	185.6
<i>Romosozumab-aqqg</i>	38,408	1	1	1	1	720	7.4	33.8
<i>Erdafitinib</i>	566	1	28	28	84	380	59.0	56.1
<i>Risankizumab-rzaa</i>	29,747	1	28	30	84	1,333	81.0	111.6
<i>Tafamidis</i>	4,927	1	30	108	253	1,269	198.8	235.4
<i>Alpelisib</i>	4,484	1	28	28	56	1,161	63.0	81.4
<i>Polatuzumab Vedotin-piiq</i>	2,469	1	1	1	1	112	1.1	3.0
<i>Bremelanotide</i>	899	1	15	15	30	323	24.3	21.1
<i>Selinexor</i>	2,314	1	28	28	56	420	42.4	35.9
<i>Imipenem Cilastatin and Relebactam</i>	312	1	1	1	1	172	3.6	12.9
<i>Ferric Maltol</i>	330	1	30	30	60	210	47.6	34.7
<i>Darolutamide</i>	3,777	1	30	60	120	1,121	98.4	123.4
<i>Pexidartinib</i>	85	2	30	30	60	360	72.4	82.5
<i>Pretomanid</i>	23	26	26	34	136	208	81.3	69.2
<i>Pitolisant</i>	2,703	1	30	60	120	1,091	109.9	150.3
<i>Entrectinib</i>	331	2	30	30	60	505	58.7	72.9
<i>Fedratinib</i>	807	2	30	30	74	960	76.9	111.2
<i>Upadacitinib</i>	23,228	1	30	58	116	1,217	99.8	132.6
<i>Lefamulin</i>	170	1	3	5	5	30	5.1	3.5
<i>Ga-68-DOTATOC</i>	183	1	1	1	1	1	1.0	0.0
<i>Istradefylline</i>	4,221	1	30	89	180	1,079	142.8	174.5

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>PrabotulinumtoxinA-xvfs</b>	****	****	****	****	****	****	****	****	****	****	****
Female	****	****	****	****	****	****	****	****	****	****	****
Male	****	****	****	****	****	****	****	****	****	****	****
<b>Caplacizumab-yhdp</b>	<b>147</b>	<b>111</b>	<b>100.0%</b>	****	****	****	****	<b>0</b>	NaN*	<b>0</b>	NaN*
Female	105	82	73.9%	****	****	****	****	0	NaN*	0	NaN*
Male	42	29	26.1%	****	****	****	****	0	NaN*	0	NaN*
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>76</b>	<b>100.0%</b>	<b>0</b>	NaN*	<b>0</b>	NaN*	<b>0</b>	NaN*	<b>0</b>	NaN*
Female	****	****	****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Male	****	****	****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Solriamfetol</b>	<b>9,289</b>	<b>6,005</b>	<b>100.0%</b>	<b>2,057</b>	<b>100.0%</b>	<b>987</b>	<b>100.0%</b>	<b>188</b>	<b>100.0%</b>	<b>52</b>	<b>100.0%</b>
Female	5,561	3,616	60.2%	1,236	60.1%	578	58.6%	101	53.7%	30	57.7%
Male	3,728	2,389	39.8%	821	39.9%	409	41.4%	87	46.3%	22	42.3%
<b>Siponimod</b>	<b>1,685</b>	<b>680</b>	<b>100.0%</b>	<b>443</b>	<b>100.0%</b>	<b>417</b>	<b>100.0%</b>	<b>100</b>	<b>100.0%</b>	<b>45</b>	<b>100.0%</b>
Female	1,256	511	75.1%	321	72.5%	310	74.3%	****	****	****	****
Male	429	169	24.9%	122	27.5%	107	25.7%	****	****	****	****
<b>Romosozumab-aqqg</b>	<b>38,408</b>	<b>37,006</b>	<b>100.0%</b>	<b>733</b>	<b>100.0%</b>	<b>606</b>	<b>100.0%</b>	<b>63</b>	<b>100.0%</b>	<b>0</b>	NaN*
Female	37,601	36,259	98.0%	704	96.0%	****	****	****	****	0	NaN*
Male	807	747	2.0%	29	4.0%	****	****	****	****	0	NaN*
<b>Erdafitinib</b>	<b>566</b>	<b>318</b>	<b>100.0%</b>	<b>149</b>	<b>100.0%</b>	****	****	****	****	<b>0</b>	NaN*



**Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	204	131	41.2%	48	32.2%	*****	*****	0	0.0%	0	NaN*
Male	362	187	58.8%	101	67.8%	*****	*****	*****	*****	0	NaN*
<b>Risankizumab-rzaa</b>	<b>29,747</b>	<b>15,061</b>	<b>100.0%</b>	<b>7,960</b>	<b>100.0%</b>	<b>5,860</b>	<b>100.0%</b>	<b>719</b>	<b>100.0%</b>	<b>147</b>	<b>100.0%</b>
Female	14,823	7,444	49.4%	3,898	49.0%	3,054	52.1%	347	48.3%	80	54.4%
Male	14,924	7,617	50.6%	4,062	51.0%	2,806	47.9%	372	51.7%	67	45.6%
<b>Tafamidis</b>	<b>4,927</b>	<b>1,348</b>	<b>100.0%</b>	<b>1,048</b>	<b>100.0%</b>	<b>1,748</b>	<b>100.0%</b>	<b>531</b>	<b>100.0%</b>	<b>252</b>	<b>100.0%</b>
Female	897	279	20.7%	219	20.9%	289	16.5%	86	16.2%	24	9.5%
Male	4,030	1,069	79.3%	829	79.1%	1,459	83.5%	445	83.8%	228	90.5%
<b>Alpelisib</b>	<b>4,484</b>	<b>2,735</b>	<b>100.0%</b>	<b>1,045</b>	<b>100.0%</b>	<b>639</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	4,380	2,670	97.6%	1,019	97.5%	626	98.0%	*****	*****	*****	*****
Male	104	65	2.4%	26	2.5%	13	2.0%	0	0.0%	0	0.0%
<b>Polatuzumab Vedotin-piiq</b>	<b>2,469</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	1,028	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	1,441	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>899</b>	<b>820</b>	<b>100.0%</b>	<b>66</b>	<b>100.0%</b>	<b>13</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	888	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	11	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>2,314</b>	<b>1,597</b>	<b>100.0%</b>	<b>566</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>
Female	1,103	753	47.2%	269	47.5%	*****	*****	*****	*****	0	NaN*
Male	1,211	844	52.8%	297	52.5%	*****	*****	*****	*****	0	NaN*
<b>Imipenem Cilastatin and Relebactam</b>	<b>312</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	136	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*

**Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	176	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Ferric Maltol</b>	<b>330</b>	<b>202</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>	<b>31</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	303	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	27	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Darolutamide</b>	<b>3,777</b>	<b>1,761</b>	<b>100.0%</b>	<b>953</b>	<b>100.0%</b>	<b>896</b>	<b>100.0%</b>	<b>144</b>	<b>100.0%</b>	<b>23</b>	<b>100.0%</b>
Female	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
Male	*****	1,761	100.0%	*****	*****	896	100.0%	144	100.0%	23	100.0%
<b>Pexidartinib</b>	<b>85</b>	<b>51</b>	<b>100.0%</b>	<b>14</b>	<b>100.0%</b>	<b>20</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	57	34	66.7%	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	28	17	33.3%	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Pretomanid</b>	<b>23</b>	<b>11</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Pitolisant</b>	<b>2,703</b>	<b>1,200</b>	<b>100.0%</b>	<b>698</b>	<b>100.0%</b>	<b>632</b>	<b>100.0%</b>	<b>137</b>	<b>100.0%</b>	<b>36</b>	<b>100.0%</b>
Female	1,857	833	69.4%	467	66.9%	439	69.5%	95	69.3%	23	63.9%
Male	846	367	30.6%	231	33.1%	193	30.5%	42	30.7%	13	36.1%
<b>Entrectinib</b>	<b>331</b>	<b>224</b>	<b>100.0%</b>	<b>62</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
Female	195	132	58.9%	34	54.8%	*****	*****	*****	*****	0	NaN*
Male	136	92	41.1%	28	45.2%	*****	*****	*****	*****	0	NaN*
<b>Fedratinib</b>	<b>807</b>	<b>466</b>	<b>100.0%</b>	<b>189</b>	<b>100.0%</b>	<b>129</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	388	236	50.6%	84	44.4%	57	44.2%	*****	*****	*****	*****
Male	419	230	49.4%	105	55.6%	72	55.8%	*****	*****	*****	*****

**Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Upadacitinib</b>	<b>23,228</b>	<b>10,862</b>	<b>100.0%</b>	<b>6,223</b>	<b>100.0%</b>	<b>5,002</b>	<b>100.0%</b>	<b>947</b>	<b>100.0%</b>	<b>194</b>	<b>100.0%</b>
Female	18,421	8,624	79.4%	4,902	78.8%	3,985	79.7%	757	79.9%	153	78.9%
Male	4,807	2,238	20.6%	1,321	21.2%	1,017	20.3%	190	20.1%	41	21.1%
<b>Lefamulin</b>	<b>170</b>	<b>170</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	103	103	60.6%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Male	67	67	39.4%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>183</b>	<b>183</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	98	98	53.6%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Male	85	85	46.4%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>4,221</b>	<b>1,513</b>	<b>100.0%</b>	<b>1,168</b>	<b>100.0%</b>	<b>1,121</b>	<b>100.0%</b>	<b>339</b>	<b>100.0%</b>	<b>80</b>	<b>100.0%</b>
Female	1,710	614	40.6%	466	39.9%	459	40.9%	142	41.9%	29	36.3%
Male	2,511	899	59.4%	702	60.1%	662	59.1%	197	58.1%	51	63.8%

\*NaN: Not a Number

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>147</b>	<b>1</b>	<b>22</b>	<b>30</b>	<b>30</b>	<b>144</b>	<b>31.6</b>	<b>19.8</b>
Female	105	1	23	30	30	98	31.3	17.8
Male	42	1	18	30	37	144	32.2	24.4
<b>Triclabendazole</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>30</b>	<b>2.6</b>	<b>3.3</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Solriamfetol</b>	<b>9,289</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,146</b>	<b>67.6</b>	<b>104.7</b>
Female	5,561	1	30	30	60	1,146	66.0	102.4
Male	3,728	1	30	30	60	1,146	70.1	108.1
<b>Siponimod</b>	<b>1,685</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>150</b>	<b>1,156</b>	<b>130.8</b>	<b>185.6</b>
Female	1,256	2	30	60	150	1,156	135.0	195.5
Male	429	1	30	60	144	939	118.5	152.5
<b>Romosozumab-aqqg</b>	<b>38,408</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>720</b>	<b>7.4</b>	<b>33.8</b>
Female	37,601	1	1	1	1	720	7.3	33.4
Male	807	1	1	1	1	420	14.3	47.8
<b>Erdafitinib</b>	<b>566</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>84</b>	<b>380</b>	<b>59.0</b>	<b>56.1</b>
Female	204	1	28	28	56	294	49.7	46.5
Male	362	1	28	29	84	380	64.3	60.2

**Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>29,747</b>	<b>1</b>	<b>28</b>	<b>30</b>	<b>84</b>	<b>1,333</b>	<b>81.0</b>	<b>111.6</b>
Female	14,823	1	28	30	86	1,333	82.5	112.9
Male	14,924	1	28	30	84	1,180	79.5	110.2
<b>Tafamidis</b>	<b>4,927</b>	<b>1</b>	<b>30</b>	<b>108</b>	<b>253</b>	<b>1,269</b>	<b>198.8</b>	<b>235.4</b>
Female	897	1	30	90	210	1,194	165.4	198.8
Male	4,030	1	30	120	269	1,269	206.2	242.2
<b>Alpelisib</b>	<b>4,484</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,161</b>	<b>63.0</b>	<b>81.4</b>
Female	4,380	1	28	28	56	1,161	63.4	82.0
Male	104	2	28	28	56	214	49.9	41.7
<b>Polatuzumab Vedotin-piiq</b>	<b>2,469</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>112</b>	<b>1.1</b>	<b>3.0</b>
Female	1,028	1	1	1	1	21	1.0	0.9
Male	1,441	1	1	1	1	112	1.2	3.9
<b>Bremelanotide</b>	<b>899</b>	<b>1</b>	<b>15</b>	<b>15</b>	<b>30</b>	<b>323</b>	<b>24.3</b>	<b>21.1</b>
Female	888	1	15	15	30	323	24.1	20.4
Male	11	15	15	30	45	195	42.3	52.7
<b>Selinexor</b>	<b>2,314</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>420</b>	<b>42.4</b>	<b>35.9</b>
Female	1,103	1	28	28	56	420	43.5	38.2
Male	1,211	1	28	28	56	374	41.4	33.6
<b>Imipenem Cilastatin and Relebactam</b>	<b>312</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>172</b>	<b>3.6</b>	<b>12.9</b>
Female	136	1	1	1	1	78	2.9	8.1
Male	176	1	1	1	1	172	4.2	15.6
<b>Ferric Maltol</b>	<b>330</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>210</b>	<b>47.6</b>	<b>34.7</b>
Female	303	1	30	30	60	210	47.2	34.4
Male	27	15	30	30	90	161	51.5	38.1

**Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>3,777</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>1,121</b>	<b>98.4</b>	<b>123.4</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pexidartinib</b>	<b>85</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>360</b>	<b>72.4</b>	<b>82.5</b>
Female	57	2	30	30	60	360	67.2	74.1
Male	28	7	30	30	86	330	83.0	98.1
<b>Pretomanid</b>	<b>23</b>	<b>26</b>	<b>26</b>	<b>34</b>	<b>136</b>	<b>208</b>	<b>81.3</b>	<b>69.2</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pitolisant</b>	<b>2,703</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>1,091</b>	<b>109.9</b>	<b>150.3</b>
Female	1,857	1	30	60	120	1,061	109.2	147.3
Male	846	1	30	60	120	1,091	111.5	157.0
<b>Entrectinib</b>	<b>331</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>505</b>	<b>58.7</b>	<b>72.9</b>
Female	195	2	30	30	60	505	60.6	77.8
Male	136	2	30	30	60	414	55.9	65.5
<b>Fedratinib</b>	<b>807</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>74</b>	<b>960</b>	<b>76.9</b>	<b>111.2</b>
Female	388	4	30	30	60	960	78.1	124.3
Male	419	2	30	30	86	775	75.9	97.6
<b>Upadacitinib</b>	<b>23,228</b>	<b>1</b>	<b>30</b>	<b>58</b>	<b>116</b>	<b>1,217</b>	<b>99.8</b>	<b>132.6</b>
Female	18,421	1	30	60	120	1,116	100.1	132.3
Male	4,807	1	30	52	106	1,217	98.3	133.7
<b>Lefamulin</b>	<b>170</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>5</b>	<b>30</b>	<b>5.1</b>	<b>3.5</b>
Female	103	1	3	5	5	15	4.9	3.0
Male	67	1	2	5	7	30	5.4	4.2

**Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Ga-68-DOTATOC</b>	<b>183</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
Female	98	1	1	1	1	1	1.0	0.0
Male	85	1	1	1	1	1	1.0	0.0
<b>Istradefylline</b>	<b>4,221</b>	<b>1</b>	<b>30</b>	<b>89</b>	<b>180</b>	<b>1,079</b>	<b>142.8</b>	<b>174.5</b>
Female	1,710	1	30	90	180	1,019	143.1	172.9
Male	2,511	1	30	88	180	1,079	142.6	175.7

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>147</b>	<b>111</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	42	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
41-64 years	72	53	47.7%	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	19	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>76</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
25-40 years	65	65	85.5%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*



**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
≥ 65 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Solriamfetol</b>	<b>9,289</b>	<b>6,005</b>	<b>100.0%</b>	<b>2,057</b>	<b>100.0%</b>	<b>987</b>	<b>100.0%</b>	<b>188</b>	<b>100.0%</b>	<b>52</b>	<b>100.0%</b>
0-17 years	51	31	0.5%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	665	463	7.7%	*****	*****	*****	*****	17	9.0%	*****	*****
25-40 years	2,523	1,621	27.0%	603	29.3%	238	24.1%	*****	*****	*****	*****
41-64 years	4,322	2,714	45.2%	963	46.8%	526	53.3%	91	48.4%	28	53.8%
≥ 65 years	1,728	1,176	19.6%	363	17.6%	155	15.7%	*****	*****	*****	*****
<b>Siponimod</b>	<b>1,685</b>	<b>680</b>	<b>100.0%</b>	<b>443</b>	<b>100.0%</b>	<b>417</b>	<b>100.0%</b>	<b>100</b>	<b>100.0%</b>	<b>45</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	20	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	304	136	20.0%	79	17.8%	*****	*****	21	21.0%	*****	*****
41-64 years	1,127	452	66.5%	291	65.7%	283	67.9%	*****	*****	*****	*****
≥ 65 years	234	*****	*****	*****	*****	66	15.8%	*****	*****	*****	*****
<b>Romosozumab-aqcg</b>	<b>38,408</b>	<b>37,006</b>	<b>100.0%</b>	<b>733</b>	<b>100.0%</b>	<b>606</b>	<b>100.0%</b>	<b>63</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
25-40 years	86	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
41-64 years	3,480	3,293	8.9%	*****	*****	*****	*****	*****	*****	0	NaN*
≥ 65 years	34,831	33,624	90.9%	619	84.4%	*****	*****	*****	*****	0	NaN*
<b>Erdafitinib</b>	<b>566</b>	<b>318</b>	<b>100.0%</b>	<b>149</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	126	*****	*****	*****	*****	34	35.1%	0	0.0%	0	NaN*
≥ 65 years	422	254	79.9%	106	71.1%	*****	*****	*****	*****	0	NaN*
<b>Risankizumab-rzaa</b>	<b>29,747</b>	<b>15,061</b>	<b>100.0%</b>	<b>7,960</b>	<b>100.0%</b>	<b>5,860</b>	<b>100.0%</b>	<b>719</b>	<b>100.0%</b>	<b>147</b>	<b>100.0%</b>
0-17 years	42	25	0.2%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	1,452	825	5.5%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	7,170	3,734	24.8%	2,071	26.0%	1,205	20.6%	*****	*****	*****	*****
41-64 years	15,604	7,921	52.6%	4,348	54.6%	2,905	49.6%	349	48.5%	81	55.1%
≥ 65 years	5,479	2,556	17.0%	1,163	14.6%	1,510	25.8%	213	29.6%	37	25.2%
<b>Tafamidis</b>	<b>4,927</b>	<b>1,348</b>	<b>100.0%</b>	<b>1,048</b>	<b>100.0%</b>	<b>1,748</b>	<b>100.0%</b>	<b>531</b>	<b>100.0%</b>	<b>252</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	*****	*****	0	0.0%	*****	*****	0	0.0%
41-64 years	*****	80	5.9%	*****	*****	75	4.3%	*****	*****	*****	*****
≥ 65 years	4,695	1,268	94.1%	992	94.7%	1,673	95.7%	*****	*****	*****	*****
<b>Alpelisib</b>	<b>4,484</b>	<b>2,735</b>	<b>100.0%</b>	<b>1,045</b>	<b>100.0%</b>	<b>639</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	95	66	2.4%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,649	913	33.4%	402	38.5%	290	45.4%	*****	*****	*****	*****
≥ 65 years	2,706	1,736	63.5%	619	59.2%	331	51.8%	*****	*****	*****	*****
<b>Polatuzumab Vedotin-piiq</b>	<b>2,469</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
41-64 years	336	*****	*****	0	0.0%	*****	*****	0	NaN*	0	NaN*
≥ 65 years	2,085	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>899</b>	<b>820</b>	<b>100.0%</b>	<b>66</b>	<b>100.0%</b>	<b>13</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	347	321	39.1%	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	530	478	58.3%	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>2,314</b>	<b>1,597</b>	<b>100.0%</b>	<b>566</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
41-64 years	517	337	21.1%	*****	*****	*****	*****	*****	*****	0	NaN*
≥ 65 years	1,775	1,241	77.7%	423	74.7%	111	*****	0	0.0%	0	NaN*
<b>Imipenem Cilastatin and Relebactam</b>	<b>312</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
41-64 years	101	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
≥ 65 years	179	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Ferric Maltol</b>	<b>330</b>	<b>202</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>	<b>31</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	20	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
25-40 years	140	90	44.6%	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	152	88	43.6%	50	51.5%	14	45.2%	0	NaN*	0	NaN*
≥ 65 years	*****	12	5.9%	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Darolutamide</b>	<b>3,777</b>	<b>1,761</b>	<b>100.0%</b>	<b>953</b>	<b>100.0%</b>	<b>896</b>	<b>100.0%</b>	<b>144</b>	<b>100.0%</b>	<b>23</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	253	142	8.1%	*****	*****	51	5.7%	*****	*****	*****	*****
≥ 65 years	3,524	1,619	91.9%	*****	*****	845	94.3%	*****	*****	*****	*****
<b>Pexidartinib</b>	<b>85</b>	<b>51</b>	<b>100.0%</b>	<b>14</b>	<b>100.0%</b>	<b>20</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
25-40 years	35	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	36	25	49.0%	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
<b>Pretomanid</b>	<b>23</b>	<b>11</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN*	0	NaN*
<b>Pitolisant</b>	<b>2,703</b>	<b>1,200</b>	<b>100.0%</b>	<b>698</b>	<b>100.0%</b>	<b>632</b>	<b>100.0%</b>	<b>137</b>	<b>100.0%</b>	<b>36</b>	<b>100.0%</b>

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Number of Patients by First Treatment Episode Duration											
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
0-17 years	29	14	1.2%	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	320	138	11.5%	89	12.8%	*****	*****	16	11.7%	*****	*****	*****
25-40 years	986	441	36.8%	264	37.8%	236	37.3%	*****	*****	*****	*****	*****
41-64 years	1,071	476	39.7%	255	36.5%	249	39.4%	71	51.8%	20	55.6%	*****
≥ 65 years	297	131	10.9%	*****	*****	71	11.2%	*****	*****	*****	*****	*****
<b>Entrectinib</b>	<b>331</b>	<b>224</b>	<b>100.0%</b>	<b>62</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>*****</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	*****
18-24 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN*	*****
25-40 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	*****
41-64 years	116	74	33.0%	*****	*****	*****	*****	*****	*****	0	NaN*	*****
≥ 65 years	188	135	60.3%	32	51.6%	*****	*****	*****	*****	0	NaN*	*****
<b>Fedratinib</b>	<b>807</b>	<b>466</b>	<b>100.0%</b>	<b>189</b>	<b>100.0%</b>	<b>129</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	*****
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	*****
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	*****
41-64 years	*****	*****	*****	36	19.0%	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	692	403	86.5%	153	81.0%	*****	*****	*****	*****	*****	*****	*****
<b>Upadacitinib</b>	<b>23,228</b>	<b>10,862</b>	<b>100.0%</b>	<b>6,223</b>	<b>100.0%</b>	<b>5,002</b>	<b>100.0%</b>	<b>947</b>	<b>100.0%</b>	<b>194</b>	<b>100.0%</b>	<b>*****</b>
0-17 years	91	45	0.4%	*****	*****	*****	*****	0	0.0%	0	0.0%	*****
18-24 years	446	239	2.2%	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	2,412	1,196	11.0%	692	11.1%	462	9.2%	*****	*****	*****	*****	*****
41-64 years	13,502	6,240	57.4%	3,623	58.2%	2,952	59.0%	574	60.6%	113	58.2%	*****
≥ 65 years	6,777	3,142	28.9%	1,761	28.3%	1,489	29.8%	*****	*****	*****	*****	*****

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<b>Lefamulin</b>	<b>170</b>	<b>170</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
41-64 years	65	65	38.2%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	89	89	52.4%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>183</b>	<b>183</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	133	133	72.7%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>4,221</b>	<b>1,513</b>	<b>100.0%</b>	<b>1,168</b>	<b>100.0%</b>	<b>1,121</b>	<b>100.0%</b>	<b>339</b>	<b>100.0%</b>	<b>80</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	12	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	576	*****	*****	*****	*****	*****	*****	43	12.7%	*****	*****
≥ 65 years	3,633	1,287	85.1%	1,024	87.7%	958	85.5%	296	87.3%	68	85.0%

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Caplacizumab-yhdp</b>	<b>147</b>	<b>1</b>	<b>22</b>	<b>30</b>	<b>30</b>	<b>144</b>	<b>31.6</b>	<b>19.8</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	42	1	25	30	30	60	30.4	15.5
41-64 years	72	1	22	30	33	144	33.4	21.6
≥ 65 years	19	1	14	30	30	58	25.3	15.4
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>76</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>30</b>	<b>2.6</b>	<b>3.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	65	1	1	3	3	30	2.6	3.6
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Solriamfetol</b>	<b>9,289</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,146</b>	<b>67.6</b>	<b>104.7</b>
0-17 years	51	1	30	30	60	750	86.8	145.1
18-24 years	665	1	30	30	60	1,146	69.9	124.7
25-40 years	2,523	1	30	30	60	1,079	64.3	97.7
41-64 years	4,322	1	30	30	60	1,146	71.4	109.0
≥ 65 years	1,728	1	30	30	60	1,134	61.6	93.0
<b>Siponimod</b>	<b>1,685</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>150</b>	<b>1,156</b>	<b>130.8</b>	<b>185.6</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	20	9	30	47	135	730	107.3	161.1
25-40 years	304	5	30	58	120	942	119.0	163.8
41-64 years	1,127	1	30	60	150	1,156	134.1	192.1
≥ 65 years	234	5	30	60	150	1,109	132.1	182.4
<b>Romosozumab-aqqg</b>	<b>38,408</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>720</b>	<b>7.4</b>	<b>33.8</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	86	1	1	1	1	210	10.3	27.3
41-64 years	3,480	1	1	1	1	450	10.2	36.5
≥ 65 years	34,831	1	1	1	1	720	7.2	33.5
<b>Erdafitinib</b>	<b>566</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>84</b>	<b>380</b>	<b>59.0</b>	<b>56.1</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	126	5	28	56	112	294	72.8	62.4
≥ 65 years	422	1	28	28	56	380	54.6	53.3



**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>29,747</b>	<b>1</b>	<b>28</b>	<b>30</b>	<b>84</b>	<b>1,333</b>	<b>81.0</b>	<b>111.6</b>
0-17 years	42	1	28	28	96	532	91.2	121.2
18-24 years	1,452	1	28	28	84	1,182	65.5	88.4
25-40 years	7,170	1	28	30	84	1,180	72.4	99.0
41-64 years	15,604	1	28	30	84	1,333	79.6	110.5
≥ 65 years	5,479	1	28	56	112	1,108	100.3	131.3
<b>Tafamidis</b>	<b>4,927</b>	<b>1</b>	<b>30</b>	<b>108</b>	<b>253</b>	<b>1,269</b>	<b>198.8</b>	<b>235.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	4,695	1	30	114	260	1,269	201.2	237.1
<b>Alpelisib</b>	<b>4,484</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,161</b>	<b>63.0</b>	<b>81.4</b>
0-17 years	27	23	28	28	64	193	52.5	40.6
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	1,649	1	28	28	84	1,161	74.8	103.4
≥ 65 years	2,706	1	28	28	56	846	56.3	64.3
<b>Polatuzumab Vedotin-piiq</b>	<b>2,469</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>112</b>	<b>1.1</b>	<b>3.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	336	1	1	1	1	112	1.3	6.1
≥ 65 years	2,085	1	1	1	1	80	1.1	2.2

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Bremelanotide</b>	<b>899</b>	<b>1</b>	<b>15</b>	<b>15</b>	<b>30</b>	<b>323</b>	<b>24.3</b>	<b>21.1</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	347	1	15	15	30	323	23.8	21.8
41-64 years	530	1	15	15	28	195	24.8	21.1
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Selinexor</b>	<b>2,314</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>420</b>	<b>42.4</b>	<b>35.9</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	517	2	28	28	56	420	45.6	43.5
≥ 65 years	1,775	1	28	28	56	336	41.7	33.4
<b>Imipenem Cilastatin and Relebactam</b>	<b>312</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>172</b>	<b>3.6</b>	<b>12.9</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	101	1	1	1	1	87	3.4	9.9
≥ 65 years	179	1	1	1	1	172	3.7	15.1
<b>Ferric Maltol</b>	<b>330</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>210</b>	<b>47.6</b>	<b>34.7</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	20	6	30	30	73	174	55.3	43.2
25-40 years	140	1	30	30	60	210	45.8	35.1
41-64 years	152	1	30	30	60	169	49.0	33.2
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>3,777</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>1,121</b>	<b>98.4</b>	<b>123.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	253	1	30	30	90	869	84.3	119.8
≥ 65 years	3,524	1	30	60	120	1,121	99.4	123.6
<b>Pexidartinib</b>	<b>85</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>360</b>	<b>72.4</b>	<b>82.5</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	35	7	30	30	109	360	76.4	81.6
41-64 years	36	2	30	30	60	330	72.6	93.7
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pretomanid</b>	<b>23</b>	<b>26</b>	<b>26</b>	<b>34</b>	<b>136</b>	<b>208</b>	<b>81.3</b>	<b>69.2</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pitolisant</b>	<b>2,703</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>1,091</b>	<b>109.9</b>	<b>150.3</b>
0-17 years	29	4	30	45	90	837	116.8	188.3
18-24 years	320	1	30	60	120	1,091	111.8	161.4
25-40 years	986	1	30	60	120	976	99.1	129.1
41-64 years	1,071	1	30	60	146	1,061	122.7	170.4
≥ 65 years	297	2	30	60	120	840	97.3	115.2

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Entrectinib</b>	<b>331</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>505</b>	<b>58.7</b>	<b>72.9</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	116	2	30	30	60	442	57.7	72.4
≥ 65 years	188	3	30	30	60	505	56.8	72.9
<b>Fedratinib</b>	<b>807</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>74</b>	<b>960</b>	<b>76.9</b>	<b>111.2</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	692	2	30	30	74	960	76.2	108.6
<b>Upadacitinib</b>	<b>23,228</b>	<b>1</b>	<b>30</b>	<b>58</b>	<b>116</b>	<b>1,217</b>	<b>99.8</b>	<b>132.6</b>
0-17 years	91	1	30	35	90	327	67.7	63.9
18-24 years	446	1	30	30	90	967	71.0	91.5
25-40 years	2,412	1	30	36	90	994	80.2	101.8
41-64 years	13,502	1	30	60	120	1,217	100.9	133.4
≥ 65 years	6,777	1	30	60	120	1,107	106.7	142.3
<b>Lefamulin</b>	<b>170</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>5</b>	<b>30</b>	<b>5.1</b>	<b>3.5</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	65	1	2	5	5	15	4.6	3.0
≥ 65 years	89	1	4	5	5	14	4.9	2.6

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Ga-68-DOTATOC</b>	<b>183</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	133	1	1	1	1	1	1.0	0.0
<b>Istradefylline</b>	<b>4,221</b>	<b>1</b>	<b>30</b>	<b>89</b>	<b>180</b>	<b>1,079</b>	<b>142.8</b>	<b>174.5</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	12	30	45	105	180	874	165.3	231.2
41-64 years	576	1	30	63	180	1,031	137.0	170.1
≥ 65 years	3,633	1	30	90	180	1,079	143.6	175.0

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
<i>PrabotulinumtoxinA-xvfs</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Caplacizumab-yhdp</i>	78	54	69.2%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Brexanolone</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Solriamfetol</i>	21,977	15,127	68.8%	5,015	22.8%	1,666	7.6%	148	0.7%	21	0.1%
<i>Siponimod</i>	3,491	1,585	45.4%	975	27.9%	760	21.8%	144	4.1%	27	0.8%
<i>Romosozumab-aqqg</i>	236,914	234,148	98.8%	1,844	0.8%	900	0.4%	22	0.0%	0	0.0%
<i>Erdafitinib</i>	645	441	68.4%	161	25.0%	*****	*****	*****	*****	0	0.0%
<i>Risankizumab-rzaa</i>	54,082	19,663	36.4%	24,746	45.8%	8,561	15.8%	1,015	1.9%	97	0.2%
<i>Tafamidis</i>	7,688	3,204	41.7%	2,268	29.5%	1,743	22.7%	372	4.8%	101	1.3%
<i>Alpelisib</i>	4,797	2,864	59.7%	1,249	26.0%	645	13.4%	*****	*****	*****	*****
<i>Polatuzumab Vedotin-piiq</i>	6,225	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Bremelanotide</i>	317	278	87.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Selinexor</i>	1,803	1,243	68.9%	445	24.7%	115	6.4%	0	0.0%	0	0.0%
<i>Imipenem Cilastatin and Relebactam</i>	158	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Ferric Maltol</i>	106	86	81.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Darolutamide</i>	7,255	4,038	55.7%	1,940	26.7%	1,152	15.9%	113	1.6%	12	0.2%
<i>Pexidartinib</i>	212	129	60.8%	60	28.3%	23	10.8%	0	0.0%	0	0.0%
<i>Pretomanid</i>	36	16	44.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Pitolisant</i>	3,410	1,745	51.2%	947	27.8%	628	18.4%	*****	*****	*****	*****
<i>Entrectinib</i>	359	236	65.7%	77	21.4%	*****	*****	*****	*****	0	0.0%
<i>Fedratinib</i>	1,412	809	57.3%	375	26.6%	207	14.7%	*****	*****	*****	*****
<i>Upadacitinib</i>	45,845	25,631	55.9%	12,740	27.8%	6,770	14.8%	637	1.4%	67	0.1%

**Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Lefamulin</i>	101	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Ga-68-DOTATOC</i>	22	22	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Istradefylline</i>	4,182	1,726	41.3%	1,216	29.1%	1,033	24.7%	186	4.4%	21	0.5%

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>PrabotulinumtoxinA-xvfs</i>	0	.	.	.	.	.	.	.
<i>Caplacizumab-yhdp</i>	78	1	5	27	60	600	50.2	89.3
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.
<i>Brexanolone</i>	0	.	.	.	.	.	.	.
<i>Solriamfetol</i>	21,977	1	30	30	60	1,110	52.6	63.3
<i>Siponimod</i>	3,491	1	30	60	112	1,160	101.0	132.4
<i>Romosozumab-aqqg</i>	236,914	1	1	1	1	689	2.6	14.0
<i>Erdafitinib</i>	645	1	28	28	56	448	44.1	40.1
<i>Risankizumab-rzaa</i>	54,082	1	30	31	84	1,184	78.9	91.6
<i>Tafamidis</i>	7,688	1	30	60	120	1,194	112.9	151.3
<i>Alpelisib</i>	4,797	1	28	28	56	977	58.5	66.8
<i>Polatuzumab Vedotin-piiq</i>	6,225	1	1	1	1	63	1.0	1.3
<i>Bremelanotide</i>	317	1	15	15	30	240	24.9	24.9
<i>Selinexor</i>	1,803	1	28	28	56	362	42.9	34.8
<i>Imipenem Cilastatin and Relebactam</i>	158	1	1	1	6	310	9.1	30.7
<i>Ferric Maltol</i>	106	1	30	30	30	113	35.7	19.9
<i>Darolutamide</i>	7,255	1	30	30	90	930	71.9	87.3
<i>Pexidartinib</i>	212	2	30	30	60	270	55.3	48.1
<i>Pretomanid</i>	36	22	26	51	56	125	49.6	28.2
<i>Pitolisant</i>	3,410	1	30	30	90	937	80.7	100.0
<i>Entrectinib</i>	359	1	30	30	60	727	61.5	91.5
<i>Fedratinib</i>	1,412	1	30	30	60	1,027	68.6	83.5
<i>Upadacitinib</i>	45,845	1	30	30	79	1,070	69.0	82.6
<i>Lefamulin</i>	101	1	1	1	2	70	4.2	9.2
<i>Ga-68-DOTATOC</i>	22	1	1	1	1	1	1.0	0.0



**Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Istradefylline</i>	4,182	1	30	60	120	935	107.2	127.5

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>PrabotulinumtoxinA-xvfs</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
<b>Caplacizumab-yhdp</b>	<b>78</b>	<b>54</b>	<b>100.0%</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
Female	54	42	77.8%	*****	*****	*****	*****	*****	*****	0	NaN*
Male	24	12	22.2%	*****	*****	*****	*****	*****	*****	0	NaN*
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.	.	.	.
<b>Solriamfetol</b>	<b>21,977</b>	<b>15,127</b>	<b>100.0%</b>	<b>5,015</b>	<b>100.0%</b>	<b>1,666</b>	<b>100.0%</b>	<b>148</b>	<b>100.0%</b>	<b>21</b>	<b>100.0%</b>
Female	13,449	9,310	61.5%	3,028	60.4%	1,009	60.6%	*****	*****	*****	*****
Male	8,528	5,817	38.5%	1,987	39.6%	657	39.4%	*****	*****	*****	*****
<b>Siponimod</b>	<b>3,491</b>	<b>1,585</b>	<b>100.0%</b>	<b>975</b>	<b>100.0%</b>	<b>760</b>	<b>100.0%</b>	<b>144</b>	<b>100.0%</b>	<b>27</b>	<b>100.0%</b>
Female	2,563	1,148	72.4%	709	72.7%	576	75.8%	*****	*****	*****	*****
Male	928	437	27.6%	266	27.3%	184	24.2%	*****	*****	*****	*****
<b>Romosozumab-aqqg</b>	<b>236,914</b>	<b>234,148</b>	<b>100.0%</b>	<b>1,844</b>	<b>100.0%</b>	<b>900</b>	<b>100.0%</b>	<b>22</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
Female	232,777	230,103	98.3%	1,782	96.6%	*****	*****	*****	*****	0	NaN*
Male	4,137	4,045	1.7%	62	3.4%	*****	*****	*****	*****	0	NaN*
<b>Erdafitinib</b>	<b>645</b>	<b>441</b>	<b>100.0%</b>	<b>161</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>

**Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	260	172	39.0%	*****	*****	*****	*****	0	0.0%	0	NaN*
Male	385	269	61.0%	*****	*****	*****	*****	*****	*****	0	NaN*
<b>Risankizumab-rzaa</b>	<b>54,082</b>	<b>19,663</b>	<b>100.0%</b>	<b>24,746</b>	<b>100.0%</b>	<b>8,561</b>	<b>100.0%</b>	<b>1,015</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>
Female	25,310	9,142	46.5%	11,370	45.9%	4,253	49.7%	501	49.4%	44	45.4%
Male	28,772	10,521	53.5%	13,376	54.1%	4,308	50.3%	514	50.6%	53	54.6%
<b>Tafamidis</b>	<b>7,688</b>	<b>3,204</b>	<b>100.0%</b>	<b>2,268</b>	<b>100.0%</b>	<b>1,743</b>	<b>100.0%</b>	<b>372</b>	<b>100.0%</b>	<b>101</b>	<b>100.0%</b>
Female	1,467	679	21.2%	420	18.5%	291	16.7%	65	17.5%	12	11.9%
Male	6,221	2,525	78.8%	1,848	81.5%	1,452	83.3%	307	82.5%	89	88.1%
<b>Alpelisib</b>	<b>4,797</b>	<b>2,864</b>	<b>100.0%</b>	<b>1,249</b>	<b>100.0%</b>	<b>645</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	4,705	2,803	97.9%	*****	*****	*****	*****	*****	*****	*****	*****
Male	92	61	2.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
<b>Polatuzumab Vedotin-piiq</b>	<b>6,225</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	2,656	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
Male	3,569	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>317</b>	<b>278</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	301	*****	*****	28	*****	*****	*****	0	NaN*	0	NaN*
Male	16	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>1,803</b>	<b>1,243</b>	<b>100.0%</b>	<b>445</b>	<b>100.0%</b>	<b>115</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	902	608	48.9%	228	51.2%	66	57.4%	0	NaN*	0	NaN*
Male	901	635	51.1%	217	48.8%	49	42.6%	0	NaN*	0	NaN*
<b>Imipenem Cilastatin and Relebactam</b>	<b>158</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	83	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*

**Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	75	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Ferric Maltol</b>	<b>106</b>	<b>86</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Darolutamide</b>	<b>7,255</b>	<b>4,038</b>	<b>100.0%</b>	<b>1,940</b>	<b>100.0%</b>	<b>1,152</b>	<b>100.0%</b>	<b>113</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Male	7,255	4,038	100.0%	1,940	100.0%	1,152	100.0%	113	100.0%	12	100.0%
<b>Pexidartinib</b>	<b>212</b>	<b>129</b>	<b>100.0%</b>	<b>60</b>	<b>100.0%</b>	<b>23</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	140	90	69.8%	38	63.3%	12	52.2%	0	NaN*	0	NaN*
Male	72	39	30.2%	22	36.7%	11	47.8%	0	NaN*	0	NaN*
<b>Pretomanid</b>	<b>36</b>	<b>16</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	25	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
Male	11	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Pitolisant</b>	<b>3,410</b>	<b>1,745</b>	<b>100.0%</b>	<b>947</b>	<b>100.0%</b>	<b>628</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	2,323	1,230	70.5%	612	64.6%	426	67.8%	*****	*****	*****	*****
Male	1,087	515	29.5%	335	35.4%	202	32.2%	*****	*****	*****	*****
<b>Entrectinib</b>	<b>359</b>	<b>236</b>	<b>100.0%</b>	<b>77</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>
Female	234	149	63.1%	51	66.2%	*****	*****	*****	*****	0	NaN*
Male	125	87	36.9%	26	33.8%	*****	*****	*****	*****	0	NaN*
<b>Fedratinib</b>	<b>1,412</b>	<b>809</b>	<b>100.0%</b>	<b>375</b>	<b>100.0%</b>	<b>207</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	676	385	47.6%	186	49.6%	*****	*****	*****	*****	*****	*****
Male	736	424	52.4%	189	50.4%	*****	*****	*****	*****	0	0.0%

**Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Upadacitinib</b>	<b>45,845</b>	<b>25,631</b>	<b>100.0%</b>	<b>12,740</b>	<b>100.0%</b>	<b>6,770</b>	<b>100.0%</b>	<b>637</b>	<b>100.0%</b>	<b>67</b>	<b>100.0%</b>
Female	37,483	21,007	82.0%	10,399	81.6%	5,513	81.4%	512	80.4%	52	77.6%
Male	8,362	4,624	18.0%	2,341	18.4%	1,257	18.6%	125	19.6%	15	22.4%
<b>Lefamulin</b>	<b>101</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	51	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
Male	50	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>22</b>	<b>22</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
Female	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
Male	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>4,182</b>	<b>1,726</b>	<b>100.0%</b>	<b>1,216</b>	<b>100.0%</b>	<b>1,033</b>	<b>100.0%</b>	<b>186</b>	<b>100.0%</b>	<b>21</b>	<b>100.0%</b>
Female	1,679	719	41.7%	470	38.7%	406	39.3%	*****	*****	*****	*****
Male	2,503	1,007	58.3%	746	61.3%	627	60.7%	*****	*****	*****	*****

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>PrabotulinumtoxinA-xvfs</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Caplacizumab-yhdp</b>	<b>78</b>	<b>1</b>	<b>5</b>	<b>27</b>	<b>60</b>	<b>600</b>	<b>50.2</b>	<b>89.3</b>
Female	54	1	5	17	30	600	43.6	92.6
Male	24	3	27	41	67	390	65.1	81.2
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Solriamfetol</b>	<b>21,977</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,110</b>	<b>52.6</b>	<b>63.3</b>
Female	13,449	1	30	30	60	987	52.0	62.7
Male	8,528	1	30	30	60	1,110	53.6	64.1
<b>Siponimod</b>	<b>3,491</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>112</b>	<b>1,160</b>	<b>101.0</b>	<b>132.4</b>
Female	2,563	1	30	60	120	1,160	103.0	135.1
Male	928	1	30	55	90	1,066	95.7	124.7
<b>Romozumab-aqqg</b>	<b>236,914</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>689</b>	<b>2.6</b>	<b>14.0</b>
Female	232,777	1	1	1	1	576	2.6	13.8
Male	4,137	1	1	1	1	689	4.4	20.3
<b>Erdafitinib</b>	<b>645</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>448</b>	<b>44.1</b>	<b>40.1</b>
Female	260	1	28	28	56	280	44.7	38.6
Male	385	2	28	28	56	448	43.7	41.1

**Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Risankizumab-rzaa</b>	<b>54,082</b>	<b>1</b>	<b>30</b>	<b>31</b>	<b>84</b>	<b>1,184</b>	<b>78.9</b>	<b>91.6</b>
Female	25,310	1	30	36	84	1,109	80.8	92.8
Male	28,772	1	30	31	84	1,184	77.2	90.5
<b>Tafamidis</b>	<b>7,688</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>1,194</b>	<b>112.9</b>	<b>151.3</b>
Female	1,467	1	30	60	96	976	100.3	132.6
Male	6,221	1	30	60	120	1,194	115.9	155.2
<b>Alpelisib</b>	<b>4,797</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>977</b>	<b>58.5</b>	<b>66.8</b>
Female	4,705	1	28	28	56	977	58.7	67.2
Male	92	1	28	28	56	270	47.2	43.1
<b>Polatuzumab Vedotin-piiq</b>	<b>6,225</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>63</b>	<b>1.0</b>	<b>1.3</b>
Female	2,656	1	1	1	1	63	1.1	1.6
Male	3,569	1	1	1	1	63	1.0	1.1
<b>Bremelanotide</b>	<b>317</b>	<b>1</b>	<b>15</b>	<b>15</b>	<b>30</b>	<b>240</b>	<b>24.9</b>	<b>24.9</b>
Female	301	1	15	15	30	240	25.0	25.4
Male	16	1	15	21	30	45	24.3	13.1
<b>Selinexor</b>	<b>1,803</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>362</b>	<b>42.9</b>	<b>34.8</b>
Female	902	3	28	28	56	362	44.5	38.4
Male	901	1	28	28	56	308	41.2	30.8
<b>Imipenem Cilastatin and Relebactam</b>	<b>158</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>6</b>	<b>310</b>	<b>9.1</b>	<b>30.7</b>
Female	83	1	1	1	7	70	5.7	9.9
Male	75	1	1	1	6	310	12.9	43.1
<b>Ferric Maltol</b>	<b>106</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>113</b>	<b>35.7</b>	<b>19.9</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****

**Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>7,255</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>930</b>	<b>71.9</b>	<b>87.3</b>
Female	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
Male	7,255	1	30	30	90	930	71.9	87.3
<b>Pexidartinib</b>	<b>212</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>270</b>	<b>55.3</b>	<b>48.1</b>
Female	140	2	30	30	60	270	50.3	41.4
Male	72	3	30	30	79	270	65.1	58.0
<b>Pretomanid</b>	<b>36</b>	<b>22</b>	<b>26</b>	<b>51</b>	<b>56</b>	<b>125</b>	<b>49.6</b>	<b>28.2</b>
Female	25	22	26	26	52	125	46.2	29.7
Male	11	26	50	52	78	104	57.5	24.0
<b>Pitolisant</b>	<b>3,410</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>937</b>	<b>80.7</b>	<b>100.0</b>
Female	2,323	1	30	30	90	906	78.4	96.3
Male	1,087	1	30	54	90	937	85.7	107.4
<b>Entrectinib</b>	<b>359</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>727</b>	<b>61.5</b>	<b>91.5</b>
Female	234	1	30	30	60	727	67.2	102.2
Male	125	4	30	30	54	607	50.9	66.3
<b>Fedratinib</b>	<b>1,412</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,027</b>	<b>68.6</b>	<b>83.5</b>
Female	676	1	30	30	60	1,027	68.0	88.1
Male	736	1	30	30	78	618	69.1	79.0
<b>Upadacitinib</b>	<b>45,845</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>79</b>	<b>1,070</b>	<b>69.0</b>	<b>82.6</b>
Female	37,483	1	30	30	77	1,070	68.8	82.1
Male	8,362	1	30	30	85	1,054	69.8	84.7
<b>Lefamulin</b>	<b>101</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>70</b>	<b>4.2</b>	<b>9.2</b>
Female	51	1	1	1	5	70	5.3	10.5
Male	50	1	1	2	2	55	3.1	7.7



**Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Ga-68-DOTATOC</b>	<b>22</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
Female	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****
<b>Istradefylline</b>	<b>4,182</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>935</b>	<b>107.2</b>	<b>127.5</b>
Female	1,679	1	30	60	120	924	105.4	126.0
Male	2,503	1	30	60	120	935	108.3	128.4

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
<b>PrabotulinumtoxinA-xvfs</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.	.
<b>Caplacizumab-yhdp</b>	<b>78</b>	<b>54</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0	NaN*
25-40 years	32	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN*
41-64 years	25	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN*
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0	NaN*
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>0</b>	.	.	.	.	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.	.	.	.	.

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	0	.	.	.	.	.	.	.	.	.	.
<b>Solriamfetol</b>	<b>21,977</b>	<b>15,127</b>	<b>100.0%</b>	<b>5,015</b>	<b>100.0%</b>	<b>1,666</b>	<b>100.0%</b>	<b>148</b>	<b>100.0%</b>	<b>21</b>	<b>100.0%</b>
0-17 years	112	75	0.5%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	1,784	1,283	8.5%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	5,865	4,187	27.7%	1,243	24.8%	399	23.9%	*****	*****	*****	*****
41-64 years	10,694	7,321	48.4%	2,447	48.8%	834	50.1%	*****	*****	*****	*****
≥ 65 years	3,522	2,261	14.9%	925	18.4%	311	18.7%	*****	*****	*****	*****
<b>Siponimod</b>	<b>3,491</b>	<b>1,585</b>	<b>100.0%</b>	<b>975</b>	<b>100.0%</b>	<b>760</b>	<b>100.0%</b>	<b>144</b>	<b>100.0%</b>	<b>27</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	28	11	0.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	627	313	19.7%	157	16.1%	133	17.5%	*****	*****	*****	*****
41-64 years	2,387	1,079	68.1%	673	69.0%	509	67.0%	*****	*****	*****	*****
≥ 65 years	449	182	11.5%	*****	*****	*****	*****	18	12.5%	*****	*****
<b>Romozosumab-aqqg</b>	<b>236,914</b>	<b>234,148</b>	<b>100.0%</b>	<b>1,844</b>	<b>100.0%</b>	<b>900</b>	<b>100.0%</b>	<b>22</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN*
18-24 years	28	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
25-40 years	345	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
41-64 years	18,310	17,866	7.6%	289	15.7%	*****	*****	*****	*****	0	NaN*
≥ 65 years	218,231	215,929	92.2%	1,540	83.5%	*****	*****	*****	*****	0	NaN*
<b>Erdafitinib</b>	<b>645</b>	<b>441</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>41</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	117	*****	*****	*****	*****	12	29.3%	*****	*****	0	NaN*
≥ 65 years	515	360	81.6%	*****	*****	29	70.7%	*****	*****	0	NaN*
<b>Risankizumab-rzaa</b>	<b>54,082</b>	<b>19,663</b>	<b>100.0%</b>	<b>24,746</b>	<b>100.0%</b>	<b>8,561</b>	<b>100.0%</b>	<b>1,015</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>
0-17 years	84	17	0.1%	54	0.2%	*****	*****	*****	*****	0	0.0%
18-24 years	2,775	1,036	5.3%	1,360	5.5%	*****	*****	*****	*****	*****	*****
25-40 years	13,497	5,294	26.9%	6,211	25.1%	1,780	20.8%	*****	*****	*****	*****
41-64 years	30,318	11,646	59.2%	13,608	55.0%	4,475	52.3%	533	52.5%	56	57.7%
≥ 65 years	7,408	1,670	8.5%	3,513	14.2%	1,940	22.7%	255	25.1%	30	30.9%
<b>Tafamidis</b>	<b>7,688</b>	<b>3,204</b>	<b>100.0%</b>	<b>2,268</b>	<b>100.0%</b>	<b>1,743</b>	<b>100.0%</b>	<b>372</b>	<b>100.0%</b>	<b>101</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	354	173	5.4%	103	4.5%	63	3.6%	*****	*****	*****	*****
≥ 65 years	7,334	3,031	94.6%	2,165	95.5%	1,680	96.4%	*****	*****	*****	*****
<b>Alpelisib</b>	<b>4,797</b>	<b>2,864</b>	<b>100.0%</b>	<b>1,249</b>	<b>100.0%</b>	<b>645</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	85	47	1.6%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,822	1,153	40.3%	435	34.8%	222	34.4%	*****	*****	*****	*****
≥ 65 years	2,856	1,643	57.4%	777	62.2%	410	63.6%	*****	*****	*****	*****
<b>Polatuzumab Vedotin-piiq</b>	<b>6,225</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*	0	NaN*

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*	0	NaN*
41-64 years	582	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	5,563	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
<b>Bremelanotide</b>	<b>317</b>	<b>278</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
25-40 years	108	96	34.5%	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	193	167	60.1%	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Selinexor</b>	<b>1,803</b>	<b>1,243</b>	<b>100.0%</b>	<b>445</b>	<b>100.0%</b>	<b>115</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	439	311	25.0%	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	1,351	921	74.1%	349	78.4%	81	70.4%	0	NaN*	0	NaN*
<b>Imipenem Cilastatin and Relebactam</b>	<b>158</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
25-40 years	36	*****	*****	0	0.0%	*****	*****	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
≥ 65 years	33	33	21.9%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
<b>Ferric Maltol</b>	<b>106</b>	<b>86</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
25-40 years	34	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
41-64 years	64	50	58.1%	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*
<b>Darolutamide</b>	<b>7,255</b>	<b>4,038</b>	<b>100.0%</b>	<b>1,940</b>	<b>100.0%</b>	<b>1,152</b>	<b>100.0%</b>	<b>113</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	378	219	5.4%	104	5.4%	*****	*****	*****	*****	*****	*****
≥ 65 years	6,877	3,819	94.6%	1,836	94.6%	*****	*****	*****	*****	*****	*****
<b>Pexidartinib</b>	<b>212</b>	<b>129</b>	<b>100.0%</b>	<b>60</b>	<b>100.0%</b>	<b>23</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
25-40 years	76	46	35.7%	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	111	71	55.0%	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN*	0	NaN*
<b>Pretomanid</b>	<b>36</b>	<b>16</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
≥ 65 years	15	*****	*****	*****	*****	*****	*****	0	NaN*	0	NaN*
<b>Pitolisant</b>	<b>3,410</b>	<b>1,745</b>	<b>100.0%</b>	<b>947</b>	<b>100.0%</b>	<b>628</b>	<b>100.0%</b>	*****	*****	*****	*****

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	28	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	461	244	14.0%	130	13.7%	*****	*****	*****	*****	*****	*****
25-40 years	1,227	659	37.8%	332	35.1%	204	32.5%	*****	*****	*****	*****
41-64 years	1,347	698	40.0%	*****	*****	253	40.3%	35	*****	*****	*****
≥ 65 years	347	*****	*****	119	12.6%	80	12.7%	*****	*****	*****	*****
<b>Entrectinib</b>	<b>359</b>	<b>236</b>	<b>100.0%</b>	<b>77</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN*</b>
0-17 years	12	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN*
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN*
25-40 years	26	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN*
41-64 years	128	77	32.6%	*****	*****	*****	*****	*****	*****	0	NaN*
≥ 65 years	193	133	56.4%	38	49.4%	*****	*****	*****	*****	0	NaN*
<b>Fedratinib</b>	<b>1,412</b>	<b>809</b>	<b>100.0%</b>	<b>375</b>	<b>100.0%</b>	<b>207</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	27	15	1.9%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	207	132	16.3%	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	1,178	662	81.8%	319	85.1%	177	85.5%	*****	*****	*****	*****
<b>Upadacitinib</b>	<b>45,845</b>	<b>25,631</b>	<b>100.0%</b>	<b>12,740</b>	<b>100.0%</b>	<b>6,770</b>	<b>100.0%</b>	<b>637</b>	<b>100.0%</b>	<b>67</b>	<b>100.0%</b>
0-17 years	64	39	0.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	664	440	1.7%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	4,410	2,758	10.8%	1,134	8.9%	478	7.1%	*****	*****	*****	*****
41-64 years	27,570	15,755	61.5%	7,551	59.3%	3,870	57.2%	355	55.7%	39	58.2%
≥ 65 years	13,137	6,639	25.9%	3,885	30.5%	2,348	34.7%	*****	*****	*****	*****

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Lefamulin</b>	<b>101</b>	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
0-17 years	0	0	0.0%	0	0.0%	0	NaN*	0	NaN*	0	NaN*
18-24 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*	0	NaN*
25-40 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*	0	NaN*
41-64 years	70	*****	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN*	0	NaN*	0	NaN*
<b>Ga-68-DOTATOC</b>	<b>22</b>	<b>22</b>	<b>100.0%</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>	<b>0</b>	<b>NaN*</b>
0-17 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
18-24 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
25-40 years	0	0	0.0%	0	NaN*	0	NaN*	0	NaN*	0	NaN*
41-64 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
≥ 65 years	*****	*****	*****	0	NaN*	0	NaN*	0	NaN*	0	NaN*
<b>Istradefylline</b>	<b>4,182</b>	<b>1,726</b>	<b>100.0%</b>	<b>1,216</b>	<b>100.0%</b>	<b>1,033</b>	<b>100.0%</b>	<b>186</b>	<b>100.0%</b>	<b>21</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	17	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	608	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	3,557	1,454	84.2%	1,013	83.3%	910	88.1%	*****	*****	*****	*****

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.



**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Caplacizumab-yhdp</b>	<b>78</b>	<b>1</b>	<b>5</b>	<b>27</b>	<b>60</b>	<b>600</b>	<b>50.2</b>	<b>89.3</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	32	3	8	25	60	390	47.3	74.6
41-64 years	25	4	14	30	60	600	68.0	126.6
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Solriamfetol</b>	<b>21,977</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,110</b>	<b>52.6</b>	<b>63.3</b>
0-17 years	112	15	30	30	60	505	52.3	56.9
18-24 years	1,784	1	30	30	60	951	49.4	58.3
25-40 years	5,865	1	30	30	60	940	50.1	59.5
41-64 years	10,694	1	30	30	60	1,110	53.2	65.4
≥ 65 years	3,522	1	30	30	60	840	56.7	64.9
<b>Siponimod</b>	<b>3,491</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>112</b>	<b>1,160</b>	<b>101.0</b>	<b>132.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	28	5	30	60	153	305	103.6	95.9
25-40 years	627	1	30	31	92	1,066	91.0	124.0
41-64 years	2,387	1	30	60	117	1,160	102.5	134.6
≥ 65 years	449	4	30	60	120	1,058	107.1	134.0
<b>Romosozumab-aqqg</b>	<b>236,914</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>689</b>	<b>2.6</b>	<b>14.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	28	1	1	30	60	90	31.4	29.6
25-40 years	345	1	1	1	1	270	5.8	25.1
41-64 years	18,310	1	1	1	1	470	4.4	19.8
≥ 65 years	218,231	1	1	1	1	689	2.5	13.3
<b>Erdafitinib</b>	<b>645</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>448</b>	<b>44.1</b>	<b>40.1</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	117	2	28	28	56	392	50.0	51.8
≥ 65 years	515	1	28	28	56	448	42.9	37.2

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Risankizumab-rzaa</b>	<b>54,082</b>	<b>1</b>	<b>30</b>	<b>31</b>	<b>84</b>	<b>1,184</b>	<b>78.9</b>	<b>91.6</b>
0-17 years	84	1	31	84	84	519	83.5	82.1
18-24 years	2,775	1	30	31	84	816	67.3	68.3
25-40 years	13,497	1	30	31	84	1,184	70.1	81.7
41-64 years	30,318	1	30	31	84	1,171	75.5	89.8
≥ 65 years	7,408	1	31	84	150	1,152	112.9	113.4
<b>Tafamidis</b>	<b>7,688</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>1,194</b>	<b>112.9</b>	<b>151.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	354	4	30	36	90	1,107	90.6	126.1
≥ 65 years	7,334	1	30	60	120	1,194	114.0	152.3
<b>Alpelisib</b>	<b>4,797</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>977</b>	<b>58.5</b>	<b>66.8</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	85	2	28	28	56	504	55.0	62.7
41-64 years	1,822	1	28	28	56	750	54.9	61.5
≥ 65 years	2,856	1	28	28	56	977	61.1	70.3
<b>Polatuzumab Vedotin-piiq</b>	<b>6,225</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>63</b>	<b>1.0</b>	<b>1.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	582	1	1	1	1	42	1.1	1.9
≥ 65 years	5,563	1	1	1	1	63	1.0	1.3

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Bremelanotide</b>	<b>317</b>	<b>1</b>	<b>15</b>	<b>15</b>	<b>30</b>	<b>240</b>	<b>24.9</b>	<b>24.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	108	1	15	15	30	240	25.0	28.3
41-64 years	193	1	15	15	30	222	25.5	23.7
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Selinexor</b>	<b>1,803</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>362</b>	<b>42.9</b>	<b>34.8</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	439	1	28	28	56	362	43.1	37.9
≥ 65 years	1,351	2	28	28	56	315	42.9	33.8
<b>Imipenem Cilastatin and Relebactam</b>	<b>158</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>6</b>	<b>310</b>	<b>9.1</b>	<b>30.7</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	36	1	1	1	1	310	20.5	61.3
41-64 years	85	1	1	2	6	70	5.4	9.4
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Ferric Maltol</b>	<b>106</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>113</b>	<b>35.7</b>	<b>19.9</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	64	1	30	30	30	113	37.9	23.1
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Darolutamide</b>	<b>7,255</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>930</b>	<b>71.9</b>	<b>87.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	378	1	30	30	60	847	65.1	87.8
≥ 65 years	6,877	1	30	30	90	930	72.3	87.2
<b>Pexidartinib</b>	<b>212</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>270</b>	<b>55.3</b>	<b>48.1</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	76	3	30	30	60	257	57.7	51.0
41-64 years	111	3	30	30	60	270	53.2	48.4
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pretomanid</b>	<b>36</b>	<b>22</b>	<b>26</b>	<b>51</b>	<b>56</b>	<b>125</b>	<b>49.6</b>	<b>28.2</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	15	22	26	30	52	104	46.7	28.2
<b>Pitolisant</b>	<b>3,410</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>937</b>	<b>80.7</b>	<b>100.0</b>
0-17 years	28	22	30	60	150	576	122.1	135.8
18-24 years	461	3	30	30	90	767	71.8	86.6
25-40 years	1,227	1	30	30	90	937	76.9	98.3
41-64 years	1,347	1	30	30	90	742	81.2	99.0
≥ 65 years	347	2	30	60	120	906	101.0	118.5

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Entrectinib</b>	<b>359</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>727</b>	<b>61.5</b>	<b>91.5</b>
0-17 years	12	23	30	30	83	210	65.7	66.1
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	26	14	30	30	60	547	63.0	104.9
41-64 years	128	1	30	30	60	727	63.0	98.5
≥ 65 years	193	4	30	30	60	668	60.1	86.7
<b>Fedratinib</b>	<b>1,412</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,027</b>	<b>68.6</b>	<b>83.5</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	27	15	30	30	60	480	67.9	93.4
41-64 years	207	1	30	30	60	300	57.1	55.4
≥ 65 years	1,178	1	30	30	68	1,027	70.6	87.1
<b>Upadacitinib</b>	<b>45,845</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>79</b>	<b>1,070</b>	<b>69.0</b>	<b>82.6</b>
0-17 years	64	1	30	30	64	166	49.0	37.5
18-24 years	664	1	30	30	60	610	53.9	61.0
25-40 years	4,410	1	30	30	60	1,054	57.8	68.4
41-64 years	27,570	1	30	30	60	1,070	67.2	80.8
≥ 65 years	13,137	1	30	30	90	1,000	77.3	90.5
<b>Lefamulin</b>	<b>101</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>70</b>	<b>4.2</b>	<b>9.2</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	70	1	1	1	2	70	4.2	10.7
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Ga-68-DOTATOC</b>	<b>22</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****
<b>Istradefylline</b>	<b>4,182</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>935</b>	<b>107.2</b>	<b>127.5</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	17	30	30	30	60	463	80.1	109.9
41-64 years	608	4	30	60	90	924	96.3	122.9
≥ 65 years	3,557	1	30	60	120	935	109.1	128.2

\*NaN: Not a Number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>PrabotulinumtoxinA-xvfs</i>	0	.	.	.	.	.	.	.
<i>Caplacizumab-yhdp</i>	78	1	2	4	16	1,201	71.5	202.6
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.
<i>Brexanolone</i>	0	.	.	.	.	.	.	.
<i>Solriamfetol</i>	21,977	1	3	7	19	983	20.8	48.1
<i>Siponimod</i>	3,491	1	2	6	13	829	15.5	41.3
<i>Romozosumab-aqqg</i>	236,914	1	27	30	34	1,047	32.4	20.9
<i>Erdafitinib</i>	645	1	4	9	23	504	18.8	30.9
<i>Risankizumab-rzaa</i>	54,082	1	9	35	56	999	43.2	56.9
<i>Tafamidis</i>	7,688	1	2	5	12	942	19.9	63.7
<i>Alpelisib</i>	4,797	1	3	7	18	843	17.9	44.9
<i>Polatuzumab Vedotin-piiq</i>	6,225	1	20	20	24	841	25.9	28.8
<i>Bremelanotide</i>	317	1	8	14	39	667	42.1	80.4
<i>Selinexor</i>	1,803	1	4	10	26	955	25.5	57.8
<i>Imipenem Cilastatin and Relebactam</i>	158	1	2	6	20	288	21.0	40.3
<i>Ferric Maltol</i>	106	1	4	12	31	247	26.2	39.2
<i>Darolutamide</i>	7,255	1	3	6	16	600	16.2	35.6
<i>Pexidartinib</i>	212	1	3	7	13	127	12.0	16.4
<i>Pretomanid</i>	36	1	2	4	9	47	6.5	8.6
<i>Pitolisant</i>	3,410	1	3	6	14	801	19.4	55.2
<i>Entrectinib</i>	359	1	3	7	19	652	18.2	43.8
<i>Fedratinib</i>	1,412	1	3	7	19	545	16.8	34.2
<i>Upadacitinib</i>	45,845	1	3	7	17	998	17.8	40.2
<i>Lefamulin</i>	101	1	23	27	52	664	55.5	87.6



**Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Ga-68-DOTATOC</i>	22	84	224	311	375	489	298.7	113.4
<i>Istradefylline</i>	4,182	1	3	6	17	761	19.9	48.8

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Caplacizumab-yhdp</b>	<b>78</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>16</b>	<b>1,201</b>	<b>71.5</b>	<b>202.6</b>
Female	54	1	2	3	14	1,042	70.0	180.8
Male	24	1	3	11	16	1,201	75.0	249.1
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Solriamfetol</b>	<b>21,977</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>983</b>	<b>20.8</b>	<b>48.1</b>
Female	13,449	1	3	7	19	788	20.2	45.4
Male	8,528	1	3	7	19	983	21.8	52.0
<b>Siponimod</b>	<b>3,491</b>	<b>1</b>	<b>2</b>	<b>6</b>	<b>13</b>	<b>829</b>	<b>15.5</b>	<b>41.3</b>
Female	2,563	1	2	6	14	829	16.1	42.2
Male	928	1	3	5	11	674	14.0	38.7
<b>Romozumab-aqqg</b>	<b>236,914</b>	<b>1</b>	<b>27</b>	<b>30</b>	<b>34</b>	<b>1,047</b>	<b>32.4</b>	<b>20.9</b>
Female	232,777	1	27	30	34	1,047	32.4	20.9
Male	4,137	1	27	28	32	662	30.9	20.7
<b>Erdafitinib</b>	<b>645</b>	<b>1</b>	<b>4</b>	<b>9</b>	<b>23</b>	<b>504</b>	<b>18.8</b>	<b>30.9</b>
Female	260	1	4	9	26	148	19.0	24.2
Male	385	1	4	9	21	504	18.7	34.7

**Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>54,082</b>	<b>1</b>	<b>9</b>	<b>35</b>	<b>56</b>	<b>999</b>	<b>43.2</b>	<b>56.9</b>
Female	25,310	1	9	34	56	999	42.5	56.1
Male	28,772	1	9	35	56	972	43.9	57.5
<b>Tafamidis</b>	<b>7,688</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>12</b>	<b>942</b>	<b>19.9</b>	<b>63.7</b>
Female	1,467	1	2	5	13	760	20.5	64.2
Male	6,221	1	2	5	12	942	19.7	63.5
<b>Alpelisib</b>	<b>4,797</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>843</b>	<b>17.9</b>	<b>44.9</b>
Female	4,705	1	3	7	18	843	17.8	44.5
Male	92	1	3	5	13	403	21.6	63.0
<b>Polatuzumab Vedotin-piiq</b>	<b>6,225</b>	<b>1</b>	<b>20</b>	<b>20</b>	<b>24</b>	<b>841</b>	<b>25.9</b>	<b>28.8</b>
Female	2,656	3	20	20	26	565	26.3	28.0
Male	3,569	1	20	20	23	841	25.7	29.5
<b>Bremelanotide</b>	<b>317</b>	<b>1</b>	<b>8</b>	<b>14</b>	<b>39</b>	<b>667</b>	<b>42.1</b>	<b>80.4</b>
Female	301	1	8	13	39	667	41.9	81.2
Male	16	1	8	31	42	265	46.1	65.7
<b>Selinexor</b>	<b>1,803</b>	<b>1</b>	<b>4</b>	<b>10</b>	<b>26</b>	<b>955</b>	<b>25.5</b>	<b>57.8</b>
Female	902	1	4	9	25	499	22.8	43.6
Male	901	1	4	11	27	955	28.2	69.1
<b>Imipenem Cilastatin and Relebactam</b>	<b>158</b>	<b>1</b>	<b>2</b>	<b>6</b>	<b>20</b>	<b>288</b>	<b>21.0</b>	<b>40.3</b>
Female	83	1	3	6	20	156	17.9	30.0
Male	75	1	2	6	20	288	24.3	49.3
<b>Ferric Maltol</b>	<b>106</b>	<b>1</b>	<b>4</b>	<b>12</b>	<b>31</b>	<b>247</b>	<b>26.2</b>	<b>39.2</b>
Female	98	1	4	10	29	247	26.0	40.5
Male	8	3	14	24	51	52	29.0	20.1
<b>Darolutamide</b>	<b>7,255</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>16</b>	<b>600</b>	<b>16.2</b>	<b>35.6</b>

**Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
Male	7,255	1	3	6	16	600	16.2	35.6
<b>Pexidartinib</b>	<b>212</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>13</b>	<b>127</b>	<b>12.0</b>	<b>16.4</b>
Female	140	1	3	7	14	127	12.5	16.8
Male	72	1	2	7	13	86	11.1	15.6
<b>Pretomanid</b>	<b>36</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>9</b>	<b>47</b>	<b>6.5</b>	<b>8.6</b>
Female	25	1	2	4	5	16	4.8	4.3
Male	11	1	1	4	13	47	10.2	13.8
<b>Pitolisant</b>	<b>3,410</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>14</b>	<b>801</b>	<b>19.4</b>	<b>55.2</b>
Female	2,323	1	3	6	15	801	18.7	52.0
Male	1,087	1	3	6	14	709	21.0	61.3
<b>Entrectinib</b>	<b>359</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>652</b>	<b>18.2</b>	<b>43.8</b>
Female	234	1	3	7	19	327	17.9	32.4
Male	125	1	4	7	17	652	18.7	59.7
<b>Fedratinib</b>	<b>1,412</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>545</b>	<b>16.8</b>	<b>34.2</b>
Female	676	1	3	8	20	288	17.1	26.7
Male	736	1	3	6	18	545	16.6	39.9
<b>Upadacitinib</b>	<b>45,845</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>17</b>	<b>998</b>	<b>17.8</b>	<b>40.2</b>
Female	37,483	1	3	7	17	998	18.0	40.8
Male	8,362	1	3	6	16	838	16.6	37.6
<b>Lefamulin</b>	<b>101</b>	<b>1</b>	<b>23</b>	<b>27</b>	<b>52</b>	<b>664</b>	<b>55.5</b>	<b>87.6</b>
Female	51	1	14	27	52	664	67.1	114.4
Male	50	5	26	26	54	289	43.6	44.9
<b>Ga-68-DOTATOC</b>	<b>22</b>	<b>84</b>	<b>224</b>	<b>311</b>	<b>375</b>	<b>489</b>	<b>298.7</b>	<b>113.4</b>
Female	8	118	231	360	437	489	332.6	130.4

**Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	14	84	224	300	369	419	279.4	102.4
<b>Istradefylline</b>	<b>4,182</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>17</b>	<b>761</b>	<b>19.9</b>	<b>48.8</b>
Female	1,679	1	3	7	19	761	22.1	56.1
Male	2,503	1	3	6	16	619	18.4	43.1

\*NaN: Not a Number

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>PrabotulinumtoxinA-xvfs</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Caplacizumab-yhdp</b>	<b>78</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>16</b>	<b>1,201</b>	<b>71.5</b>	<b>202.6</b>
0-17 years	2	9	9	59	108	108	58.5	70.0
18-24 years	11	1	1	2	3	3	2.1	0.8
25-40 years	32	1	2	8	33	474	53.3	117.8
41-64 years	25	1	2	4	12	1,201	108.4	312.7
≥ 65 years	8	1	2	3	280	451	127.8	190.9
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Solriamfetol</b>	<b>21,977</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>983</b>	<b>20.8</b>	<b>48.1</b>
0-17 years	112	1	3	10	25	229	22.2	34.9
18-24 years	1,784	1	4	9	22	736	21.5	41.8
25-40 years	5,865	1	3	7	18	812	19.5	46.1
41-64 years	10,694	1	3	7	19	929	20.7	47.1
≥ 65 years	3,522	1	3	7	21	983	23.1	56.8
<b>Siponimod</b>	<b>3,491</b>	<b>1</b>	<b>2</b>	<b>6</b>	<b>13</b>	<b>829</b>	<b>15.5</b>	<b>41.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	28	1	2	3	9	31	6.5	7.5
25-40 years	627	1	2	6	13	468	13.1	30.8
41-64 years	2,387	1	3	6	13	829	16.1	41.5
≥ 65 years	449	1	2	5	13	709	16.4	52.5
<b>Romozozumab-aqqg</b>	<b>236,914</b>	<b>1</b>	<b>27</b>	<b>30</b>	<b>34</b>	<b>1,047</b>	<b>32.4</b>	<b>20.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	28	1	6	22	34	356	36.3	67.4
25-40 years	345	1	27	29	34	209	33.7	22.6
41-64 years	18,310	1	27	29	34	664	32.1	21.8
≥ 65 years	218,231	1	27	30	34	1,047	32.4	20.8
<b>Erdafitinib</b>	<b>645</b>	<b>1</b>	<b>4</b>	<b>9</b>	<b>23</b>	<b>504</b>	<b>18.8</b>	<b>30.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	4	5	7	20	30	30	18.5	13.4
25-40 years	9	2	6	8	25	97	24.2	32.0
41-64 years	117	1	4	9	21	112	17.4	21.8
≥ 65 years	515	1	4	9	23	504	19.1	32.7

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>54,082</b>	<b>1</b>	<b>9</b>	<b>35</b>	<b>56</b>	<b>999</b>	<b>43.2</b>	<b>56.9</b>
0-17 years	84	1	6	15	45	246	33.5	42.5
18-24 years	2,775	1	12	38	60	717	47.8	61.8
25-40 years	13,497	1	11	38	57	921	45.6	58.2
41-64 years	30,318	1	10	38	57	999	44.0	55.6
≥ 65 years	7,408	1	6	14	49	906	34.0	57.0
<b>Tafamidis</b>	<b>7,688</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>12</b>	<b>942</b>	<b>19.9</b>	<b>63.7</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	354	1	3	6	16	711	19.2	49.2
≥ 65 years	7,334	1	2	5	12	942	19.9	64.3
<b>Alpelisib</b>	<b>4,797</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>843</b>	<b>17.9</b>	<b>44.9</b>
0-17 years	26	1	3	5	8	74	9.8	17.1
18-24 years	8	4	8	11	16	23	11.9	6.4
25-40 years	85	1	3	6	13	359	15.4	40.9
41-64 years	1,822	1	3	7	17	817	16.7	45.6
≥ 65 years	2,856	1	3	7	19	843	18.8	44.8
<b>Polatuzumab Vedotin-piiq</b>	<b>6,225</b>	<b>1</b>	<b>20</b>	<b>20</b>	<b>24</b>	<b>841</b>	<b>25.9</b>	<b>28.8</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	10	19	20	21	41	118	35.2	30.7
25-40 years	70	16	20	20	27	196	28.8	25.3
41-64 years	582	3	20	20	24	565	26.2	30.1
≥ 65 years	5,563	1	20	20	24	841	25.9	28.8



**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Bremelanotide</b>	<b>317</b>	<b>1</b>	<b>8</b>	<b>14</b>	<b>39</b>	<b>667</b>	<b>42.1</b>	<b>80.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	2	2	2	4	6	6	4.0	2.8
25-40 years	108	1	5	14	39	667	44.4	89.7
41-64 years	193	1	8	14	42	645	43.2	78.0
≥ 65 years	14	5	9	12	17	41	15.4	10.9
<b>Selinexor</b>	<b>1,803</b>	<b>1</b>	<b>4</b>	<b>10</b>	<b>26</b>	<b>955</b>	<b>25.5</b>	<b>57.8</b>
0-17 years	2	6	6	23	40	40	23.0	24.0
18-24 years	1	27	27	27	27	27	27.0	NaN*
25-40 years	10	1	1	5	11	40	9.0	11.8
41-64 years	439	1	4	10	26	595	26.4	57.0
≥ 65 years	1,351	1	4	10	26	955	25.3	58.3
<b>Imipenem Cilastatin and Relebactam</b>	<b>158</b>	<b>1</b>	<b>2</b>	<b>6</b>	<b>20</b>	<b>288</b>	<b>21.0</b>	<b>40.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	4	6	10	15	53	89	31.0	38.9
25-40 years	36	1	3	6	13	288	22.4	52.1
41-64 years	85	1	1	5	18	198	14.5	27.1
≥ 65 years	33	1	4	6	33	156	34.8	51.0
<b>Ferric Maltol</b>	<b>106</b>	<b>1</b>	<b>4</b>	<b>12</b>	<b>31</b>	<b>247</b>	<b>26.2</b>	<b>39.2</b>
0-17 years	1	2	2	2	2	2	2.0	NaN*
18-24 years	2	2	2	11	19	19	10.5	12.0
25-40 years	34	1	3	8	28	247	24.1	44.3
41-64 years	64	1	4	15	33	180	28.0	38.5
≥ 65 years	5	8	8	31	52	52	30.2	22.0

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>7,255</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>16</b>	<b>600</b>	<b>16.2</b>	<b>35.6</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	378	1	3	5	12	506	14.3	34.5
≥ 65 years	6,877	1	3	6	16	600	16.3	35.7
<b>Pexidartinib</b>	<b>212</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>13</b>	<b>127</b>	<b>12.0</b>	<b>16.4</b>
0-17 years	1	10	10	10	10	10	10.0	NaN*
18-24 years	22	1	4	6	14	64	12.1	14.5
25-40 years	76	1	3	6	12	69	10.0	11.7
41-64 years	111	1	3	8	14	127	13.3	19.4
≥ 65 years	2	9	9	18	27	27	18.0	12.7
<b>Pretomanid</b>	<b>36</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>9</b>	<b>47</b>	<b>6.5</b>	<b>8.6</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	13	1	2	3	4	9	3.4	2.2
41-64 years	8	1	1	4	12	16	6.4	6.3
≥ 65 years	15	1	2	4	13	47	9.2	11.9
<b>Pitolisant</b>	<b>3,410</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>14</b>	<b>801</b>	<b>19.4</b>	<b>55.2</b>
0-17 years	28	1	3	8	18	709	54.1	145.5
18-24 years	461	1	3	6	16	391	18.6	44.5
25-40 years	1,227	1	3	6	15	708	20.6	62.7
41-64 years	1,347	1	3	6	14	801	18.7	51.0
≥ 65 years	347	1	3	5	14	383	16.1	39.4

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Entrectinib</b>	<b>359</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>652</b>	<b>18.2</b>	<b>43.8</b>
0-17 years	12	1	4	6	13	56	11.6	14.9
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	26	1	2	6	10	40	9.7	11.2
41-64 years	128	1	3	6	18	203	16.3	28.5
≥ 65 years	193	1	4	9	21	652	21.0	54.7
<b>Fedratinib</b>	<b>1,412</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>545</b>	<b>16.8</b>	<b>34.2</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	27	1	2	4	25	276	22.4	53.7
41-64 years	207	1	3	9	21	288	17.5	28.6
≥ 65 years	1,178	1	3	7	19	545	16.6	34.6
<b>Upadacitinib</b>	<b>45,845</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>17</b>	<b>998</b>	<b>17.8</b>	<b>40.2</b>
0-17 years	64	1	4	9	14	77	11.9	13.3
18-24 years	664	1	3	7	17	404	17.8	35.9
25-40 years	4,410	1	3	8	18	878	19.4	44.2
41-64 years	27,570	1	3	7	17	998	17.5	39.2
≥ 65 years	13,137	1	3	7	17	933	17.8	41.2
<b>Lefamulin</b>	<b>101</b>	<b>1</b>	<b>23</b>	<b>27</b>	<b>52</b>	<b>664</b>	<b>55.5</b>	<b>87.6</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	2	8	8	140	272	272	140.0	186.7
25-40 years	1	20	20	20	20	20	20.0	NaN*
41-64 years	70	1	20	27	55	664	53.5	91.7
≥ 65 years	28	7	26	26	41	289	55.6	71.1

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Ga-68-DOTATOC</b>	<b>22</b>	<b>84</b>	<b>224</b>	<b>311</b>	<b>375</b>	<b>489</b>	<b>298.7</b>	<b>113.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	4	182	211	299	423	489	317.0	135.8
≥ 65 years	18	84	224	311	375	438	294.7	111.9
<b>Istradefylline</b>	<b>4,182</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>17</b>	<b>761</b>	<b>19.9</b>	<b>48.8</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	17	1	2	5	8	21	6.6	6.1
41-64 years	608	1	3	6	15	682	19.4	49.7
≥ 65 years	3,557	1	3	7	18	761	20.1	48.7

\*NaN: Not a Number

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>PrabotulinumtoxinA-xvfs</i>	0	.	.	.	.	.	.	.
<i>Caplacizumab-yhdp</i>	43	1	2	7	38	1,201	103.1	254.0
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.
<i>Brexanolone</i>	0	.	.	.	.	.	.	.
<i>Solriamfetol</i>	5,477	1	3	9	23	983	27.4	64.9
<i>Siponimod</i>	1,059	1	3	7	15	829	17.8	50.1
<i>Romozosumab-aqqg</i>	33,783	1	27	30	34	1,047	33.4	30.8
<i>Erdafitinib</i>	250	1	4	7	17	152	14.2	20.7
<i>Risankizumab-rzaa</i>	19,404	1	6	19	49	972	36.5	60.5
<i>Tafamidis</i>	2,404	1	2	5	14	942	28.2	87.7
<i>Alpelisib</i>	2,093	1	4	8	20	817	20.8	52.0
<i>Polatuzumab Vedotin-piiq</i>	1,844	1	20	20	24	671	26.5	31.0
<i>Bremelanotide</i>	184	1	8	17	43	667	45.8	82.2
<i>Selinexor</i>	912	1	4	11	27	955	27.6	64.3
<i>Imipenem Cilastatin and Relebactam</i>	50	1	6	16	44	288	36.5	52.9
<i>Ferric Maltol</i>	72	1	4	13	30	247	27.6	43.2
<i>Darolutamide</i>	2,181	1	3	6	16	600	16.8	36.4
<i>Pexidartinib</i>	48	1	2	7	12	127	13.7	22.6
<i>Pretomanid</i>	17	1	2	5	10	47	8.8	11.3
<i>Pitolisant</i>	1,219	1	3	7	17	801	25.0	72.1
<i>Entrectinib</i>	146	1	4	8	19	203	16.6	24.5
<i>Fedratinib</i>	447	1	3	8	21	317	18.8	33.9
<i>Upadacitinib</i>	13,557	1	3	7	19	998	20.6	49.1
<i>Lefamulin</i>	37	1	13	26	43	664	61.1	118.6
<i>Ga-68-DOTATOC</i>	19	84	276	341	377	489	323.1	99.2

**Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Istradefylline</i>	1,785	1	3	7	19	682	23.6	59.9

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Caplacizumab-yhdp</b>	<b>43</b>	<b>1</b>	<b>2</b>	<b>7</b>	<b>38</b>	<b>1,201</b>	<b>103.1</b>	<b>254.0</b>
Female	29	1	2	5	38	1,042	95.2	219.3
Male	14	1	3	11	18	1,201	119.6	323.3
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Solriamfetol</b>	<b>5,477</b>	<b>1</b>	<b>3</b>	<b>9</b>	<b>23</b>	<b>983</b>	<b>27.4</b>	<b>64.9</b>
Female	3,288	1	3	9	22	785	25.7	60.6
Male	2,189	1	3	8	24	983	29.9	70.9
<b>Siponimod</b>	<b>1,059</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>15</b>	<b>829</b>	<b>17.8</b>	<b>50.1</b>
Female	795	1	3	7	16	829	17.7	49.7
Male	264	1	3	6	14	674	18.2	51.7
<b>Romozozumab-aqqg</b>	<b>33,783</b>	<b>1</b>	<b>27</b>	<b>30</b>	<b>34</b>	<b>1,047</b>	<b>33.4</b>	<b>30.8</b>
Female	33,144	1	27	30	34	1,047	33.5	31.0
Male	639	1	27	27	33	224	30.7	18.5
<b>Erdafitinib</b>	<b>250</b>	<b>1</b>	<b>4</b>	<b>7</b>	<b>17</b>	<b>152</b>	<b>14.2</b>	<b>20.7</b>
Female	95	1	4	8	20	110	15.7	19.6
Male	155	1	3	7	14	152	13.3	21.3
<b>Risankizumab-rzaa</b>	<b>19,404</b>	<b>1</b>	<b>6</b>	<b>19</b>	<b>49</b>	<b>972</b>	<b>36.5</b>	<b>60.5</b>

**Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	9,401	1	6	18	49	894	35.9	59.4
Male	10,003	1	6	19	49	972	37.0	61.5
<b>Tafamidis</b>	<b>2,404</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>14</b>	<b>942</b>	<b>28.2</b>	<b>87.7</b>
Female	450	1	2	5	16	695	26.9	77.8
Male	1,954	1	2	5	13	942	28.5	89.8
<b>Alpelisib</b>	<b>2,093</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>20</b>	<b>817</b>	<b>20.8</b>	<b>52.0</b>
Female	2,050	1	4	8	20	817	20.8	51.7
Male	43	1	3	7	13	359	24.2	64.5
<b>Polatuzumab Vedotin-piiq</b>	<b>1,844</b>	<b>1</b>	<b>20</b>	<b>20</b>	<b>24</b>	<b>671</b>	<b>26.5</b>	<b>31.0</b>
Female	774	6	20	20	25	503	27.2	34.7
Male	1,070	1	20	20	24	671	25.9	27.9
<b>Bremelanotide</b>	<b>184</b>	<b>1</b>	<b>8</b>	<b>17</b>	<b>43</b>	<b>667</b>	<b>45.8</b>	<b>82.2</b>
Female	176	1	8	16	42	667	44.9	82.1
Male	8	2	12	35	80	265	64.9	88.0
<b>Selinexor</b>	<b>912</b>	<b>1</b>	<b>4</b>	<b>11</b>	<b>27</b>	<b>955</b>	<b>27.6</b>	<b>64.3</b>
Female	449	1	3	10	27	499	24.8	52.8
Male	463	1	5	12	28	955	30.3	73.7
<b>Imipenem Cilastatin and Relebactam</b>	<b>50</b>	<b>1</b>	<b>6</b>	<b>16</b>	<b>44</b>	<b>288</b>	<b>36.5</b>	<b>52.9</b>
Female	26	1	3	14	44	139	27.8	34.2
Male	24	1	6	18	58	288	45.9	67.2
<b>Ferric Maltol</b>	<b>72</b>	<b>1</b>	<b>4</b>	<b>13</b>	<b>30</b>	<b>247</b>	<b>27.6</b>	<b>43.2</b>
Female	67	1	4	12	29	247	27.7	44.5
Male	5	3	11	16	50	52	26.4	22.9
<b>Darolutamide</b>	<b>2,181</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>16</b>	<b>600</b>	<b>16.8</b>	<b>36.4</b>
Female	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*



**Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	2,181	1	3	6	16	600	16.8	36.4
<b>Pexidartinib</b>	<b>48</b>	<b>1</b>	<b>2</b>	<b>7</b>	<b>12</b>	<b>127</b>	<b>13.7</b>	<b>22.6</b>
Female	32	1	3	8	14	127	16.1	25.4
Male	16	1	1	6	9	64	8.9	15.2
<b>Pretomanid</b>	<b>17</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>10</b>	<b>47</b>	<b>8.8</b>	<b>11.3</b>
Female	11	1	1	4	9	15	5.3	4.5
Male	6	1	2	11	20	47	15.3	17.0
<b>Pitolisant</b>	<b>1,219</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>17</b>	<b>801</b>	<b>25.0</b>	<b>72.1</b>
Female	827	1	3	7	17	801	23.7	67.9
Male	392	1	3	7	17	709	27.7	80.4
<b>Entrectinib</b>	<b>146</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>19</b>	<b>203</b>	<b>16.6</b>	<b>24.5</b>
Female	88	1	3	8	19	203	16.5	25.7
Male	58	1	4	8	19	105	16.8	22.8
<b>Fedratinib</b>	<b>447</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>21</b>	<b>317</b>	<b>18.8</b>	<b>33.9</b>
Female	211	1	4	8	21	288	19.8	33.8
Male	236	1	3	8	20	317	17.9	34.0
<b>Upadacitinib</b>	<b>13,557</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>998</b>	<b>20.6</b>	<b>49.1</b>
Female	10,926	1	3	8	19	998	21.2	50.6
Male	2,631	1	3	7	17	545	18.4	42.1
<b>Lefamulin</b>	<b>37</b>	<b>1</b>	<b>13</b>	<b>26</b>	<b>43</b>	<b>664</b>	<b>61.1</b>	<b>118.6</b>
Female	19	1	8	20	52	664	72.3	153.2
Male	18	5	23	26	43	289	49.3	68.2
<b>Ga-68-DOTATOC</b>	<b>19</b>	<b>84</b>	<b>276</b>	<b>341</b>	<b>377</b>	<b>489</b>	<b>323.1</b>	<b>99.2</b>
Female	7	182	280	362	438	489	363.3	105.2
Male	12	84	258	311	372	419	299.7	91.9

**Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Sex**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Istradefylline</b>	<b>1,785</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>682</b>	<b>23.6</b>	<b>59.9</b>
Female	721	1	3	7	20	682	28.1	71.9
Male	1,064	1	3	6	17	619	20.6	49.9

\*NaN: Not a Number

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>PrabotulinumtoxinA-xvfs</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Caplacizumab-yhdp</b>	<b>43</b>	<b>1</b>	<b>2</b>	<b>7</b>	<b>38</b>	<b>1,201</b>	<b>103.1</b>	<b>254.0</b>
0-17 years	2	9	9	59	108	108	58.5	70.0
18-24 years	3	1	1	2	3	3	2.0	1.0
25-40 years	17	1	3	13	38	395	60.4	118.2
41-64 years	16	1	2	7	17	1,201	166.3	382.7
≥ 65 years	5	1	2	3	167	451	124.8	195.8
<b>Triclabendazole</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Brexanolone</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Solriamfetol</b>	<b>5,477</b>	<b>1</b>	<b>3</b>	<b>9</b>	<b>23</b>	<b>983</b>	<b>27.4</b>	<b>64.9</b>
0-17 years	28	1	5	13	30	84	21.0	22.1
18-24 years	403	1	4	10	24	411	24.0	45.1
25-40 years	1,473	1	3	9	23	734	26.4	62.0
41-64 years	2,613	1	3	8	22	785	26.2	58.8
≥ 65 years	960	1	3	8	24	983	33.7	88.5
<b>Siponimod</b>	<b>1,059</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>15</b>	<b>829</b>	<b>17.8</b>	<b>50.1</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	12	1	2	4	10	17	5.7	5.0
25-40 years	197	1	3	7	18	468	17.6	40.5
41-64 years	712	1	3	6	15	829	19.2	56.5
≥ 65 years	138	1	3	6	13	197	12.1	20.8
<b>Romosozumab-aqqg</b>	<b>33,783</b>	<b>1</b>	<b>27</b>	<b>30</b>	<b>34</b>	<b>1,047</b>	<b>33.4</b>	<b>30.8</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	6	9	19	31	44	83	36.0	26.0
25-40 years	69	1	27	27	33	206	35.5	33.6
41-64 years	2,956	1	27	29	34	614	33.5	31.4
≥ 65 years	30,752	1	27	30	34	1,047	33.4	30.7
<b>Erdafitinib</b>	<b>250</b>	<b>1</b>	<b>4</b>	<b>7</b>	<b>17</b>	<b>152</b>	<b>14.2</b>	<b>20.7</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	2	9	9	20	30	30	19.5	14.8
25-40 years	4	5	6	9	18	25	11.8	9.2
41-64 years	50	1	3	7	11	110	11.4	18.2
≥ 65 years	194	1	4	7	18	152	15.0	21.5

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Risankizumab-rzaa</b>	<b>19,404</b>	<b>1</b>	<b>6</b>	<b>19</b>	<b>49</b>	<b>972</b>	<b>36.5</b>	<b>60.5</b>
0-17 years	30	1	4	12	35	194	23.1	36.6
18-24 years	974	1	7	22	52	608	39.2	63.0
25-40 years	4,790	1	7	21	50	831	38.2	60.9
41-64 years	10,427	1	6	20	49	972	36.8	60.9
≥ 65 years	3,183	1	5	12	45	906	32.1	57.5
<b>Tafamidis</b>	<b>2,404</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>14</b>	<b>942</b>	<b>28.2</b>	<b>87.7</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	112	1	2	4	11	210	17.1	39.0
≥ 65 years	2,292	1	2	5	14	942	28.7	89.4
<b>Alpelisib</b>	<b>2,093</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>20</b>	<b>817</b>	<b>20.8</b>	<b>52.0</b>
0-17 years	14	1	2	5	8	74	10.3	18.7
18-24 years	4	10	10	11	16	19	12.8	4.3
25-40 years	45	1	3	7	13	359	20.0	55.0
41-64 years	766	1	4	7	18	817	21.2	61.7
≥ 65 years	1,264	1	4	9	21	571	20.8	45.4
<b>Polatuzumab Vedotin-piiq</b>	<b>1,844</b>	<b>1</b>	<b>20</b>	<b>20</b>	<b>24</b>	<b>671</b>	<b>26.5</b>	<b>31.0</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	5	19	20	26	41	47	30.6	12.7
25-40 years	23	20	20	21	33	118	31.3	24.1
41-64 years	213	17	20	20	27	328	27.9	28.4
≥ 65 years	1,603	1	20	20	24	671	26.2	31.4

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Bremelanotide</b>	<b>184</b>	<b>1</b>	<b>8</b>	<b>17</b>	<b>43</b>	<b>667</b>	<b>45.8</b>	<b>82.2</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	2	2	2	4	6	6	4.0	2.8
25-40 years	63	1	6	21	46	667	53.7	109.1
41-64 years	117	1	8	16	42	336	42.6	65.0
≥ 65 years	2	10	10	24	38	38	24.0	19.8
<b>Selinexor</b>	<b>912</b>	<b>1</b>	<b>4</b>	<b>11</b>	<b>27</b>	<b>955</b>	<b>27.6</b>	<b>64.3</b>
0-17 years	2	6	6	23	40	40	23.0	24.0
18-24 years	1	27	27	27	27	27	27.0	NaN*
25-40 years	5	1	5	11	13	40	14.0	15.3
41-64 years	216	1	3	10	26	526	27.1	63.3
≥ 65 years	688	1	4	11	28	955	27.9	65.0
<b>Imipenem Cilastatin and Relebactam</b>	<b>50</b>	<b>1</b>	<b>6</b>	<b>16</b>	<b>44</b>	<b>288</b>	<b>36.5</b>	<b>52.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	2	13	13	51	89	89	51.0	53.7
25-40 years	12	1	5	9	58	288	46.5	83.1
41-64 years	22	1	3	14	31	78	20.0	21.5
≥ 65 years	14	2	6	31	105	155	51.6	53.9
<b>Ferric Maltol</b>	<b>72</b>	<b>1</b>	<b>4</b>	<b>13</b>	<b>30</b>	<b>247</b>	<b>27.6</b>	<b>43.2</b>
0-17 years	1	2	2	2	2	2	2.0	NaN*
18-24 years	2	2	2	11	19	19	10.5	12.0
25-40 years	27	1	4	9	30	247	25.6	47.3
41-64 years	40	1	4	17	32	180	30.4	42.9
≥ 65 years	2	8	8	30	52	52	30.0	31.1

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Darolutamide</b>	<b>2,181</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>16</b>	<b>600</b>	<b>16.8</b>	<b>36.4</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	125	1	3	5	14	206	16.2	32.3
≥ 65 years	2,056	1	3	6	17	600	16.9	36.7
<b>Pexidartinib</b>	<b>48</b>	<b>1</b>	<b>2</b>	<b>7</b>	<b>12</b>	<b>127</b>	<b>13.7</b>	<b>22.6</b>
0-17 years	1	10	10	10	10	10	10.0	NaN*
18-24 years	5	1	3	6	9	64	16.6	26.7
25-40 years	17	1	1	6	9	22	6.4	5.8
41-64 years	23	1	2	8	14	127	18.2	29.4
≥ 65 years	2	9	9	18	27	27	18.0	12.7
<b>Pretomanid</b>	<b>17</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>10</b>	<b>47</b>	<b>8.8</b>	<b>11.3</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	6	1	1	3	5	9	3.7	3.0
41-64 years	5	1	2	6	9	15	6.6	5.7
≥ 65 years	6	1	4	12	20	47	15.8	16.7
<b>Pitolisant</b>	<b>1,219</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>17</b>	<b>801</b>	<b>25.0</b>	<b>72.1</b>
0-17 years	15	1	3	9	73	709	91.3	193.8
18-24 years	146	1	4	8	18	371	20.5	41.7
25-40 years	461	1	3	7	15	708	26.3	80.7
41-64 years	468	1	3	7	17	801	26.4	72.1
≥ 65 years	129	1	4	6	14	124	12.0	18.1

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Entrectinib</b>	<b>146</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>19</b>	<b>203</b>	<b>16.6</b>	<b>24.5</b>
0-17 years	4	4	4	5	31	56	17.5	25.7
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	14	1	3	7	11	40	10.9	12.1
41-64 years	49	1	3	7	16	203	16.4	32.4
≥ 65 years	79	1	4	9	24	92	17.8	20.4
<b>Fedratinib</b>	<b>447</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>21</b>	<b>317</b>	<b>18.8</b>	<b>33.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	6	3	4	7	25	55	16.8	20.4
41-64 years	60	1	3	9	25	288	22.5	42.4
≥ 65 years	381	1	3	8	20	317	18.2	32.6
<b>Upadacitinib</b>	<b>13,557</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>998</b>	<b>20.6</b>	<b>49.1</b>
0-17 years	36	1	3	6	13	77	11.0	13.7
18-24 years	245	1	4	8	18	349	18.6	39.8
25-40 years	1,373	1	3	8	18	715	22.0	54.9
41-64 years	7,910	1	3	7	18	998	20.1	49.1
≥ 65 years	3,993	1	3	8	20	933	21.5	47.7
<b>Lefamulin</b>	<b>37</b>	<b>1</b>	<b>13</b>	<b>26</b>	<b>43</b>	<b>664</b>	<b>61.1</b>	<b>118.6</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	1	8	8	8	8	8	8.0	NaN*
25-40 years	1	20	20	20	20	20	20.0	NaN*
41-64 years	19	1	5	23	35	664	63.8	152.2
≥ 65 years	16	7	26	27	76	289	63.9	75.2



**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023, by Age Group**

	Total Number of Gaps	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Ga-68-DOTATOC</b>	<b>19</b>	<b>84</b>	<b>276</b>	<b>341</b>	<b>377</b>	<b>489</b>	<b>323.1</b>	<b>99.2</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
41-64 years	4	182	211	299	423	489	317.0	135.8
≥ 65 years	15	84	280	341	377	438	324.7	93.2
<b>Istradefylline</b>	<b>1,785</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>682</b>	<b>23.6</b>	<b>59.9</b>
0-17 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
18-24 years	0	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*	NaN*
25-40 years	4	1	2	3	5	6	3.3	2.2
41-64 years	247	1	3	6	16	682	21.3	58.3
≥ 65 years	1,534	1	3	7	19	678	24.1	60.2

\*NaN: Not a Number

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

		Censoring Reason											
		End of Exposure		Occurrence of		Evidence of Death <sup>4</sup>		Disenrollment <sup>5</sup>		End of Data <sup>6</sup>		End of Study	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Caplacizumab-yhdp</i>	225	224	99.6%	0	0.0%	*****	*****	16	7.1%	*****	*****	*****	*****
<i>Triclabendazole</i>	0	.	.	.	.	.	.	.	.	.	.	.	.
<i>Brexanolone</i>	76	76	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	*****	*****
<i>Solriamfetol</i>	31,266	31,244	99.9%	0	0.0%	25	0.1%	3,449	11.0%	2,328	7.4%	2,328	7.4%
<i>Siponimod</i>	5,176	5,160	99.7%	0	0.0%	17	0.3%	971	18.8%	637	12.3%	637	12.3%
<i>Romozumab-aqqg</i>	275,322	275,298	100.0%	0	0.0%	26	0.0%	1,554	0.6%	1,387	0.5%	1,387	0.5%
<i>Erdafitinib</i>	1,211	1,162	96.0%	0	0.0%	55	4.5%	112	9.2%	64	5.3%	64	5.3%
<i>Risankizumab-rzaa</i>	83,829	83,712	99.9%	0	0.0%	122	0.1%	17,616	21.0%	12,013	14.3%	12,013	14.3%
<i>Tafamidis</i>	12,615	12,172	96.5%	0	0.0%	472	3.7%	2,656	21.1%	2,256	17.9%	2,256	17.9%
<i>Alpelisib</i>	9,281	9,051	97.5%	0	0.0%	259	2.8%	676	7.3%	428	4.6%	428	4.6%
<i>Polatuzumab Vedotin-piiq</i>	8,694	8,691	100.0%	0	0.0%	*****	*****	12	0.1%	11	0.1%	11	0.1%
<i>Bremelanotide</i>	1,216	1,216	100.0%	0	0.0%	0	0.0%	110	9.0%	77	6.3%	77	6.3%
<i>Selinexor</i>	4,117	3,891	94.5%	0	0.0%	254	6.2%	292	7.1%	224	5.4%	224	5.4%
<i>Imipenem Cilastatin and Relebactan</i>	470	469	99.8%	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****
<i>Ferric Maltol</i>	436	436	100.0%	0	0.0%	0	0.0%	130	29.8%	103	23.6%	103	23.6%
<i>Darolutamide</i>	11,032	10,912	98.9%	0	0.0%	129	1.2%	1,633	14.8%	1,469	13.3%	1,469	13.3%
<i>Pexidartinib</i>	297	297	100.0%	0	0.0%	0	0.0%	46	15.5%	30	10.1%	30	10.1%
<i>Pretomanid</i>	59	59	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	*****	*****
<i>Pitolisant</i>	6,113	6,105	99.9%	0	0.0%	*****	*****	1,220	20.0%	841	13.8%	841	13.8%
<i>Entrectinib</i>	690	660	95.7%	0	0.0%	34	4.9%	106	15.4%	71	10.3%	71	10.3%
<i>Fedratinib</i>	2,219	2,129	95.9%	0	0.0%	100	4.5%	186	8.4%	151	6.8%	151	6.8%
<i>Upadacitinib</i>	69,073	68,887	99.7%	0	0.0%	204	0.3%	11,959	17.3%	8,672	12.6%	8,672	12.6%
<i>Lefamulin</i>	271	271	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%

**Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

		Censoring Reason											
		End of Exposure		Occurrence of		Evidence of Death <sup>4</sup>		Disenrollment <sup>5</sup>		End of Data <sup>6</sup>		End of Study	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Ga-68-DOTATOC</i>	205	205	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	*****	*****
<i>Istradefylline</i>	8,403	8,212	97.7%	0	0.0%	204	2.4%	1,492	17.8%	1,265	15.1%	1,265	15.1%

<sup>1</sup>An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

<sup>2</sup>Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

<sup>3</sup>Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

<sup>4</sup>Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

<sup>5</sup>Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

<sup>6</sup>Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

<sup>7</sup>Represents episodes censored due to user-specified study end date.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period is due to their inability to be calculated. This table may not use all data representations.

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	PrabotulinumtoxinA-xvfs		Caplacizumab-yhdp		Triclabendazole		Brexanolone	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*
Had required coverage type (medical and/or drug coverage)	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948
Enrolled during specified age range	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250
Had requestable medical charts	194,643,737	0	194,643,737	0	194,643,737	0	194,643,737	0
Met demographic requirements (sex, race, and Hispanic origin)	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	*****	*****	184	194,577,156	0	194,577,340	89	194,577,251
Claim recorded during specified age range	*****	*****	184	0	0	0	89	0
Episode defining index claim recorded during the query period	*****	*****	184	0	0	0	89	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	*****	*****	147	37	0	0	76	13
Met inclusion and exclusion criteria	*****	*****	147	0	0	0	76	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	*****	0	147	0	0	0	76	0
<b>Final cohort</b>								
Number of members	*****	N/A*	147	N/A*	0	N/A*	76	N/A*

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Solriamfetol		Siponimod		Romosozumab-aqqg		Erdafitinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*
Had required coverage type (medical and/or drug coverage)	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948
Enrolled during specified age range	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250
Had requestable medical charts	194,643,737	0	194,643,737	0	194,643,737	0	194,643,737	0
Met demographic requirements (sex, race, and Hispanic origin)	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	10,532	194,566,808	1,959	194,575,381	39,801	194,537,539	625	194,576,715
Claim recorded during specified age range	10,532	0	1,959	0	39,801	0	625	0
Episode defining index claim recorded during the query period	10,532	0	1,959	0	39,801	0	625	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	9,289	1,243	1,685	274	38,408	1,393	566	59
Met inclusion and exclusion criteria	9,289	0	1,685	0	38,408	0	566	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	9,289	0	1,685	0	38,408	0	566	0
<b>Final cohort</b>								
Number of members	9,289	N/A*	1,685	N/A*	38,408	N/A*	566	N/A*

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Risankizumab-rzaa		Tafamidis		Alpelisib		Polatuzumab Vedotin-piiq	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*
Had required coverage type (medical and/or drug coverage)	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948
Enrolled during specified age range	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250
Had requestable medical charts	194,643,737	0	194,643,737	0	194,643,737	0	194,643,737	0
Met demographic requirements (sex, race, and Hispanic origin)	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	33,633	194,543,707	5,277	194,572,063	4,903	194,572,437	2,654	194,574,686
Claim recorded during specified age range	33,633	0	5,277	0	4,903	0	2,654	0
Episode defining index claim recorded during the query period	33,633	0	5,277	0	4,903	0	2,654	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	29,747	3,886	4,927	350	4,484	419	2,469	185
Met inclusion and exclusion criteria	29,747	0	4,927	0	4,484	0	2,469	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	29,747	0	4,927	0	4,484	0	2,469	0
<b>Final cohort</b>								
Number of members	29,747	N/A*	4,927	N/A*	4,484	N/A*	2,469	N/A*

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Bremelanotide		Selinexor		Imipenem Cilastatin and Relebactam		Ferric Maltol	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*
Had required coverage type (medical and/or drug coverage)	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948
Enrolled during specified age range	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250
Had requestable medical charts	194,643,737	0	194,643,737	0	194,643,737	0	194,643,737	0
Met demographic requirements (sex, race, and Hispanic origin)	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	1,029	194,576,311	2,450	194,574,890	336	194,577,004	384	194,576,956
Claim recorded during specified age range	1,029	0	2,450	0	336	0	384	0
Episode defining index claim recorded during the query period	1,029	0	2,450	0	336	0	384	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	899	130	2,314	136	312	24	330	54
Met inclusion and exclusion criteria	899	0	2,314	0	312	0	330	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	899	0	2,314	0	312	0	330	0
<b>Final cohort</b>								
Number of members	899	N/A*	2,314	N/A*	312	N/A*	330	N/A*

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Darolutamide		Pexidartinib		Pretomanid		Pitolisant	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*
Had required coverage type (medical and/or drug coverage)	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948
Enrolled during specified age range	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250
Had requestable medical charts	194,643,737	0	194,643,737	0	194,643,737	0	194,643,737	0
Met demographic requirements (sex, race, and Hispanic origin)	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	4,000	194,573,340	100	194,577,240	*****	*****	3,136	194,574,204
Claim recorded during specified age range	4,000	0	100	0	*****	0	3,136	0
Episode defining index claim recorded during the query period	4,000	0	100	0	*****	0	3,136	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	3,777	223	85	15	*****	*****	2,703	433
Met inclusion and exclusion criteria	3,777	0	85	0	*****	0	2,703	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	3,777	0	85	0	23	0	2,703	0
<b>Final cohort</b>								
Number of members	3,777	N/A*	85	N/A*	23	N/A*	2,703	N/A*



**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Entrectinib		Fedratinib		Upadacitinib		Lefamulin	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*	266,245,935	N/A*
Had required coverage type (medical and/or drug coverage)	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948	194,669,987	71,575,948
Enrolled during specified age range	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250	194,643,737	26,250
Had requestable medical charts	194,643,737	0	194,643,737	0	194,643,737	0	194,643,737	0
Met demographic requirements (sex, race, and Hispanic origin)	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397	194,577,340	66,397
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	381	194,576,959	855	194,576,485	26,355	194,550,985	189	194,577,151
Claim recorded during specified age range	381	0	855	0	26,355	0	189	0
Episode defining index claim recorded during the query period	381	0	855	0	26,355	0	189	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	331	50	807	48	23,228	3,127	170	19
Met inclusion and exclusion criteria	331	0	807	0	23,228	0	170	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	331	0	807	0	23,228	0	170	0
<b>Final cohort</b>								
Number of members	331	N/A*	807	N/A*	23,228	N/A*	170	N/A*

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

	Ga-68-DOTATOC		Istradefylline	
	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>				
Enrolled at any point during the query period	266,245,935	N/A*	266,245,935	N/A*
Had required coverage type (medical and/or drug coverage)	194,669,987	71,575,948	194,669,987	71,575,948
Enrolled during specified age range	194,643,737	26,250	194,643,737	26,250
Had requestable medical charts	194,643,737	0	194,643,737	0
Met demographic requirements (sex, race, and Hispanic origin)	194,577,340	66,397	194,577,340	66,397
<b>Members with a valid index event</b>				
Had any cohort-defining claim during the query period	200	194,577,140	4,530	194,572,810
Claim recorded during specified age range	200	0	4,530	0
Episode defining index claim recorded during the query period	200	0	4,530	0
<b>Members with required pre-index history</b>				
Had sufficient pre-index continuous enrollment	183	17	4,221	309
Met inclusion and exclusion criteria	183	0	4,221	0
<b>Members with required post-index follow-up</b>				
Had sufficient post-index continuous enrollment	183	0	4,221	0
<b>Final cohort</b>				
Number of members	183	N/A*	4,221	N/A*

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A\*: Not applicable

**Figure 1a. Patient Entry into Study by Month for PrabotulinumtoxinA-xvfs in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on February 2, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1b. Patient Entry into Study by Month for Caplacizumab-yhdp in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on February 6, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1c. Patient Entry into Study by Month for Triclabendazole in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on February 13, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1d. Patient Entry into Study by Month for Brexanolone in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on March 19, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1e. Patient Entry into Study by Month for Solriamfetol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on March 20, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1f. Patient Entry into Study by Month for Siponimod in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---


*The FDA approval date for this drug was on March 26, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**



**Figure 1g. Patient Entry into Study by Month for Romosozumab-aqqg in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

The FDA approval date for this drug was on April 9, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>



**Figure 1h. Patient Entry into Study by Month for Erdafitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on April 12, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1i. Patient Entry into Study by Month for Risankizumab-rzaa in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on April 23, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1j. Patient Entry into Study by Month for Tafamidis in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on May 3, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1k. Patient Entry into Study by Month for Alpelisib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on May 24, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1I. Patient Entry into Study by Month for Polatuzumab Vedotin-piiq in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on June 10, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1m. Patient Entry into Study by Month for Bremelanotide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on June 21, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1n. Patient Entry into Study by Month for Selinexor in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on July 3, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**



**Figure 1o. Patient Entry into Study by Month for Imipenem Cilastatin and Relebactam in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on July 16, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1p. Patient Entry into Study by Month for Ferric Maltol in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on July 25, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

***\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.***

**Figure 1q. Patient Entry into Study by Month for Darolutamide in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on July 30, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1r. Patient Entry into Study by Month for Pexidartinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on August 2, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1s. Patient Entry into Study by Month for Pretomanid in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on August 14, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1t. Patient Entry into Study by Month for Pitolisant in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on August 14, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1u. Patient Entry into Study by Month for Entrectinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on August 15, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1v. Patient Entry into Study by Month for Fedratinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on August 16, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**



**Figure 1w. Patient Entry into Study by Month for Upadacitinib in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on August 16, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1x. Patient Entry into Study by Month for Lefamulin in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on August 19, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1y. Patient Entry into Study by Month for Ga-68-DOTATOC in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on August 21, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Figure 1z. Patient Entry into Study by Month for Istradefylline in the Sentinel Distributed Database from January 1, 2019 to May 31, 2023**

---

*The FDA approval date for this drug was on August 27, 2019, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>*

**\*\*\*\*Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.**

**Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (July 25, 2023)**

Masked DP ID	DP Start Date	DP End Date <sup>1</sup>
DP01	01/01/2004	11/30/2022
DP02	01/01/2005	07/31/2022
DP03	01/01/2008	08/31/2022
DP04	01/01/2006	10/31/2022
DP05	01/01/2000	05/31/2023
DP06	01/01/2000	05/31/2022
DP07	01/01/2000	08/31/2022
DP08	01/01/2000	08/31/2022
DP09	01/01/2000	10/31/2022
DP10	01/01/2007	09/30/2022
DP11	01/01/2014	12/31/2020
DP12	01/01/2008	12/31/2022
DP13	01/01/2010	09/30/2022

<sup>1</sup>End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

**Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
<b>PrabotulinumtoxinA-xvfs</b>	
prabotulinumtoxinA-xvfs	Jeuveau
<b>Caplacizumab-yhdp</b>	
caplacizumab-yhdp	Cablivi
<b>Triclabendazole</b>	
triclabendazole	Egaten
<b>Brexanolone</b>	
brexanolone	Zulresso
<b>Solriamfetol</b>	
solriamfetol HCl	Sunosi
<b>Siponimod</b>	
siponimod	Mayzent
siponimod	Mayzent Starter(for 1mg maint)
siponimod	Mayzent Starter(for 2mg maint)
<b>Romozosumab-aqqg</b>	
romozosumab-aqqg	Evenity
<b>Erdafitinib</b>	
erdafitinib	Balversa
<b>Risankizumab-rzaa</b>	
risankizumab-rzaa	Skyrizi
<b>Tafamidis</b>	
tafamidis meglumine	Vyndaqel
tafamidis	Vyndamax
<b>Alpelisib</b>	
alpelisib	Piqray
alpelisib	Vijoice
<b>Polatuzumab Vedotin-piiq</b>	
polatuzumab vedotin-piiq	Polivy
<b>Bremelanotide</b>	
bremelanotide acetate	Vyleesi
<b>Selinexor</b>	
selinexor	Xpovio
<b>Imipenem Cilastatin and Relebactam</b>	
imipenem/cilastatin sodium/relebactam	Recarbrio
<b>Ferric Maltol</b>	
ferric maltol	Accrufer

**Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
<b>Darolutamide</b>	
darolutamide	Nubeqa
<b>Pexidartinib</b>	
pexidartinib hydrochloride	Turalio
<b>Pretomanid</b>	
pretomanid	pretomanid
<b>Pitolisant</b>	
pitolisant HCl	Wakix
<b>Entrectinib</b>	
entrectinib	Rozlytrek
<b>Fedratinib</b>	
fedratinib dihydrochloride	Inrebic
<b>Upadacitinib</b>	
upadacitinib	Rinvoq
<b>Lefamulin</b>	
lefamulin acetate	Xenleta
<b>Ga-68-DOTATOC</b>	
gallium Ga-68 dotatoc	gallium Ga-68 dotatoc
<b>Istradefylline</b>	
istradefylline	Nourianz

**Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, and Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
<b>Caplacizumab-yhdp</b>			
C9047	Injection, caplacizumab-yhdp, 1 mg	Procedure	HCPCS
<b>Brexanolone</b>			
C9055	Injection, brexanolone, 1 mg	Procedure	HCPCS
J1632	Injection, brexanolone, 1 mg	Procedure	HCPCS
XW03306	Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW04306	Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
<b>Romosozumab-aqqg</b>			
J3111	Injection, romosozumab-aqqg, 1 mg	Procedure	HCPCS
<b>Erdafitinib</b>			
XW0DXL5	Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
<b>Risankizumab-rzaa</b>			
J2327	Injection, risankizumab-rzaa, intravenous, 1 mg	Procedure	HCPCS
<b>Polatuzumab Vedotin-piiq</b>			
J9309	Injection, polatuzumab vedotin-piiq, 1 mg	Procedure	HCPCS
<b>Imipenem Cilastatin and Relebactam</b>			
J0742	Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg	Procedure	HCPCS
XW033U5	Introduction of Imipenem-cilastatin-relebactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043U5	Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
<b>Lefamulin</b>			
C9054	Injection, lefamulin (Xenleta), 1 mg	Procedure	HCPCS
J0691	Injection, lefamulin, 1 mg	Procedure	HCPCS
XW03366	Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW04366	Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW0DX66	Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6	Procedure	ICD-10-PCS
<b>Ga-68-DOTATOC</b>			
C9067	Gallium Ga-68, Dotatoc, diagnostic, 0.01 mCi	Procedure	HCPCS



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
<b>Acquired Hypothyroidism</b>			
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	Iodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
<b>Alcohol Abuse</b>			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnesic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
<b>Alzheimers</b>			
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
<b>Acute Myocardial Infarction</b>			
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
<b>Anemia</b>			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
281.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM
282.44	Beta thalassemia	Diagnosis	ICD-9-CM
282.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
282.46	Thalassemia minor	Diagnosis	ICD-9-CM
282.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
282.49	Other thalassemia	Diagnosis	ICD-9-CM
282.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
282.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM
282.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM
282.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
283.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
283.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
283.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
284.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
284.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
284.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
284.19	Other pancytopenia	Diagnosis	ICD-9-CM
284.2	Myelophthisis	Diagnosis	ICD-9-CM
284.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
284.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
284.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
285.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
285.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
285.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM
285.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
285.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
285.8	Other specified anemias	Diagnosis	ICD-9-CM
285.9	Unspecified anemia	Diagnosis	ICD-9-CM
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
<b>Asthma</b>			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
<b>Atrial Fibrillation</b>			
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
<b>Benign Prostatic Hyperplasia</b>			
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.3	Cyst of prostate	Diagnosis	ICD-9-CM
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
<b>Breast Cancer</b>			
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
<b>Cardiac Arrest</b>			
V12.53	Personal history of sudden cardiac arrest	Diagnosis	ICD-9-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
<b>Chronic Kidney Disease</b>			
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
<b>Colorectal Cancer</b>			
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
<b>Chronic Obstructive Pulmonary Disease</b>			
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
<b>Coronary Angioplasty Bypass</b>			
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
<b>Depression</b>			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
<b>Diabetes</b>			
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
<b>Drug Abuse</b>			
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
<b>Endometrial Cancer</b>			
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
<b>Glaucoma</b>			
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
<b>Heart Failure</b>			
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
<b>Hyperlipidemia</b>			
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
<b>Hypertension</b>			
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
<b>Ischemic Heart Disease</b>			
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
<b>Lung Cancer</b>			
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
<b>Obesity</b>			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-9-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
<b>Osteoporosis</b>			
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM
M80.00X	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M80.019 A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021 A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022 A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029 A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031 A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032 A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039 A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041 A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042 A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049 A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051 A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052 A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059 A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061 A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062 A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069 A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071 A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072 A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079 A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08X A	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AX A	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M80.80X A	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811 A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812 A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819 A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821 A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822 A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829 A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831 A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832 A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839 A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841 A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842 A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849 A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851 A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852 A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859 A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861 A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862 A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869 A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871 A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872 A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M80.879 A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88X A	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AX A	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
<b>Overweight</b>			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
<b>Prostate</b>			
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
<b>Rheumatoid Arthritis</b>			
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
715.00	Generalized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.04	Generalized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.09	Generalized osteoarthritis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.13	Primary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthritis, hand	Diagnosis	ICD-9-CM
715.15	Primary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthritis, other specified sites	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
715.20	Secondary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.22	Secondary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.23	Secondary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.24	Secondary localized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.25	Secondary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.26	Secondary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.27	Secondary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.28	Secondary localized osteoarthritis, other specified site	Diagnosis	ICD-9-CM
715.30	Localized osteoarthritis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
715.31	Localized osteoarthritis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM
715.32	Localized osteoarthritis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
715.33	Localized osteoarthritis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM
715.34	Localized osteoarthritis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM
715.35	Localized osteoarthritis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
715.36	Localized osteoarthritis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
715.37	Localized osteoarthritis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
715.38	Localized osteoarthritis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
715.80	Osteoarthritis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthritis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
715.90	Osteoarthritis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM
715.91	Osteoarthritis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthritis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthritis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthritis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM
715.95	Osteoarthritis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthritis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthritis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthritis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
<b>Smoking</b>			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
<b>Transient Ischemic Attack</b>			
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request.**

Code	Description	Code	
		Category	Code Type
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

**Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request**

Non-Proprietary Name	Proprietary Name
<b>Obesity</b>	
Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup	Optifast 70
Benzphetamine HCl	Benzphetamine
Benzphetamine HCl	Regimex
Diethylpropion HCl	Diethylpropion
Diethylpropion HCl	Diethylpropion HCl (bulk)
Liraglutide	Saxenda
Liraglutide	Victoza 2-Pak
Liraglutide	Victoza 3-Pak
Lorcaserin HCl	Belviq
Lorcaserin HCl	Belviq XR
Naltrexone HCl/Bupropion HCl	Contrave
Orlistat	Alli
Orlistat	Xenical
Phendimetrazine Tartrate	Bontril PDM
Phendimetrazine Tartrate	Phendimetrazine Tartrate
Phentermine HCl	Adipex-P
Phentermine HCl	Lomaira
Phentermine HCl	Phentermine
Phentermine HCl	Phentermine HCl (bulk)
Phentermine HCl	Suprenza
Phentermine HCl/Topiramate	Qsymia
Resveratrol/Chromium Pico/Green Tea/EGCG/Caffeine/Digestive3	Resveratrol Diet
<b>Smoking</b>	
Nicotine	NTS Step 1
Nicotine	Nicoderm CQ
Nicotine	Nicotine
Nicotine	Nicotrol
Nicotine	Nicotrol NS
Nicotine Bitartrate	Nicotine Tartrate
Nicotine Polacrilex	Nicorelief
Nicotine Polacrilex	Nicorette
Nicotine Polacrilex	Nicotine (Polacrilex)
Nicotine Polacrilex	Nicotine Polacrilex (bulk)
Nicotine Polacrilex	Quit 2
Nicotine Polacrilex	Quit 4
Nicotine Polacrilex	Stop Smoking Aid

**Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Covariates in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
Varenicline Tartrate	Chantix
Varenicline Tartrate	Chantix Continuing Month Box
Varenicline Tartrate	Chantix Starting Month Box
Varenicline Tartrate	Tyrvaya
Varenicline Tartrate	Varenicline

**Appendix F. Specifications Defining Parameters for this Request**

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 12.1.2, to assess utilization and uptake of the 2019 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

**Query period:** 01/01/2019 - Most recent available data  
**Coverage requirement:** Medical and Drug Coverage  
**Pre-index enrollment requirement:** 183 days  
**Post-index requirement:** 0 days  
**Enrollment gap:** 45 days  
**Age groups:** 0-17, 18-24, 25-40, 41-64, 65+ years  
**Stratifications:** Age group, Sex, Calendar Month  
**Restrictions:** Male and Female  
**Distribution of index-defining codes:** No  
**Envelope macro:** Reclassify encounters during inpatient stay as inpatient  
**Freeze data:** No

**Exposure**

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	Prabotulinumtoxin A-xvfs	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
2	Caplacizumab-yhdp	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	Triclabendazole	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date



<b>Appendix F. Specifications Defining Parameters for this Request</b>											
The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 12.1.2, to assess utilization and uptake of the 2019 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).											
4	Brexanolone	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
5	Solriamfetol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
6	Siponimod	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
7	Romosozumab-aqqg	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
8	Erdafitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
9	Risankizumab-rzaa	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
10	Tafamidis	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

<b>Appendix F. Specifications Defining Parameters for this Request</b>											
The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 12.1.2, to assess utilization and uptake of the 2019 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).											
11	Alpelisib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
12	Polatuzumab Vedotin-piiq	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
13	Bremelanotide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
14	Selinexor	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
15	Imipenem, Cilastatin and Relebactam	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
16	Ferric Maltol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
17	Darolutamide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

<b>Appendix F. Specifications Defining Parameters for this Request</b>											
The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 12.1.2, to assess utilization and uptake of the 2019 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).											
18	Pexidartinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
19	Pretomanid	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
20	Pitolisant	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
21	Entrectinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
22	Fedratinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
23	Upadacitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
24	Lefamulin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

**Appendix F. Specifications Defining Parameters for this Request**

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 12.1.2, to assess utilization and uptake of the 2019 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).


25	Ga-68-DOTATOC	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
26	Istradefylline	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

N/A: Not Applicable

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.

National Drug codes (NDC) codes are checked against First Data Bank's FDB MedKnowledge®.

## Appendix G. Design Diagram Used in this Request



<sup>1</sup> Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

<sup>2</sup> 26 scenarios defined on initiation of NMEs approved in 2019 part 1 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.

<sup>3</sup> Baseline characteristics:

Window I: Age, Sex, Year

Window II: Chronic Conditions Data Warehouse (CCW): Acute Myocardial Infarction, Alzheimer's Disease and related conditions, Atrial Fibrillation, Diabetes, Heart Failure, Hyperlipidemia, Hypertension, Depression, Ischemic Heart Disease, Rheumatoid Arthritis/Osteoarthritis, Stroke/Transient Ischemic Attack (TIA), Breast Cancer, Colorectal Cancer, Prostate Cancer, Lung Cancer, Endometrial Cancer, Acquired Hypothyroidism, Anemia, Asthma, Benign Prostatic Hyperplasia, Chronic Kidney Disease, COPD and Bronchiectasis, Glaucoma, Osteoporosis; and Other: Obesity Diagnosis/Procedure, Obesity NDCs, Overweight, Smoking Diagnosis/Procedure, Smoking NDCs, Alcohol Abuse or Dependence, Drug Abuse or Dependence, History of Cardiac Arrest, History of Coronary Angioplasty or Bypass

<sup>4</sup> Censoring: earliest of death, disenrollment, data partner data end date, query end date

**Appendix H. Specifications Defining Parameters for Baseline Characteristics in this Request**

Covariates							
Covariate	Covariate Number	Care setting/ Principal diagnosis <sup>1</sup>	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>							
Acute Myocardial Infarction	1	IPP, IPS	-183	-1	N/A	1	N/A
Alzheimer's Disease and related conditions	2	Any	-183	-1	N/A	1	N/A
Atrial Fibrillation	3	IPP, IPS or	-183	-1	N/A	1	N/A
	4	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	5	3 or 4	-183	-1	N/A	N/A	N/A
Diabetes	6	IP*, IS* or	-183	-1	N/A	1	N/A
	7	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	8	6 or 7	-183	-1	N/A	N/A	N/A
Heart Failure	9	IP*, AV*, ED*, OA*	-183	-1	N/A	1	N/A
Hyperlipidemia	10	IP*, IS* or	-183	-1	N/A	1	N/A
	11	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	12	10 or 11	-183	-1	N/A	N/A	N/A
Hypertension	13	IP*, IS* or	-183	-1	N/A	1	N/A
	14	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	15	13 or 14	-183	-1	N/A	N/A	N/A
Depression	16	Any	-183	-1	N/A	1	N/A
Ischemic Heart Disease	17	Any	-183	-1	N/A	1	N/A
Rheumatoid Arthritis/Osteoarthritis	18	Any	-183	-1	N/A	2	N/A
Stroke/Transient Ischemic Attack (TIA)	19	IP*	-183	-1	N/A	1	N/A
	20	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	21	19 or 20	-183	-1	N/A	N/A	N/A
Breast Cancer	22	IP*, IS* or	-183	-1	N/A	1	N/A
	23	AV*, ED* OA*	-183	-1	N/A	2	N/A
	24	22 or 23	-183	-1	N/A	N/A	N/A
Colorectal Cancer	25	IP*, IS* or	-183	-1	N/A	1	N/A
	26	AV*, ED* OA*	-183	-1	N/A	2	N/A
	27	25 or 26	-183	-1	N/A	N/A	N/A

**Appendix H. Specifications Defining Parameters for Baseline Characteristics in this Request**

**Covariates**

Covariate	Covariate Number	Care setting/ Principal diagnosis <sup>1</sup>	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>							
Prostate Cancer	28	IP*, IS* or	-183	-1	N/A	1	N/A
	29	AV*, ED* OA*	-183	-1	N/A	2	N/A
	30	28 or 29	-183	-1	N/A	N/A	N/A
Lung Cancer	31	IP*, IS* or	-183	-1	N/A	1	N/A
	32	AV*, ED* OA*	-183	-1	N/A	2	N/A
	33	31 or 32	-183	-1	N/A	N/A	N/A
Endometrial Cancer	34	IP*, IS* or	-183	-1	N/A	1	N/A
	35	AV*, ED* OA*	-183	-1	N/A	2	N/A
	36	34 or 35	-183	-1	N/A	N/A	N/A
Acquired Hypothyroidism	37	IP*, IS*, or	-183	-1	N/A	1	N/A
	38	AV*, ED* OA*	-183	-1	N/A	2	N/A
	39	37 or 38	-183	-1	N/A	N/A	N/A
Anemia	40	Any	-183	-1	N/A	1	N/A
Asthma	41	IP*, IS*, or	-183	-1	N/A	1	N/A
	42	AV*, ED* OA*	-183	-1	N/A	2	N/A
	43	41 or 42	-183	-1	N/A	N/A	N/A
Benign Prostatic Hyperplasia	44	IP*, IS*, or	-183	-1	N/A	1	N/A
	45	AV*, ED* OA*	-183	-1	N/A	2	N/A
	46	44 or 45	-183	-1	N/A	N/A	N/A
Chronic Kidney Disease	47	IP*, IS*, or	-183	-1	N/A	1	N/A
	48	AV*, ED* OA*	-183	-1	N/A	2	N/A
	49	47 or 48	-183	-1	N/A	N/A	N/A
COPD and Bronchiectasis	50	IP*, IS*, or	-183	-1	N/A	1	N/A
	51	AV*, ED* OA*	-183	-1	N/A	2	N/A
	52	50 or 51	-183	-1	N/A	N/A	N/A
Glaucoma	53	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Osteoporosis	54	IP*, IS*, or	-183	-1	N/A	1	N/A
	55	AV*, ED* OA*	-183	-1	N/A	2	N/A
	56	54 or 55	-183	-1	N/A	N/A	N/A

## Appendix H. Specifications Defining Parameters for Baseline Characteristics in this Request

Covariates							
Covariate	Covariate Number	Care setting/ Principal diagnosis <sup>1</sup>	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>							
<i>Other</i>							
Obesity: diagnosed or identified by weight management procedures	57	Any	-183	-1	N/A	1	N/A
Obesity: identified by weight management-related prescriptions	58	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Overweight	59	Any	-183	-1	N/A	1	N/A
Smoking: diagnosed or identified by smoking cessation procedures	60	Any	-183	-1	N/A	1	N/A
Smoking: identified by smoking-related prescriptions	61	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Alcohol Abuse or Dependence	62	Any	-183	-1	N/A	1	N/A
Drug Abuse or Dependence	63	Any	-183	-1	N/A	1	N/A
History of Cardiac Arrest	64	Any	-183	-1	N/A	1	N/A
History of Coronary Angioplasty or Bypass	65	Any	-183	-1	N/A	1	N/A

**\*The wildcard symbol (\*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes. The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scoundary) uses the second diagnosis position.**

N/A: Not Applicable

### <sup>1</sup>Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.